Avermectin derivative

MYPI2025003780A0Undetermined Publication Date: 2024-06-23THE KITASATO INSTITUTE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003780
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-23
Filing Date
2023-12-22
Publication Date
2024-06-23

AI Technical Summary

Technical Problem

Current antiviral compounds against SARS-CoV-2 have limited efficacy and safety data, and there is a need for further development of antiviral agents effective against severe COVID-19 cases.

Method used

A novel avermectin derivative with a specific chemical structure, represented by general formula (I), exhibiting antiviral activity against coronaviruses, including SARS-CoV-2, is developed for use in compositions to treat or prevent coronavirus-related diseases.

Benefits of technology

The avermectin derivative demonstrates excellent antiviral activity against coronaviruses, potentially offering effective treatment or prevention options for COVID-19 and other coronavirus-related conditions, with a focus on severe cases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof: [Chem. 1] [In the formula (I), n represents an integer of 0 to 2; X represents CH, CF, CCl, N, CHCH=N, CHCH=CH, or CHCH=CF; Y represents O, NH, or a single bond; Z represents a hydroxy group or an oxo group; R1 represents a hydrogen atom, a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, a 4- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a group represented by -CO-R2, a group represented by -COO-R2, a group represented by -CONH-R2, or a group represented by -B(OR4)OR5, and these groups may be substituted; and R2, R4, and R5 each represent a hydrogen atom, an alkyl group, etc.].
Need to check novelty before this filing date? Find Prior Art

Description

Avermectin derivatives

[0001] The present invention relates to an avermectin derivative and a composition containing the same, and more particularly to a novel avermectin derivative having antiviral activity against coronaviruses and a composition containing the same as an active ingredient.

[0002] Coronaviruses (CoVs) are enveloped viruses with a single-stranded positive-sense RNA genome of 26-32 kb, the largest among RNA viruses, and are classified in the subfamily Orthocoronavirinae of the family Coronaviridae of the order Nidovirales. The subfamily Orthocoronavirinae is further divided into four genera: alpha (α), beta (β), gamma (γ), and delta (δ). Coronaviruses are characterized by high rates of genetic recombination and mutation, resulting in high diversity and enabling them to easily adapt to and infect a wide range of hosts, from birds to cetaceans.

[0003] Currently, seven types of coronaviruses have been confirmed to infect humans. For example, human coronaviruses (HCoV) 229E, OC43, NL63, and HKU1 account for 10% to 30% of upper respiratory tract infections annually and are characterized by causing mild respiratory illnesses such as the common cold. On the other hand, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (novel coronavirus, SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV) can cause respiratory illnesses and may lead to high mortality rates if they spread (Non-Patent Documents 1 and 2). In particular, the novel coronavirus disease (COVID-19), which is believed to have originated in Wuhan, China in December 2019, is caused by SARS-CoV-2. Due to its high infectiousness, SARS-CoV-2 has spread and become epidemic worldwide, with a cumulative total of 600 million infected people and 6.46 million deaths as of September 7, 2022 (Non-Patent Document 3), and is still spreading, posing a major global threat.

[0004] Much research has been conducted on compounds with antiviral activity against coronaviruses, particularly SARS-CoV-2. Many of these compounds were discovered to have antiviral activity through drug repositioning of existing drugs. However, newly created compounds that have already been approved in Japan include small molecule compounds such as molnupiravir (product name: LaGebrio) (Patent Documents 1 and 2) and a combination of nilmatrervir and ritonavir (product name: Paquilobid) (Patent Document 3), as shown below. However, these compounds were granted special approval as treatments for COVID-19 in December 2021 and February 2022, and information regarding their efficacy and safety at the time of approval was limited. Furthermore, because the efficacy of these compounds has not yet been established for severely ill COVID-19 patients, further development of compounds with antiviral activity against SARS-CoV-2 is urgently needed.

[0005]

[0006] In addition, several other compounds are known to have antiviral activity against SARS-CoV-2, such as the following encitrevir (Patent Document 4) and compounds described in Patent Documents 5 and 6.

[0007]

[0008] Furthermore, in addition to the above compounds, it was reported in 2020 that ivermectin, a compound obtained by reducing the double bonds at positions 22 and 23 of avermectin, has antiviral activity against SARS-CoV-2 (Patent Document 7, Non-Patent Document 4).

[0009] Avermectin and its derivatives are a group of compounds characterized by having a 16-membered ring macrolide structure, a hexahydrobenzofuran skeleton, and a bispiran structure containing a spiro ring, and the avermectin derivative ivermectin is widely known as a treatment for river blindness and scabies. Avermectin derivatives other than ivermectin include emamectin, epinomectin, milbemycin oxime, lepimectin, nemadectin, and moxidectin, which are widely used as anthelmintics in humans, pesticides, and veterinary drugs.

[0010] For this reason, extensive research has been conducted into the synthesis and pharmacological effects of avermectin derivatives and analogs. For example, Patent Documents 8 to 13 describe that the compounds described in these documents exhibit anthelmintic activity, and Patent Document 14 describes that the compound represented by general formula (I) in the same document exhibits FXR regulating activity. Furthermore, Non-Patent Document 5 describes that ivermectin binds to TELO2 and exhibits inhibitory activity on the Wnt / β-catenin pathway.

[0011] International Publication No. WO 2019 / 113462, International Publication No. WO 2019 / 173602, International Publication No. WO 2021 / 250648, International Publication No. WO 2022 / 138988, International Publication No. WO 2021 / 176010, International Publication No. WO 2022 / 010948, International Publication No. WO 2021 / 179050, International Publication No. WO 94 / 15944, International Publication No. WO 95 / 22552, International Publication No. WO 95 / 04746, JP 63-045281 A, International Publication No. WO 2000 / 47597, International Publication No. WO 2002 / 12248, International Publication No. WO 2018 / 185684

[0012] H. Yang and Z. Rao, Nature Reviews Microbiology, 2021, 19, pp. 685-700 Journal of the Japanese Society for Virology, Vol. 70, No. 1, pp. 29-36, 2020 Weekly epidemiological update on COVID-19-7 September 2022, https: / / www. who. int / publications / m / item / weekly-epidemiological-update-on-covid-19---7-september-2022 Kylie M. Wagstaff et al. , Antiviral Research, 2020, 178, 104787Naoyuki Nishiya et al. ,iScience,2021,25,3,103912

[0013] The present invention has been made in consideration of the above-mentioned problems associated with the prior art, and aims to provide a novel compound that has antiviral activity against coronaviruses and is useful for treating or preventing diseases or conditions associated with coronaviruses, as well as a composition for treating or preventing diseases or conditions associated with coronaviruses, which contains the compound as an active ingredient.

[0014] As a result of extensive research to achieve the above object, the present inventors have found that avermectin derivatives represented by the following general formula (I) have excellent antiviral activity against coronaviruses, leading to the completion of the present invention. The aspects of the present invention obtained based on this finding are as follows:

[0015] [1] The following general formula (I):

[0016]

[0017] [In the formula (I), n represents an integer of 0, 1, or 2; X represents CH, CF, CCl, N, CHCH═N, CHCH═CH, or CHCH═CF; Y represents O, NH, or a single bond; Z represents a hydroxy group or an oxo group; R 1represents a hydrogen atom; a halogen atom; a C1-C6 alkyl group; a 3- to 6-membered cycloalkyl group; a 4- to 8-membered heterocycloalkyl group; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group; a C2-C6 alkenyl group; a C2-C6 alkynyl group; -CO-R 2 a group represented by -COO-R 2 a group represented by -CONH-R 2 or a group represented by -B(OR 4 ) OR 5 where R 1 is other than a hydrogen atom or a C1-C6 alkyl group, 1 represents a halogen atom, a hydroxy group, an amino group, a cyano group, a nitro group, a formyl group, a sulfanyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 aminoalkyl group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -COO-R 2 a group represented by -CONH-R 2 a group represented by -NHCO-R 2 a group represented by -NHSO 2 -R 2 and —NHSO 2 NH-R 2 and R 1 is a C1-C6 alkyl group, the C1-C6 alkyl group is selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a nitro group, a cyano group, an oxo group, a hydroxy group, an amino group, and —CONH—R 2 a group represented by -NHCO-R 2 or a group represented by —NHSO 2 -R 2 a 3- to 6-membered cycloalkyl group optionally substituted with a group represented by the formula: 2 a group represented by -O-CO-R 2a group represented by the formula: -O-CONH-R 2 a group represented by -N-R 2 R 3 a group represented by -S-R 2 a group represented by -CONH-R 2 a group represented by the formula: -NHCO-R 2 a group represented by -COO-R 2 a group represented by the formula: -NHCOO-R 2 a group represented by -NHCONH-R 2 a group represented by the formula: -NHSO 2 -R 2 a group represented by -CO-R 2 a group represented by the formula: 2 -R 2 and —NHSO 2 NH-R 2 and R 2 represents a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C3 haloalkyl group, a hydroxy group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkoxy group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered cycloalkyl C1-C3 alkyl group, a 4- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 6- to 10-membered aryl C1-C3 alkyl group, a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl C1-C3 alkyl group, a C1-C3 alkoxy C1-C3 alkyl group, an amino group, a C1-C6 alkylamino group, a C1-C6 dialkylamino group, a sulfanyl group, or a C1-C6 trialkylsilyl group, wherein R 2 The 5- to 10-membered heteroaryl group represented by is a halogen atom, a hydroxy group, an amino group, a cyano group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 aminoalkyl group, a C1-C3 haloalkyl group, -N-R 2 R 3 and -CONH-R 2 and R 2The heteroaryl group of the 5- to 10-membered heteroaryl C1-C3 alkyl group represented by R may be further substituted with an amino group or a C1-C3 alkyl group, 3 represents a hydrogen atom or a C1-C6 alkyl group, R 4 and R 5 are all hydrogen atoms or each independently represent a C1-C10 alkyl group which may be bonded to each other to form a ring structure, and the numbers 3, 4, 22, and 23 each represent the position numbers of carbon atoms, and the bond between positions 3 and 4, and between positions 22 and 23, may each independently be a single bond or a double bond.] or a pharmaceutically acceptable salt thereof.

[0018] [2] The compound according to [1], wherein in the formula (I), X is N, Y is O, and a single bond is formed between the 3-position and the 4-position, or a pharmaceutically acceptable salt thereof.

[0019] [3] In the formula (I), R 1 is an optionally substituted C1-C6 alkyl group, or a pharmaceutically acceptable salt thereof.

[0020] [4] In the formula (I), R 1 is a 5- to 10-membered heteroaryl group, —CONH—R 2 or a group represented by —CO—R 2

[0023] The compound according to any one of [1] to [3], wherein the C1-C6 alkyl group is substituted with a group represented by the following formula:

[0021] [5] The compound according to [1], wherein in the formula (I), X is N, Y is O, and there is a double bond between the 3-position and the 4-position, or a pharmaceutically acceptable salt thereof.

[0022] [6] In the formula (I), X is N, Y is O, and R 1 is a hydrogen atom; a C2-C6 alkenyl group; a C2-C6 alkynyl group; a halogen atom; a 3- to 6-membered cycloalkyl group optionally substituted with a hydroxy group; a 4- to 8-membered heterocycloalkyl group; or -O-R 2 a group represented by —O—CONH—R 2a group represented by -COO-R 2 a group represented by -CONH-R 2 a group represented by -NHCONH-R 2 a group represented by -CO-R 2 and —NHSO 2 -R 2 or a pharmaceutically acceptable salt thereof.

[0023] [7] The compound represented by formula (I) is represented by the following formulas (1) to (94):

[0024]

[0025]

[0026]

[0027]

[0028]

[0029]

[0030]

[0031]

[0032]

[0033]

[0034]

[0035]

[0036]

[0037]

[0038]

[0039]

[0040] The compound according to any one of [1] to [6], or a pharmaceutically acceptable salt thereof, selected from compounds represented by any one of [1] to [6].

[0041] [8] The compound according to [1], or a pharmaceutically acceptable salt thereof, wherein, in the formula (I), X is CH, CF, or CHCH═CH, and a single bond is formed between the 3-position and the 4-position.

[0042] [9] The compound according to [1], wherein in the formula (I), X is CH, CF, or CHCH═CH, and there is a double bond between the 3-position and the 4-position, or a pharmaceutically acceptable salt thereof.

[0043]

[10] In the formula (I), X is CH, CF, or CHCH═CH, Y is a single bond, and R 1 a 4- to 8-membered heterocycloalkyl group optionally substituted by an oxo group; —COO—R 2 a halogen atom, a hydroxy group, an amino group, a cyano group, a formyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -NHCO-R 2 and -CONH-R 2 a 5- to 10-membered heteroaryl group optionally substituted with one or more substituents (preferably one substituent) selected from the group represented by the formula: 2 and —COO—R 2 or a pharmaceutically acceptable salt thereof.

[0044]

[11] The compound represented by formula (I) is represented by the following formulas (201) to (271):

[0045]

[0046]

[0047]

[0048]

[0049]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057] The compound according to [1] or [8], or a pharmaceutically acceptable salt thereof, selected from compounds represented by any one of the following:

[0058]

[12] In the formula (I), X is N, Y is NH, and R 1 Ga-CO-R 2 The compound according to [1], wherein R is a group represented by the formula: or a pharmaceutically acceptable salt thereof.

[0059]

[13] The compound according to any one of [1] to

[12] or a pharmaceutically acceptable salt thereof, which has antiviral activity against coronavirus.

[0060]

[14] The compound or a pharmaceutically acceptable salt thereof according to

[13] , wherein the coronavirus is a coronavirus classified in the genus Betacoronavirus.

[0061]

[15] The compound or pharmaceutically acceptable salt thereof according to

[13] or

[14] , wherein the coronavirus is at least one selected from the group consisting of human coronavirus (HCoV), severe acute respiratory syndrome coronavirus (SARS-CoV), novel coronavirus (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV).

[0062]

[16] A composition for treating or preventing a disease or condition associated with coronavirus, comprising the compound according to any one of [1] to

[12] or a pharmaceutically acceptable salt thereof as an active ingredient.

[0063]

[17] The composition according to

[16] , wherein the coronavirus is a coronavirus classified in the genus Betacoronavirus.

[0064]

[18] The composition according to

[16] or

[17] , wherein the coronavirus is at least one selected from the group consisting of human coronavirus (HCoV), severe acute respiratory syndrome coronavirus (SARS-CoV), novel coronavirus (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV).

[0065]

[19] A method for treating or preventing a disease or condition associated with coronavirus, comprising administering to a subject the compound according to any one of [1] to

[12] or a pharmaceutically acceptable salt thereof.

[0066]

[20] Use of the compound according to any one of [1] to

[12] or a pharmaceutically acceptable salt thereof for the manufacture of a composition for treating or preventing a disease or condition associated with coronavirus.

[0067] According to the present invention, it is possible to provide a novel compound that has antiviral activity against coronaviruses and is useful for treating or preventing diseases or conditions associated with coronaviruses, as well as a composition for treating or preventing diseases or conditions associated with coronaviruses, which contains the compound as an active ingredient.

[0068] The present invention will be described in detail below with reference to preferred embodiments thereof. In the following description, the same or corresponding elements are designated by the same reference numerals, and redundant description will be omitted.

[0069] <Avermectin Derivative> The present invention relates to an avermectin derivative having the following general formula (I):

[0070]

[0071] and pharmaceutically acceptable salts thereof (sometimes collectively referred to herein as "compounds of the present invention"). As described above, the compound represented by formula (I) is an avermectin derivative having a 16-membered ring macrolide structure, a hexahydrobenzofuran skeleton, and a bispiran structure containing a spiro ring. In formula (I), the numbers 3, 4, 22, and 23 each represent the position numbers of carbon atoms, and the bonds between positions 3 and 4, and between positions 22 and 23, may each independently be a single bond or a double bond. Furthermore, in formula (I), Me represents a methyl group.

[0072] In the formula (I), n represents an integer of 0, 1, or 2.

[0073] In the formula (I), X represents CH, CF, CCl, N, CHCH═N, CHCH═CH, or CHCH═CF. When X represents CHCH═N, CHCH═CH, or CHCH═CF, that is, the structure represented by "═X~" represents the structure represented by "═CHCH═N~", "═CHCH═CH~", or "═CHCH═CF~", respectively.

[0074] In this specification, a wavy line representing a single bond between atoms in a structural formula, for example, a wavy line (~) representing a single bond between X and Y in formula (I), when geometric isomers exist, indicates that the compound has one of the isomer structures ((E) form or (Z) form) shown below, and in this case, the compound represented by formula (I) may be any one of these isomers or a mixture thereof. In addition, in this specification, a single bond represented by a straight line (-) in a structural formula, when stereoisomers exist, indicates that the compound represented by formula (I) is either a "wedge bond" or a "dashed bond", and in this case, the compound represented by formula (I) may be any one of these isomers or a mixture thereof.

[0075]

[0076] In the formula (I), Y represents O, NH, or a single bond.

[0077] In the formula (I), Z represents a hydroxy group or an oxo group. When Z is a hydroxy group, a single bond is formed between OH and the carbon atom to which it is bonded, and when Z is an oxo group, a double bond is formed between O and the carbon atom to which it is bonded.

[0078] In the formula (I), R 1 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, a 4- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, -CO-R 2 (C has O through a double bond and R 2 are bonds. The same applies below), -COO-R 2 a group represented by -CONH-R 2 or a group represented by -B(OR 4 ) OR 5 represents a group represented by the formula:

[0079] Here, R 1 is other than a hydrogen atom or a C1-C6 alkyl group, 1 represents a halogen atom, a hydroxy group, an amino group, a cyano group, a nitro group, a formyl group, a sulfanyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 aminoalkyl group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -COO-R 2 a group represented by -CONH-R 2 a group represented by -NHCO-R 2 a group represented by -NHSO 2 -R 2 and —NHSO 2 NH-R 2 In this specification, when a group is substituted with an oxo group, it means that two hydrogen atoms bonded to a carbon atom contained in the group are substituted with one oxygen atom.

[0080] Also, R 1is a C1-C6 alkyl group, the C1-C6 alkyl group is selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a nitro group, a cyano group, an oxo group, a hydroxy group, an amino group, and —CONH—R 2 a group represented by -NHCO-R 2 or a group represented by —NHSO 2 -R 2 a 3- to 6-membered cycloalkyl group optionally substituted with a group represented by the formula: 2 a group represented by -O-CO-R 2 a group represented by the formula: -O-CONH-R 2 a group represented by -N-R 2 R 3 a group represented by -S-R 2 a group represented by -CONH-R 2 a group represented by the formula: -NHCO-R 2 a group represented by -COO-R 2 a group represented by the formula: -NHCOO-R 2 a group represented by -NHCONH-R 2 a group represented by the formula: -NHSO 2 -R 2 a group represented by -CO-R 2 a group represented by the formula: 2 -R 2 and —NHSO 2 NH-R 2 may be substituted with one or more substituents selected from the groups represented by the following formula:

[0081] In the formula (I), R 1 In this case, R 2represents a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C3 haloalkyl group, a hydroxy group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkoxy group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered cycloalkyl C1-C3 alkyl group, a 4- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 6- to 10-membered aryl C1-C3 alkyl group, a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl C1-C3 alkyl group, a C1-C3 alkoxy C1-C3 alkyl group, an amino group, a C1-C6 alkylamino group, a C1-C6 dialkylamino group, a sulfanyl group, or a C1-C6 trialkylsilyl group. 2 The 5- to 10-membered heteroaryl group represented by is a halogen atom, a hydroxy group, an amino group, a cyano group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 aminoalkyl group, a C1-C3 haloalkyl group, -N-R 2 R 3 and -CONH-R 2 and R 2 The heteroaryl group of the 5- to 10-membered heteroaryl C1-C3 alkyl group represented by the formula (I) may be further substituted with an amino group or a C1-C3 alkyl group.

[0082] In addition, in the formula (I), R 1 In this case, R 3 represents a hydrogen atom or a C1-C6 alkyl group. 1 In this case, R 4 and R 5 are each a hydrogen atom, or each independently a C1-C10 alkyl group which may be bonded to each other to form a ring structure.

[0083] In this specification, the term "C1-C6 alkyl group" refers to an alkyl group having 1 to 6 carbon atoms, and may be linear or branched. Specific examples include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a 1-methylbutyl group, a 2-methylbutyl group, a 1,2-dimethylpropyl group, a tert-pentyl group, a 3-methylbutyl group (isopentyl group), a neopentyl group, a 1-ethylpropyl group, an n-hexyl group, an isohexyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 2,3-dimethylbutyl group, a 1,1-dimethylbutyl group, a 1,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a 2,2-dimethylbutyl group, a 2,3-dimethylbutyl group, a 3,3-dimethylbutyl group, and a 2-ethylbutyl group. In addition, in this specification, the term "C1-C3 alkyl group" refers to an alkyl group having 1 to 3 carbon atoms, which may be linear or branched, and specific examples include a methyl group, an ethyl group, an n-propyl group, and an isopropyl group.

[0084] In the present specification, the term "3- to 6-membered cycloalkyl group" refers to a cyclic alkyl group having 3 to 6 carbon atoms, and specific examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group. In addition, in the present specification, when the range indicating the number of members of a ring structure is referred to as "3- to 6-membered," this includes any range between 3 or more and 6 or less members (for example, "3- to 4-membered," "4- to 5-membered," etc.). The same applies to other ring structures.

[0085] As used herein, the term "4- to 8-membered heterocycloalkyl group" refers to a 4- to 8-membered monocyclic or bicyclic ring structure consisting of carbon atoms and one or more heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms. Specific examples include an oxetanyl group, an azetidyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a 1,4-dioxanyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an oxadiazolidinyl group (e.g., a 1,2,4-oxadiazolidinyl group, a 1,3,4-oxadiazolidinyl group), a morpholinyl group, a thiomorpholino group, an azepanyl group, an oxepanyl group, a 2,6-diazaspiro[3.3]heptyl group, and an octahydropyrrolo[3,4-c]pyrrolyl group, each of which is bonded to any available carbon atom or nitrogen atom.

[0086] In the present specification, the term "6- to 10-membered aryl group" refers to a 6- to 10-membered monocyclic or bicyclic aromatic hydrocarbon group consisting of carbon atoms, and specific examples thereof include a phenyl group, a 1-naphthyl group, a 2-naphthyl group, and an azulenyl group.

[0087] In the present specification, the term "5- to 10-membered heteroaryl group" refers to a 5- to 10-membered monocyclic or bicyclic aromatic hydrocarbon group containing one or more heteroatoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom in the ring-constituting atoms. Specific examples thereof include a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a triazolyl group (e.g., a 1,2,3-triazolyl group or a 1,2,4-triazolyl group), an oxadiazolyl group (e.g., a 1,2,4-oxadiazolyl group or a 1,3,4-oxadiazolyl group), a 1,3,4-thiadiazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidyl group, a pyrazinyl group, a triazinyl group, a purinyl group, an indolyl group, a benzofuryl group, a benzothienyl group, a benzimidazolyl group, an indolyl group, a benzofuryl group, a benzothienyl group, a benzimidazolyl group, an indolyl group, a benzofuryl group, a benzothienyl group, a benzo ... a benzofuryl group, a benzoimidazolyl group, a benzofuryl group, a benzothienyl group, a benzoimidazolyl group, a benzofuryl group, a benzofuryl group, Examples thereof include a benzothiazolyl group, a benzopyrazolyl group, a benzotriazolyl group, an isobenzofuryl group, an isoindolyl group, an indolizinyl group, a thienopyridinyl group, a thienopyrimidinyl group, a pyrazolopyrimidinyl group, a pyrazolopyridyl group, a pyrazolopyridazyl group, an imidazopyridyl group, an imidazopyrimidyl group, a triazolopyridyl group, a benzofuranyl group, a benzothienyl group, a benzisoxazolyl group, a benzisothiazolyl group, a quinolyl group, an isoquinolyl group, a cinnolinyl group, a quinazolinyl group, and a tetrazolyl group.

[0088] In this specification, the term "C2-C6 alkenyl group" refers to an alkenyl group having 2 to 6 carbon atoms and containing at least one double bond, and may be linear or branched. Specific examples include vinyl, allyl, 2-propenyl, isopropenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-methyl-1-butenyl, 1-methyl-2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-methyl-1-butenyl, 1-methyl-2-butenyl, 1,3-butadienyl, 1,3-butenyl, 1,3-butadienyl, 1,3-penten ... Examples of the alkyl group include 1-methyl-3-butenyl group, 3-methyl-1-butenyl group, 1,2-dimethyl-2-propenyl group, 1,1-dimethyl-2-propenyl group, 2-methyl-2-butenyl group, 3-methyl-2-butenyl group, 1,2-dimethyl-1-propenyl group, 2-methyl-3-butenyl group, 3-methyl-3-butenyl group, 1,3-pentadienyl group, 1-vinyl-2-propenyl group, 1-hexenyl group, 3-hexenyl group, and 5-hexenyl group.

[0089] In this specification, the term "C2-C6 alkynyl group" refers to an alkynyl group having 2 to 6 carbon atoms and containing at least one triple bond, and may be linear or branched. Specific examples include ethynyl, propargyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 3-methyl-1-butyn-3-yl, prop-1-yn-1yl, and 4-methyl-2-pentynyl.

[0090] In this specification, the term "halogen atom" includes a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.

[0091] As used herein, "hydroxy group, amino group, -CONH-R 2 a group represented by -NHCO-R 2 or a group represented by —NHSO 2 -R 2"The 3- to 6-membered cycloalkyl group which may be substituted with a group represented by the formula:" refers to the 3- to 6-membered cycloalkyl group, or the 3- to 6-membered cycloalkyl group in which one or more (preferably one) hydrogen atoms are substituted with a hydroxy group, an amino group, -CONH-R 2 a group represented by -NHCO-R 2 and —NHSO 2 -R 2 When there are a plurality of substituted substituents, they may be the same or different. In the 3- to 6-membered cycloalkyl group substituted with the substituent, the substituent may be bonded to the carbon atom at the attachment point of the ring structure.

[0092] In the present specification, the term "a 6- to 10-membered aryl group optionally substituted with a halogen atom or a C1-C3 alkyl group" refers to the 6- to 10-membered aryl group or the 6- to 10-membered aryl group in which one or more hydrogen atoms have been substituted with the halogen atom and / or the C1-C3 alkyl group.

[0093] As used herein, the term "C1-C3 aminoalkyl group" refers to a group in which one hydrogen atom of the above-mentioned C1-C3 alkyl group is substituted with an amino group. Specific examples include an aminomethyl group, an aminoethyl group, and an aminopropyl group.

[0094] In the present specification, the term "C1-C3 haloalkyl group" refers to the above-mentioned C1-C3 alkyl group in which 1 to 6, preferably 1 to 3, hydrogen atoms have been substituted with the above-mentioned halogen atoms. Specific examples include a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a chloromethyl group, a dichloromethyl group, a trichloromethyl group, a bromomethyl group, a tribromomethyl group, a chlorofluoromethyl group, a dichlorofluoromethyl group, a chlorodifluoromethyl group, a 2-fluoroethyl group, a 2,2-difluoroethyl group, a 2,2,2-trifluoroethyl group, a pentafluoroethyl group, a 2-chloroethyl group, a 2,2,2-trichloroethyl group, a 2-chloro-2-fluoroethyl group, a 2-chloro-2,2-difluoroethyl group, a 2,2-dichloro-2-fluoroethyl group, a 2-fluoropropyl group, a 3-fluoropropyl group, a 2,2-difluoropropyl group, a 3,3,3-trifluoropropyl group, and a 1,1,1,3,3,3-hexafluoro-2-propyl group.

[0095] As used herein, the term "C1-C3 hydroxyalkyl group" refers to a group in which one hydrogen atom of the above-mentioned C1-C3 alkyl group is substituted with a hydroxy group. Specific examples include a hydroxymethyl group, a hydroxyethyl group, a hydroxypropyl group, and a hydroxyisopropyl group.

[0096] As used herein, the term "C1-C6 alkoxy group" refers to a group represented by -O-Alk, where Alk is the C1-C6 alkyl group described above. Specific examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isoamyloxy, neopentyloxy, 2-pentyloxy, 3-pentyloxy, 2-methylbutyloxy, hexyloxy, isohexyloxy, 3-methylpentyloxy, and 4-methylpentyloxy. Furthermore, as used herein, the term "C1-C3 alkoxy group" refers to a group represented by -O-Alk, where Alk is the C1-C3 alkyl group described above. Specific examples include methoxy, ethoxy, propoxy, and isopropoxy.

[0097] In the present specification, the term "C1-C3 haloalkoxy group" refers to a group represented by -O-Alk', where Alk' is the C1-C3 haloalkyl group defined above. Specific examples thereof include a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a chloromethoxy group, a dichloromethoxy group, a trichloromethoxy group, a chlorofluoromethoxy group, a dichlorofluoromethoxy group, a chlorodifluoromethoxy group, a 2-fluoroethoxy group, a 2,2-difluoroethoxy group, a 2,2,2-trifluoroethoxy group, a pentafluoroethoxy group, a pentachloroethoxy group, a 2-chloroethoxy group, a 2-chloro-2-fluoroethoxy group, a 2-chloro-2,2-difluoroethoxy group, a 2,2,2-trichloro Examples of such groups include an ethoxy group, a 2,2,2-tribromoethoxy group, a 2-fluoropropoxy group, a 3-fluoropropoxy group, a 2,2-difluoropropoxy group, a 2,3-difluoropropoxy group, a 3,3-trifluoropropoxy group, a heptafluoropropoxy group, a 2-chloropropoxy group, a 3-chloropropoxy group, a 2,3-dichloropropoxy group, a 3,3,3-trichloropropoxy group, a heptachloropropoxy group, a 2-bromopropoxy group, a 3-bromopropoxy group, a 3,3,3-tribromopropoxy group, and a heptabromopropoxy group.

[0098] In the present specification, the term "3- to 6-membered cycloalkyl C1-C3 alkyl group" refers to a group in which one hydrogen atom of the C1-C3 alkyl group is substituted with the 3- to 6-membered cycloalkyl group.

[0099] In the present specification, the term "6- to 10-membered aryl C1-C3 alkyl group" refers to a group in which one hydrogen atom of the C1-C3 alkyl group is substituted with the 6- to 10-membered aryl group.

[0100] As used herein, the term "5- to 10-membered heteroaryl C1-C3 alkyl group" refers to a group in which one hydrogen atom of the C1-C3 alkyl group is substituted with the 5- to 10-membered heteroaryl group. When the 6- to 10-membered aryl C1-C3 alkyl group is substituted with a substituent, it is preferable that one or two hydrogen atoms bonded to carbon atoms constituting the ring structure of the aryl group are substituted with the substituent.

[0101] As used herein, the term "C1-C3 alkoxy C1-C3 alkyl group" refers to a group in which one hydrogen atom of the C1-C3 alkyl group is substituted with the C1-C3 alkoxy group.

[0102] In the present specification, the term "C1-C6 alkylamino group" refers to a group in which one hydrogen atom of an amino group is substituted with the above-mentioned C1-C6 alkyl group. Specific examples include a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, an n-butylamino group, an isobutylamino group, a tert-butylamino group, a sec-butylamino group, an n-pentylamino group, a 1-methylbutylamino group, a 2-methylbutylamino group, a 1,2-dimethylpropylamino group, a tert-pentylamino group, a 3-methylbutylamino group (isopentyl group), a neopentylamino group, a 1-ethylpropylamino group, an n-hexylamino group, an isohexylamino group, a 2-methylpentylamino group, a 3-methylpentylamino group, a 2,3-dimethylbutylamino group, a 1,1-dimethylbutylamino group, a 1,2-dimethylbutylamino group, a 1,3-dimethylbutylamino group, a 2,2-dimethylbutylamino group, a 2,3-dimethylbutylamino group, a 3,3-dimethylbutylamino group, and a 2-ethylbutylamino group.

[0103] In the present specification, the term "C1-C6 dialkylamino group" refers to a group in which two hydrogen atoms of an amino group are substituted with the above-mentioned C1-C6 alkyl groups, which may be the same or different. Specific examples include a dimethylamino group, a diethylamino group, an N-ethyl-N-methylamino group, a di(n-propyl)amino group, an N-methyl-N-(n-propyl)amino group, an N-ethyl-N-n-propylamino group, a diisopropylamino group, an N-ethyl-N-isopropylamino group, a di(n-butyl)amino group, an N-methyl-N-sec-butylamino group, a di(n-heptyl)amino group, an N-(n-heptyl)-N-methylamino group, an N-ethyl-N-(n-heptyl)amino group, a diisoheptylamino group, an N-isoheptyl-N-methylamino group, an N-ethyl-N-isoheptylamino group, a di(n-hexyl)amino group, an N-hexyl-N-methylamino group, an N-ethyl-N-hexylamino group, a diisohexylamino group, an N-isohexyl-N-methylamino group, and an N-ethyl-N-isohexylamino group.

[0104] As used herein, the term "C1-C6 trialkylsilyl group" refers to a silyl group in which three hydrogen atoms are substituted with the above-mentioned C1-C6 alkyl groups, which may be the same or different. Specific examples include a trimethylsilyl group, a triethylsilyl group, a triisopropylsilyl group, a tert-butyldimethylsilyl group, and a tri(tert-butyl)silyl group.

[0105] In this specification, “-B(OR 4 ) OR 5 The group represented by the formula "is a group represented by the formula -OR" in -B. 4 and -OR 5 Each represents a bonded group. 4 and R 5 The "C1-C10 alkyl group which may be bonded to each other to form a ring structure" shown in R 4 and R 5 each independently represents an alkyl group having 1 to 10 carbon atoms, which may be linear or branched, and such R 4 and R 5may be bonded to each other to form a ring structure such as a pinacol ester (pin) or neopentyl glycol ester (neo) of boronic acid.

[0106] In this specification, when a group is "optionally substituted," it means that the group is an unsubstituted group, or a group in which one or more hydrogen atoms of the group are substituted with atoms or substituents. When there are multiple substituted atoms or substituents, they may be the same or different. Furthermore, the number of substituted atoms or substituents is preferably, for example, 1 to 3.

[0107] When an asymmetric carbon is present in the compound represented by formula (I), the compound may be in the form of a racemate, a diastereoisomeric mixture, or an individual optically active isomer, or a mixture thereof. Furthermore, when a geometric isomer is present in the compound represented by formula (I), the compound may be in the form of an (E) isomer, a (Z) isomer, or a mixture thereof. Furthermore, in the compound represented by formula (I), any one or more hydrogen atoms present in a substituent such as an alkyl group or an alkoxy group may be replaced with a deuterium atom.

[0108] The pharmaceutically acceptable salt of the compound represented by formula (I) is not particularly limited as long as it is pharmaceutically acceptable, and includes, for example, salts with organic acids, salts with inorganic acids, and salts with amino acids.Examples of the salts with organic acids include formates, acetates, propionates, tartrates, fumaric acid, maleates, succinates, lactates, citric acid, malates, ascorbic acid, oxalates, glycolates, phenylacetates, benzoates, mandelates, butyrates, malates, methanesulfonates, and benzenesulfonates.Examples of the salts with inorganic acids include hydrochlorides, hydrobromides, phosphates, sulfamates, nitrates, and sulfates.Furthermore, examples of the salts with amino acids include aspartic acid and glutamic acid.

[0109] Next, preferred embodiments of the compound of the present invention will be described with reference to examples, but the compound of the present invention is not limited to these examples.

[0110] As the compound of the present invention, it is particularly preferable that n is 2 in the above formula (I).

[0111] In the compound of the present invention, in the formula (I), X is preferably CH, CF, N, or CHCH═CH, and more preferably CH, CF, or N.

[0112] In the compound of the present invention, Y is preferably O or a single bond in the formula (I). In the formula (I), Z is preferably either a hydroxy group or an oxo group.

[0113] The compound of the present invention is a compound represented by the formula (I) in which R 1 is a hydrogen atom; a 4- to 8-membered heterocycloalkyl group optionally substituted by an oxo group; a halogen atom, a hydroxy group, an amino group, a cyano group, a formyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -COO-R 2 a group represented by -NHCO-R 2 and -CONH-R 2 a 5- to 10-membered heteroaryl group optionally substituted with one or more substituents (preferably one substituent) selected from the group represented by the following formula: 2 a group represented by -COO-R 2 or a group represented by -CONH-R 2 or a halogen atom, a hydroxy group, an amino group, a nitro group, a cyano group, an oxo group, a 3- to 6-membered cycloalkyl group (which may be substituted with a hydroxy group), a 4- to 8-membered heterocycloalkyl group (which may be substituted with an oxo group), a 6- to 10-membered aryl group (which may be substituted with a halogen atom or a C1-C3 alkyl group), a 5- to 10-membered heteroaryl group, -O-R 2 a group represented by —O—CONH—R 2 a group represented by -N-R 2 R3 a group represented by -CONH-R 2 a group represented by -NHCO-R 2 a group represented by -COO-R 2 a group represented by -NHSO 2 -R 2 a group represented by -NHCONH-R 2 a group represented by -CO-R 2 and —SO 2 -R 2 It is preferably a C1-C6 alkyl group (preferably a C1-C3 alkyl group) optionally substituted with one or more substituents (preferably one substituent) selected from the group represented by

[0114] In the formula (I), R 1 More preferably, it is a hydrogen atom; a 4- to 8-membered heterocycloalkyl group optionally substituted with an oxo group; a C2-C6 alkenyl group; a C2-C6 alkynyl group; or —COO—R 2 or a halogen atom, a hydroxy group, an amino group, a cyano group, a formyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -COO-R 2 a group represented by -NHCO-R 2 and -CONH-R 2 or a 5- to 10-membered heteroaryl group substituted with one or more substituents (preferably one substituent) selected from the group represented by the following formula: 2 a group represented by -CONH-R 2 a group represented by -NHCO-R 2 a group represented by -NHSO 2 -R 2 a group represented by -NHCONH-R 2 a group represented by -CO-R 2and —SO 2 -R 2 and n is 0 or 1. The alkyl group is a C1-C6 alkyl group (preferably a C1-C3 alkyl group) substituted with one or more substituents (preferably one substituent) selected from the group represented by the following formula:

[0115] R 1 More preferably, each of the groups is a hydrogen atom, a halogen atom, a hydroxy group, an amino group, a cyano group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, or —N—R 2 R 3 and a C1-C3 haloalkyl group, or a 4- to 8-membered heterocycloalkyl group, a 5- to 10-membered heteroaryl group, -O-R 2 a group represented by -CONH-R 2 and —NHSO 2 -R 2 and the alkyl group is a C1-C6 alkyl group (preferably a C1-C3 alkyl group) substituted with one or more substituents (preferably one substituent) selected from the group represented by the following formula:

[0116] In the formula (I), R 2 is preferably a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C3 haloalkyl group, a C1-C3 hydroxyalkyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered cycloalkyl-C1-C3 alkyl group, a 4- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 6- to 10-membered aryl-C1-C3 alkyl group, a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl-C1-C3 alkyl group (which may be substituted with an amino group or a C1-C3 alkyl group), a C1-C3 alkylamino group, or a C1-C6 dialkylamino group.

[0117] R 2is more preferably a hydrogen atom, a C1-C6 alkyl group, a C1-C3 haloalkyl group, a C1-C3 hydroxyalkyl group, a 3- to 6-membered cycloalkyl group, a 4- to 8-membered heterocycloalkyl group, a 3- to 6-membered cycloalkyl-C1-C3 alkyl group, a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl-C1-C3 alkyl group (which may be substituted with an amino group or a C1-C3 alkyl group), or a C1-C6 dialkylamino group, and even more preferably a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, a C1-C3 haloalkyl group, a 5- to 10-membered heteroaryl group, or a 5- to 10-membered heteroaryl-C1-C3 alkyl group (which may be substituted with an amino group or a C1-C3 alkyl group).

[0118] In addition, in the compound of the present invention, it is preferable that a single bond is formed between the 22-position and the 23-position in the formula (I).

[0119] In the formula (I), n, X, Y, and R 1 , R 2 , and R 3 Preferred embodiments of the combination are not particularly limited, but include, for example, the following embodiments.

[0120] (Embodiment 1) A preferred embodiment of the compound of the present invention is embodiment 1, in which, in the formula (I), when n is 2 and X is N, Y is O.

[0121] In embodiment 1, R 1 is preferably a hydrogen atom; a 4- to 8-membered heterocycloalkyl group optionally substituted with an oxo group; a C2-C6 alkenyl group; or a C2-C6 alkynyl group; or 2 a group represented by —O—CONH—R 2 a group represented by -N-R 2 R 3 a group represented by -CONH-R 2 a group represented by -NHCO-R2 a group represented by -COO-R 2 a group represented by -NHSO 2 -R 2 a group represented by -NHCONH-R 2 and —CO—R 2 and the alkyl group is a C1-C6 alkyl group substituted with one or more substituents selected from the group represented by the following formula:

[0122] R 1 is more preferably a hydrogen atom; a C2-C6 alkenyl group; or a C2-C6 alkynyl group; a halogen atom, a hydroxy group, a 3- to 6-membered cycloalkyl group (which may be substituted with a hydroxy group), a 4- to 6-membered heterocycloalkyl group, a 5- to 10-membered heteroaryl group, or -O-R 2 a group represented by -CONH-R 2 a group represented by -NHCO-R 2 a group represented by -NHSO 2 -R 2 and -NHCONH-R 2 and the alkyl group is a C1-C6 alkyl group which may be substituted with one or more substituents selected from the groups represented by the following formula:

[0123] In embodiment 1, R 2 is preferably a hydrogen atom, a C1-C6 alkyl group, a C1-C3 haloalkyl group, a C1-C3 hydroxyalkyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered cycloalkyl C1-C3 alkyl group, a 4- to 8-membered heterocycloalkyl group, a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl C1-C3 alkyl group (which may be substituted with an amino group or a C1-C3 alkyl group), or a C1-C6 dialkylamino group.

[0124] R 2is more preferably a hydrogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 hydroxyalkyl group, a 4- to 6-membered cycloalkyl group, a 3- to 6-membered cycloalkyl C1-C3 alkyl group, a 4- to 6-membered heterocycloalkyl group, a 5- to 8-membered heteroaryl group, a 5- to 8-membered heteroaryl C1-C3 alkyl group (optionally substituted with an amino group or a C1-C3 alkyl group), or a C1-C6 dialkylamino group.

[0125] In embodiment 1, R 3 may be either a hydrogen atom or a C1-C6 alkyl group. In addition, in Aspect 1, Z may be either a hydroxy group or an oxo group. Furthermore, in Aspect 1, the bond between the 3- and 4-positions may be either a single bond or a double bond, and the bond between the 22- and 23-positions is preferably a single bond.

[0126] (Aspect 2) Another preferred aspect of the compound of the present invention is aspect 2, in which, in formula (I), n is 2, X is CH, CF, CHCH═N, or CHCH═CH, and Y is a single bond. In this case, X is preferably CH, CF, or CHCH═CH, and more preferably CH or CF.

[0127] In embodiment 2, R 1 is preferably a 4- to 8-membered heterocycloalkyl group optionally substituted with an oxo group; 2 a halogen atom, a hydroxy group, an amino group, a cyano group, a formyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkyl group, a group represented by -COO-R 2 a group represented by -N-R 2 R 3 a group represented by -NHCO-R 2 and -CONH-R 2 a 5- to 10-membered heteroaryl group optionally substituted with one or more substituents (preferably one substituent) selected from the groups represented by the following formula: 2 or a group represented by -CONH-R2 or a group represented by the formula: - hydroxy group, amino group, nitro group, cyano group, oxo group, 3- to 6-membered cycloalkyl group, 6- to 10-membered aryl group (which may be substituted with a halogen atom or a C1-C3 alkyl group), -N-R 2 R 3 a group represented by -CONH-R 2 a group represented by -COO-R 2 a group represented by -CO-R 2 and —SO 2 -R 2 and the like. It is a C1-C6 alkyl group which may be substituted with one or more substituents selected from the groups represented by the following formula:

[0128] R 1 More preferably, it is a 4- to 6-membered heterocycloalkyl group optionally substituted with an oxo group; 2 or a group represented by the following formula: a halogen atom, a hydroxy group, an amino group, a cyano group, a formyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkyl group, -COO-R 2 a group represented by -N-R 2 R 3 a group represented by -NHCO-R 2 and -CONH-R 2 or a 5- to 10-membered heteroaryl group optionally substituted with one or more substituents (preferably one substituent) selected from the group represented by the formula: 2 a group represented by -COO-R 2 a group represented by -CO-R 2 and —SO 2 -R 2 is a C1-C6 alkyl group optionally substituted with one or more substituents selected from the groups represented by the following formula:

[0129] In embodiment 2, R 2is preferably a C1-C6 alkyl group, a C2-C6 alkenyl group, a C1-C3 haloalkyl group, a C1-C3 hydroxyalkyl group, a 3- to 6-membered cycloalkyl group, a 6- to 10-membered aryl group, a 6- to 10-membered aryl C1-C3 alkyl group, a 5- to 10-membered heteroaryl C1-C3 alkyl group, or a C1-C3 alkylamino group, more preferably a C1-C6 alkyl group, a C1-C3 haloalkyl group, or a C1-C3 hydroxyalkyl group.

[0130] In embodiment 2, R 3 is preferably a hydrogen atom. In addition, in embodiment 2, Z may be either a hydroxy group or an oxo group. Furthermore, in embodiment 2, the bond between the 3-position and the 4-position may be a single bond or a double bond, and the bond between the 22-position and the 23-position is preferably a single bond.

[0131] More specifically, preferred embodiments of the compound of the present invention include, for example, compounds represented by any one of the above formulas (1) to (94) and compounds represented by any one of formulas (201) to (271). The compounds represented by formulas (1) to (94) are, in order, compounds I-1 to 5, 10, 11, 18, 19, 28, 49 to 55, 57, 59, 60, 62 to 64, 66, 68, 70, 72, 74, 79 to 82, 92 to 98, 101 to 106, 109 to 115, 120 to 127, 129 to 136, 139 to 148, 150 to 152, 155, 156, 159 to 162, 165, 166, 169 / 170, 172, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 76; the compounds represented by formula (201) to formula (271) correspond to compounds II-2 to II-5, 11, 15, 22, 23, 25 / 26, 28, 38 to 41, 43, 47, 48, 50, 54, 55, 57, 59 to 63, 65, 68, 69, 71 to 74, 76 to 80, 84 to 92, 94 to 96, 98, 99, 102, 104 to 107, 109, 110, 112, 113, 115 to 117, and 119 to 124 described in the following examples, respectively.

[0132] The method for producing the compound of the present invention is not particularly limited, and the compound can be produced by combining a wide variety of synthesis methods recognized by those skilled in the art, and methods in which the synthesis methods have been modified as necessary, using starting materials, precursors, reagents, solvents, etc. that are commercially available or can be synthesized by methods recognized by those skilled in the art. For example, the compound can be produced by the representative methods shown in Steps 1 to 5 below, but is not limited thereto.

[0133]

[0134] A compound represented by formula (III) and a compound represented by formula (IV) can be synthesized as intermediates for synthesizing a compound represented by formula (I) by, for example, an oxidation reaction and a reduction reaction according to the method shown in the above step 1. In formulas (III) and (IV), n has the same meaning as n in formula (I).

[0135] [Step 1-1] The compound represented by the formula (III) can be synthesized by carrying out an oxidation reaction of the compound represented by the formula (II) in a solvent.

[0136] The oxidation reaction in step 1-1 can be carried out by any known method or a method based thereon, and can be selected from, for example, Swern oxidation reaction, Parikh-Doering oxidation reaction, oxidation reactions using reagents such as 2-iodoxybenzoic acid, Dess-Martin Periodinane reagent, manganese dioxide, tetrapropylammonium perruthenate, etc. The amount of the reagent is preferably in the range of 2 to 100 equivalents based on the compound represented by formula (II).

[0137] The solvent in step 1-1 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include tetrahydrofuran (THF), 1,4-dioxane, acetonitrile, N,N-dimethylformamide (DMF), N,N-dimethylacetamide, dimethyl sulfoxide, dichloromethane, and chloroform, and these may be used alone or in combination of two or more.

[0138] The reaction temperature in step 1-1 is selected, for example, in the range of 0 to 100° C., preferably in the range of 0 to 50° C. The reaction time is, for example, 1 to 72 hours, preferably 12 to 48 hours.

[0139] [Step 1-2] The compound represented by the formula (IV) can be synthesized by reacting the compound represented by the formula (III) with a reducing agent in a solvent (performing a reduction reaction).

[0140] Examples of the reducing agent used in step 1-2 include sodium borohydride, lithium aluminum hydride, diisobutylaluminum hydride (DIBAL), lithium borohydride, lithium tri(sec-butyl)borohydride (L-Selectride), potassium tri(sec-butyl)borohydride (K-Selectride), and sodium triethylborohydride. The amount of the reducing agent is preferably in the range of 1 to 10 equivalents based on the compound represented by formula (III).

[0141] The solvent in step 1-2 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include tetrahydrofuran, 2-methyltetrahydrofuran, diethyl ether, 1,4-dioxane, acetonitrile, methanol, ethanol, n-hexane, heptane, and toluene, and these may be used alone or in combination of two or more.

[0142] The reaction temperature in step 1-2 is selected, for example, in the range of −100 to 50° C., preferably in the range of −78 to 0° C. The reaction time is, for example, 15 minutes to 24 hours, preferably 30 minutes to 3 hours.

[0143]

[0144] By the method shown in the above step 2, for example, among the compounds represented by formula (I), compounds represented by formula (Ia) and compounds represented by formula (Ib) can be synthesized. In step 2, the compound represented by formula (V) indicates the compound represented by formula (III) or the compound represented by formula (IV) obtained in the above step 1. In the formulas (V), (Ia), and (Ib), n, R 1 , R 2 , R 3 respectively represent n and R in the formula (I). 1 , R 2 , R 3 is synonymous with.

[0145] [Step 2-1] The compound represented by formula (Ia) can be prepared by reacting the compound represented by formula (V) with an appropriate hydroxyamine (a compound represented by formula (i): R 1 represents R in formula (Ia). 1 (same meaning as above) in a solvent in the presence of a base.

[0146] The hydroxyamine may be a hydrochloride salt. The amount of the hydroxyamine and / or its hydrochloride is preferably in the range of 1 to 20 equivalents (preferably 2 to 20 equivalents) based on the compound represented by formula (V).

[0147] Examples of the base in step 2-1 include sodium carbonate, sodium bicarbonate, potassium carbonate, cesium carbonate, sodium acetate, potassium acetate, potassium fluoride, etc. The amount of the base is preferably in the range of 1 to 30 equivalents (preferably 2 to 30 equivalents) based on the compound represented by formula (V).

[0148] The solvent in step 2-1 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include dichloromethane, chloroform, methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, diethyl ether, N,N-dimethylformamide, N,N-dimethylacetamide, acetone, dimethyl sulfoxide, and toluene, and these may be used alone or in combination of two or more.

[0149] In the reaction of step 2-1, a reaction reagent such as cerium chloride anhydrous, cerium chloride heptahydrate, lanthanum chloride anhydrous, or lanthanum chloride heptahydrate may be further added, if necessary. In this case, the amount of the reaction reagent is preferably in the range of 1 to 5 equivalents based on the compound represented by formula (V).

[0150] The reaction temperature in step 2-1 is not particularly limited and is, for example, −20 to 80° C., preferably 0 to 50° C. The reaction time is also not particularly limited and is, for example, 10 minutes to 24 hours, preferably 30 minutes to 5 hours.

[0151] [Step 2-2] The compound represented by formula (Ib) can be prepared by reacting the compound represented by formula (Ia) with an appropriate amine (a compound represented by formula (ii): R 2 , R 3 are R in the formula (Ib), respectively. 2 , R 3 (same meaning as above) in a solvent in the presence of a base using a condensing agent.

[0152] The amine may be a hydrochloride salt. The amount of the amine and / or its hydrochloride is preferably in the range of 1 to 10 equivalents (preferably 2 to 10 equivalents) based on the compound represented by formula (Ia).

[0153] Examples of the condensing agent include N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 1,1-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridinium iodine, 1-propylphosphonic acid cyclic anhydride (PPA), N,N'-dicyclohexylcarbodiimide, and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU). The amount of the condensing agent is preferably in the range of 1 to 8 equivalents based on the compound represented by formula (Ia).

[0154] Examples of the base used in step 2-2 include organic amines such as trimethylamine, triethylamine, diisopropylethylamine, tripropylamine, triisopropylamine, tributylamine, N-methylmorpholine, pyridine, N,N-dimethylpyridin-4-amine, N,N-dimethylaniline, N,N-diethylaniline, 1,5-diazabicyclo[4.3.0]nan-5-ene, 1,4-diazabicyclo[2.2.2]octane (DABCO), and 1,8-diazabicyclo[5.4.0]-7-undecene (DBU). The amount of the base is preferably in the range of 1 to 30 equivalents (preferably 5 to 30 equivalents) based on the compound represented by formula (Ia).

[0155] The solvent in step 2-2 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, diethyl ether, N,N-dimethylformamide, N,N-dimethylacetamide, acetone, dimethyl sulfoxide, and toluene, and these may be used alone or in combination of two or more.

[0156] In the reaction of step 2-2, a reaction reagent such as 1-hydroxybenzotriazole (HOBt) or N,N-dimethylpyridin-4-amine (DMAP) may be further added, if necessary.

[0157] The reaction temperature in Step 2-2 is not particularly limited and is, for example, −20 to 80° C., preferably 0 to 50° C. The reaction time is also not particularly limited and is, for example, 10 minutes to 48 hours, preferably 30 minutes to 24 hours.

[0158]

[0159] By the method shown in the above step 3, for example, among the compounds represented by formula (I), compounds represented by formula (Ic), compounds represented by formula (Id), and compounds represented by formula (Ie) can be synthesized. In step 3, the compound represented by formula (V) indicates the compound represented by formula (III) or the compound represented by formula (IV) obtained in the above step 1. In the formulas (V), (Ic), (Id), and (Ie), X is CH or CF, and n, R 2 respectively represent n and R in the formula (I). 2 is synonymous with.

[0160] [Step 3-1] The compound represented by formula (1c) can be prepared by reacting the compound represented by formula (V) with the compound represented by formula (iii) (X, R 2 respectively represent X and R in the formula (Ic). 2 and Et represents an ethyl group.) in a solvent in the presence of a base.

[0161] As the compound represented by formula (iii), various Horner-Wadsworth-Emmons reagents widely known to those skilled in the art can be used, such as ethyl 2-(diethoxyphosphoryl)acetate, ethyl 2-(diphenoxyphosphoryl)acetate, methyl 2-[bis(2,2,2-trifluoroethoxy)phosphoryl]acetate, etc. The amount of the compound represented by formula (iii) is preferably in the range of 1 to 10 equivalents based on the compound represented by formula (V).

[0162] Examples of the base in step 3-1 include sodium hydride, sodium tert-butoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, lithium hexamethyldisilazane, potassium hexamethyldisilazane, lithium diisopropylamide, and n-butyllithium. The amount of the base is preferably in the range of 1 to 10 equivalents based on the compound represented by formula (V).

[0163] The solvent in step 3-1 is not particularly limited as long as it does not significantly inhibit the reaction. Examples include tetrahydrofuran, diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, diethyl ether, 1,4-dioxane, acetonitrile, n-hexane, heptane, and toluene, and any one of these may be used alone or in combination of two or more.

[0164] The reaction temperature in step 3-1 is not particularly limited and is, for example, −100 to 60° C., preferably −78 to 20° C. The reaction time is also not particularly limited and is, for example, 10 minutes to 10 hours, preferably 30 minutes to 3 hours.

[0165] [Step 3-2] The compound represented by the formula (Id) can be synthesized by reacting the compound represented by the formula (Ic) with a reducing agent in a solvent.

[0166] Examples of the reducing agent in step 3-2 include sodium borohydride, lithium aluminum hydride, diisobutylaluminum hydride (DIBAL), lithium borohydride, lithium tri(sec-butyl)borohydride (L-Selectride), potassium tri(sec-butyl)borohydride (K-Selectride), and sodium triethylborohydride. The amount of the reducing agent is preferably in the range of 1 to 10 equivalents based on the compound represented by formula (Ic).

[0167] The solvent in step 3-2 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include tetrahydrofuran, 2-methyltetrahydrofuran, diethyl ether, 1,4-dioxane, acetonitrile, methanol, ethanol, n-hexane, heptane, dichloromethane, 1,2-dichloroethane, and toluene, and these may be used alone or in combination of two or more.

[0168] The reaction temperature in step 3-2 is selected, for example, in the range of −100 to 50° C., preferably in the range of −78 to 0° C. The reaction time is, for example, 15 minutes to 24 hours, preferably 30 minutes to 3 hours.

[0169] [Step 3-3] The compound represented by the formula (Ie) can be synthesized by carrying out an oxidation reaction of the compound represented by the formula (Id) in a solvent.

[0170] The oxidation reaction in Step 3-3 can be carried out by a known method or a method analogous thereto, and can be selected from, for example, Swern oxidation reaction, Parikh-Doering oxidation reaction, and oxidation reactions using reagents such as 2-iodoxybenzoic acid, Dess-Martin Periodinane reagent, manganese dioxide, tetrapropylammonium perruthenate (TPAP), TEMPO, etc. The amount of the reagent is preferably in the range of 2 to 100 equivalents based on the compound represented by formula (Id).

[0171] The solvent in step 3-3 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, dichloromethane, and chloroform, and any one of these may be used alone or in combination of two or more.

[0172] The reaction temperature in step 3-3 is selected, for example, in the range of 0 to 100° C., preferably in the range of 0 to 50° C. The reaction time is, for example, 1 to 24 hours, preferably 1 to 6 hours.

[0173]

[0174] By the method shown in the above step 4, for example, among the compounds represented by formula (I), compounds represented by formula (If) and compounds represented by formula (Ig) can be synthesized. In step 4, the compound represented by formula (V) indicates the compound represented by formula (III) or the compound represented by formula (IV) obtained in the above step 1. In the formulas (V), (If), and (Ig), X is CH, and n, R 1 respectively represent n and R in the formula (I). 1 In addition, L in formula (If), formula (iv), and formula (v)1 , L 2 , and L 3 each independently represents a functional group such as Cl, Br, I, an alkylstannyl group, a dihydroxyboryl group, a 4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl group, a trifluoromethylsulfoxy group, a triarylphosphinyl group, or a trialkylphosphinyl group.

[0175] [Step 4-1] The compound represented by formula (1f) can be prepared by reacting the compound represented by formula (V) with the compound represented by formula (iv) (X, L 1 respectively represent X and L in the formula (If). 1 The compound can be synthesized by reacting the compound (III) with the compound (III) in a solvent in the presence of a base.

[0176] Examples of the compound represented by formula (iv) include various Wittig reagents widely known to those skilled in the art, such as (methoxymethyl)triphenylphosphonium chloride, (bromomethyl)triphenylphosphonium bromide, and tributyl(cyanomethyl)phosphonium chloride, as well as bis(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)methane. The amount of the compound represented by formula (iv) is preferably in the range of 1 to 10 equivalents based on the compound represented by formula (V).

[0177] Examples of the base in step 4-1 include sodium hydride, sodium tert-butoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, lithium hexamethyldisilazane, sodium hexamethyldisilazane, potassium hexamethyldisilazane, lithium diisopropylamide, n-butyllithium, sec-butyllithium, and lithium 2,2,6,6-tetramethylpiperidinide. The amount of the base is preferably in the range of 1 to 10 equivalents based on the compound represented by formula (V).

[0178] The solvent in step 4-1 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include tetrahydrofuran, diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, diethyl ether, 1,4-dioxane, n-hexane, heptane, and toluene, and these may be used alone or in combination of two or more.

[0179] The reaction temperature in step 4-1 is not particularly limited and is, for example, −100 to 80° C., preferably −78 to 40° C. The reaction time is also not particularly limited and is, for example, 10 minutes to 24 hours, preferably 30 minutes to 6 hours.

[0180] [Step 4-2] The compound represented by formula (Ig) can be prepared by reacting the compound represented by formula (If), a metal catalyst, and the compound represented by formula (v) (R 1 represents R in the formula (Ig). 1 The compound can be synthesized by reacting the compound (III) with the compound (III) in a solvent in the presence of a base.

[0181] The amount of the compound represented by the formula (v) is preferably in the range of 1 to 20 equivalents based on the compound represented by the formula (If).

[0182] Examples of the metal catalyst in step 4-2 include palladium compounds such as tetrakis(triphenylphosphine)palladium(0), palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), dichlorobis(triethylphosphine)palladium(II), tris(dibenzylideneacetone)dipalladium(0), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride, and palladium(II) acetate; nickel compounds such as tetrakis(triphenylphosphine)nickel(0); rhodium compounds such as tris(triphenylphosphine)rhodium(III) chloride; cobalt compounds; copper compounds such as copper oxide and copper(I) iodide; and platinum compounds. The amount of the metal catalyst is preferably in the range of 0.01 to 2 equivalents based on the compound represented by formula (If).

[0183] Examples of the base in step 4-2 include sodium carbonate, sodium bicarbonate, potassium carbonate, cesium carbonate, sodium acetate, potassium acetate, sodium tert-butoxide, and potassium tert-butoxide. The amount of the base is preferably in the range of 1 to 30 equivalents based on the compound represented by formula (If).

[0184] The solvent in step 4-2 is not particularly limited as long as it does not significantly inhibit the reaction. Examples include tetrahydrofuran, 2-methyltetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, 1,4-dioxane, acetonitrile, ethanol, isopropanol, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, n-hexane, heptane, and toluene, and these may be used alone or in combination of two or more.

[0185] In the reaction of step 4-2, a reaction reagent such as 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 1,2-bis(diphenylphosphino)ethane, dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine, or dicyclohexyl(2',6'-diisopropyl-[1,1'-biphenyl]-2-yl)phosphine may be further added, if necessary, and the amount of the reaction reagent in this case is preferably in the range of 0.01 to 4 equivalents based on the compound represented by formula (If).

[0186] The reaction temperature in step 4-2 is selected, for example, in the range of −78 to 200° C., preferably 25 to 150° C. The reaction time is, for example, 15 minutes to 24 hours, preferably 30 minutes to 3 hours.

[0187]

[0188] For example, a compound represented by formula (Ih) among the compounds represented by formula (I) can be synthesized by the method shown in step 5. In step 5, the compound represented by formula (V) indicates the compound represented by formula (III) or the compound represented by formula (IV) obtained in step 1. In formulas (V) and (Ih), n, R 1 respectively represent n and R in the formula (I). 1 is synonymous with.

[0189] [Step 5-1] The compound represented by formula (1h) can be prepared by reacting the compound represented by formula (V) with an appropriate hydrazine (a compound represented by formula (vi): R 1 is R in the formula (Ih). 1 (same meaning as above) in a solvent in the presence of a base.

[0190] The hydrazine may be a hydrochloride salt. The amount of hydrazine and / or its hydrochloride is preferably in the range of 2 to 20 equivalents based on the compound represented by formula (V).

[0191] Examples of the base in step 5-1 include sodium carbonate, sodium bicarbonate, potassium carbonate, cesium carbonate, sodium acetate, potassium acetate, and potassium fluoride. The amount of the base is preferably in the range of 5 to 30 equivalents (preferably 2 to 30 equivalents) based on the compound represented by formula (V).

[0192] The solvent in step 5-1 is not particularly limited as long as it does not significantly inhibit the reaction. Examples thereof include dichloromethane, chloroform, methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, diethyl ether, N,N-dimethylformamide, N,N-dimethylacetamide, acetone, dimethyl sulfoxide, and toluene, and these may be used alone or in combination of two or more.

[0193] The reaction temperature in step 5-1 is not particularly limited and is, for example, −20 to 80° C., preferably 0 to 50° C. The reaction time is also not particularly limited and is, for example, 10 minutes to 24 hours, preferably 30 minutes to 5 hours.

[0194] Those skilled in the art will recognize that at any stage in the synthesis of the compound represented by formula (I), it is necessary or desirable to protect one or more labile groups in the molecule with a protecting group to prevent undesired side reactions. In particular, it is necessary or desirable to protect a hydroxy group. Examples of protecting groups used in the synthesis of the compound represented by formula (I) include groups described in, for example, Greene Wuts, PROTECTIVE GROUPS in ORGANIC SYNTHESIS THIRDEDITION, John Wiley & Sons, Inc. (methods for removing such groups are also described).

[0195] The compounds of the present invention have antiviral activity against coronaviruses. The antiviral activity of a compound can be confirmed, for example, by infecting cultured cells (e.g., VeroE6 cells) with coronaviruses (e.g., SARS-CoV-2), adding a compound diluted in a stepwise manner to the culture medium, culturing the cells, and measuring the amount of virus in the culture supernatant. More specifically, this can be confirmed by the method described in Test Example 1 below. In this case, for example, the concentration of the compound that reduces coronavirus replication by 50% is defined as the IC 50 When the value is less than 20 μM (e.g., 19.9 μM or less), preferably less than 5 μM (e.g., 4.9 μM or less), and more preferably less than 1 μM (e.g., 0.9 μM or less), it can be determined that the antibody has excellent antiviral activity against coronaviruses.

[0196] <Compositions, Treatment Methods> Because the compounds of the present invention have antiviral activity against coronaviruses as described above, compositions containing the compounds as active ingredients, preferably pharmaceutical compositions, can be used as antiviral agents or therapeutic agents for treating or preventing diseases or conditions associated with coronaviruses. Accordingly, the present invention also provides compositions containing the compounds of the present invention as active ingredients, as well as use of the compounds of the present invention for producing compositions for treating or preventing diseases or conditions associated with coronaviruses.

[0197] The present invention also provides a method for treating or preventing a disease or condition associated with coronavirus, which comprises administering the compound of the present invention directly or the composition containing the compound as an active ingredient to a subject (sometimes simply referred to herein as the "method of the present invention"). The subject can be a human or a non-human animal (preferably a mammal).

[0198] The coronavirus is preferably classified into the subfamily Orthocoronavirinae of the family Coronaviridae of the order Nidovirales, and more preferably into the genus Beta (β)coronavirus. Among these, the coronavirus is preferably at least one selected from the group consisting of human coronavirus (HCoV), severe acute respiratory syndrome coronavirus (SARS-CoV), novel coronavirus (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV), and more preferably novel coronavirus.

[0199] Diseases and conditions associated with coronaviruses include, but are not limited to, novel coronavirus disease (also known as coronavirus disease 2019 or COVID-19), severe acute respiratory syndrome, and Middle East respiratory syndrome.

[0200] The compound of the present invention and the composition of the present invention may be administered to the subject by either oral or parenteral administration route, and therefore the composition of the present invention can be formulated into a dosage form appropriate for the administration route.

[0201] Specific examples of the formulations include oral formulations such as tablets, pills, capsules, granules, powders, elixirs, suspensions, emulsions, and syrups; and parenteral formulations such as injections, inhalants, rectal administration agents, suppositories, lotions, sprays, ointments, creams, patches, and sustained-release formulations.

[0202] These various formulations can be produced by conventional methods using pharmaceutically acceptable additives and carriers, such as excipients, disintegrants, binders, lubricants, colorants, etc., which are commonly used in the field of pharmacy, as needed depending on the type of formulation. Therefore, the composition of the present invention may further contain these pharmaceutically acceptable additives and / or carriers.

[0203] In the composition of the present invention, the content of the compound of the present invention (the content of the compound represented by formula (I) or the content of a pharmaceutically acceptable salt thereof, or in the case of a mixture thereof, the total content thereof, calculated as a free form) cannot be generally determined because it is appropriately adjusted depending on the purpose of administration, the dosage form of the preparation, etc., but is usually 0.01 to 70% by mass, and preferably 0.05 to 50% by mass, calculated as a free form of the compound represented by formula (I), based on the total mass of the composition.

[0204] In the method of the present invention, the dose of the compound of the present invention (the dose of the compound represented by formula (I) or the dose of a pharmaceutically acceptable salt thereof, or the total dose in the case of a mixture thereof) is not generalizable because it is determined appropriately for each individual case taking into consideration the species, age, body weight, sex, difference in disease, severity of symptoms, etc. of the subject. For example, the dose per day for an adult human is 0.01 to 3000 mg, preferably 0.1 to 800 mg, calculated as the free form of the compound represented by formula (I), and can be administered once a day or in divided doses.

[0205] The present invention will be described in more detail below based on examples, but the present invention is not limited to the following examples.

[0206] <Production of Compounds> As examples, the production methods of the compounds of the present invention (compounds I-1 to III-5) and the1 The H-NMR spectra of each compound are shown below. 1 The H-NMR spectra are also shown below. However, the compounds of the present invention are not limited to these examples, and each Reference Example is also an illustration for specifically explaining the implementation of the present invention, and the scope of the present invention is not limited by these examples. It is self-evident that various applications, modifications, and corrections are possible within the scope of the present invention.

[0207] 1 H-NMR spectra were obtained using deuterated chloroform (CDCl 3 ), deuterated dimethyl sulfoxide (DMSO-d 6 ), heavy water (D 2 0) or deuterated methanol (CD 3 Measurements were performed using tetramethylsilane (TMS) as an internal standard in a solvent of dimethylformamide (DMSO). The chemical shift measurement results are shown as δ values ​​in ppm and J values ​​of the coupling constant in Hz. The abbreviations s, d, t, q, quartet, m, and br represent singlet, doublet, triplet, quartet, multiplet, and broad, respectively. Mass spectra (ESI-MS) were measured by electrospray ionization.

[0208] The abbreviations used in the following examples and reference examples have the following meanings: M: mol / L L-Selectride: lithium tri(sec-butyl)borohydride THF: tetrahydrofuran DMF: N,N-dimethylformamide DIPEA: N,N-diisopropylethylamine DMAP: N,N-dimethylpyridin-4-amine HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate tert: tertiary n: normal.

[0209] ​Preparation of 5-oxo-ivermectin B1a Ivermectin B1a (5.00 g, 5.71 mmol) was dissolved in dichloromethane (114 mL), and then manganese dioxide (24.9 g, 0.286 mol) was added, and the reaction solution was stirred at room temperature overnight. The reaction solution was filtered through Celite, and the solvent was distilled off from the obtained filtrate under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 5-oxo-ivermectin B1a (yield 3.87 g, 78%). 1 H-NMR(500MHz,CDCl3,δ):6.58-6.55(m,1H),5.92(td,J=10.9,2.3Hz,1H),5.82-5.68(m,2H),5.39( d,J=3.4Hz,1H),5.44-5.36(m,2H),5.01-4.96(m,1H),4.79-4.76(m,1H),4.75-4.69(m,2H),3.94(br s,1H),3.85(s,1H),3.84-3.79(m,1H),3.78-3.72(m,1H),3.71-3.65(m,1H),3.64-3.59(m,1H),3.58-3.55(m,1H), 3.50-3.43(m,2H),3.42(s,3H),3.41(s,3H),3.26-3.20(m,2H),3.16(t,J=9.2Hz,1H),2.56-2.48(m,1H),2.37-2.24 (m,4H),2.23-2.18(m,1H),1.88(d,J=1.7Hz,3H),1.90-1.85(m,1H),1.79-1.75(m,1H),1.67-1.64(m,1H),1.60-1.3 4(m,10H),1.29-1.23(m,8H),1.16(d,J=6.9Hz,3H),0.93(t,J=7.4Hz,3H),0.86(d,J=6.3Hz,3H),0.81-0.74(m,4H).

[0210] Preparation of 3,4α-dihydro-5-oxo-ivermectin B1a and 3,4β-dihydro-5-oxo-ivermectin B1a 5-oxo-ivermectin B1a (4.00 g, 4.58 mmol) was dissolved in THF (46 mL). Under an argon atmosphere, 1 M L-Selectride THF solution (5.95 mL, 5.95 mmol) was added at -78°C, and the mixture was stirred at the same temperature for 1 hour. An aqueous ammonium chloride solution was added to the reaction mixture to terminate the reaction, and the mixture was then warmed to room temperature. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 3,4β-dihydro-5-oxo-ivermectin B1a (yield 1.33 g, 33%) and 3,4α-dihydro-5-oxo-ivermectin B1a (yield 1.81 g, 45%).

[0211] (3,4β-dihydro-5-oxo-ivermectin B1a) 1 H-NMR(500MHz,CDCl3,δ):5.95-5.88(m,1H),5.81-5.71(m,1H),5.71-5.62(m,1H),5.43-5.35(m,2H) ,4.97-4.90(m,1H),4.76(d,J=2.9Hz,1H),4.67-4.56(m,2H),4.56-4.51(m,1H),4.01(s,1H),3.93(br s,1H),3.85-3.80(m,1H),3.79-3.74(m,1H),3.70-3.59(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.43-3. 41(s,3H),3.26-3.14(m,3H),3.11-3.02(m,1H),2.66-2.46(m,3H),2.36-2.19(m,5H),1.86-1.81(m,1H) ,1.76-1.72(m,1H),1.70-1.62(m,3H),1.59-1.36(m,10H),1.29-1.22(m,8H),1.15(d,J=6.9Hz,3H),1.1 1(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.80-0.75(m,4H);MSm / z897.4962[M+Na]+ 。

[0212] (3,4α-ジヒドロ-5-オキソ-イベルメクチンB1a) 1 H-NMR(500MHz,CDCl3,δ):5.85-5.81(m,1H),5.79-5.72(m,1H),5.70-5.63(m,1H),5.45-5.35(m,2H),4.98-4.91(m,1H),4.78-4.71(m,2H),4.68-4.59(m,2H),4.11(d,J=7.4Hz,1H),3.93(br s,1H),3.86-3.79(m,1H),3.76(s,1H),3.79-3.72(m,1H),3.71-3.65(m,1H),3.64-3.59(m,1H),3.51-3.45(m,1H),3.43(s,3H),3.42(s,3H),3.27-3.20(m,2H),3.16(t,J=9.2Hz,1H),3.05-3.00(m,1H),2.84-2.75(m,1H),2.53-2.46(m,1H),2.38-2.18(m,5H),2.07-2.01(m,2H),1.94-1.88(m,1H),1.77-1.72(m,1H),1.69-1.64(m,1H),1.60-1.36(m,10H),1.28-1.23(m,8H),1.15(d,J=6.9Hz,3H),1.10(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.85-0.82(m,3H),0.80-0.75(m,4H);MSm / z897.4957[M+Na] + 。

[0213] Preparation of Compound I-1 3,4β-Dihydro-5-oxo-ivermectin B1a (200 mg, 0.229 mmol) was dissolved in methanol (4.6 mL), and then sodium acetate (112 mg, 1.37 mmol) and hydroxylamine hydrochloride (95 mg, 1.37 mmol) were added successively, followed by stirring at room temperature for 1.5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-1 (yield 177 mg, 87%) as a mixture of isomers that are difficult to separate. The following 1 The H-NMR spectrum is the analytical data for the major isomers. 1 H-NMR(500MHz,CDCl3,δ):5.88-5.83(m,1H),5.76-5.65(m,2H),5.45-5.38(m,2H),4.95(d,J= 10.9Hz,1H),4.91-4.86(m,1H),4.77(d,J=4.0Hz,1H),4.68-4.57(m,3H),3.98(s,1H),3.93(br s,1H),3.86-3.74(m,2H),3.71-3.57(m,3H),3.52-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.20(m,2H) ),3.17(t,J=9.2Hz,1H),2.95-2.81(m,1H),2.52-2.45(m,1H),2.36-2.20(m,5H),1.99-1.93(m,1H),1.90(d d,J=12.0,5.2Hz,1H),1.79-1.73(m,1H),1.67(d,J=13.2Hz,1H),1.59-1.36(m,13H),1.30-1.21(m,10H),1 .15(d,J=6.9Hz,3H),0.92(t,J=7.5Hz,3H),0.86-0.80(m,4H),0.78(d,J=6.3Hz,3H);MSm / z912.5092[M+Na] + .

[0214] Preparation of Compound I-2 3,4α-Dihydro-5-oxo-ivermectin B1a (30.0 mg, 0.034 mmol) was dissolved in methanol (0.69 mL), and then sodium acetate (16.9 mg, 0.206 mmol) and hydroxylamine hydrochloride (14.9 mg, 0.206 mmol) were added sequentially, followed by stirring at room temperature for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-2 (yield 22.5 mg, 73%). 1 H-NMR(500MHz,CDCl3,δ):8.47(br s,1H),5.84(dt,J=10.6,2.4Hz,1H),5.77-5.65(m,2H),5.43-5.36(m,2H),5.02(s,1H) ,4.95(d,J=10.9Hz,1H),4.77(d,J=3.4Hz,1H),4.72-4.63(m,2H),4.61(s,1H),3.93(br s,1H),3.86-3.74(m,2H),3.70-3.60(m,2H),3.53-3.46(m,1H),3.44(s,3H),3.43(s ,4H),3.26-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.80(dd,J=12.9,3.2Hz,1H),2.75(br s,1H),2.68-2.58(m,1H),2.54-2.45(m,1H),2.36-2.30(m,2H),2.30-2 .19(m,2H),1.95-1.81(m,3H),1.77-1.70(m,1H),1.70-1.62(m,2H),1.5 9-1.37(m,10H),1.30-1.22(m,7H),1.16(t,J=6.3Hz,6H),0.92(t,J=7.5 Hz,3H),0.83(d,J=6.3Hz,3H),0.82-0.75(m,4H);MSm / z912.5093[M+Na] + .

[0215] Preparation of Compound I-3 and Compound I-4 3,4β-Dihydro-5-oxo-ivermectin B1a (250 mg, 0.286 mmol) was dissolved in methanol (5.7 mL), and then sodium acetate (70.3 mg, 0.857 mmol) and O-(prop-2-yn-1-yl)hydroxylamine hydrochloride (92.0 mg, 0.857 mmol) were added sequentially, followed by stirring at room temperature for 3 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) and high-performance liquid chromatography (acetonitrile / water = 85:15) to obtain Compound I-3 (yield 8.4 mg, 3.2%) and Compound I-4 (yield 2.8 mg, 1.1%), respectively. (Compound I-3) 1 H-NMR(500MHz,CDCl3,δ):5.86(dt,J=10.3,2.3Hz,1H),5.78-5.65(m,2H),5.46-5.35(m,2 H),4.95(d,J=11.5Hz,1H),4.83(s,1H),4.77(d,J=3.4Hz,1H),4.71-4.58(m,5H),3.93(br s,1H),3.87-3.72(m,2H),3.71-3.57(m,2H),3.52-3.45(m,1H),3.45(s,3H),3.43(s,3H) ),3.28-3.20(m,2H),3.17(t,J=9.2Hz,1H),2.94-2.86(m,2H),2.58-2.46(m,2H),2.43( t,J=2,6Hz,1H),2.39-2.19(m,5H),1.93-1.86(m,1H),1.79-1.71(m,1H),1.70-1.35(m, 16H),1.32-1.23(m,8H),1.16(d,J=6.9Hz,3H),0.92(t,J=7.5Hz,3H),0.89-0.76(m,7H). (Compound I-4) 1H-NMR(500MHz,CDCl3,δ):5.86(dt,J=10.4,2.5Hz,1H),5.78-5.63(m,2H),5.46-5.37(m,2H),4.95(d,J= 12.6Hz,1H),4.77(d,J=3.4Hz,1H),4.71(dd,J=2.3,1.2Hz,2H),4.69-4.56(m,3H),4.00(s,1H),3.94(br s,1H),3.87-3.73(m,2H),3.72-3.60(m,2H),3.56-3.46(m,2H),3.45(s,3H),3.43(s,3H),3.29-3. 20(m,2H),3.17(t,J=9.2Hz,1H),2.90(dd,J=13.8,2.9Hz,1H),2.53-2.47(m,2H),2.46-2.45(m,1H) ,2.38-2.31(m,2H),2.31-2.20(m,3H),1.93-1.87(m,1H),1.80-1.73(m,1H),1.69-1.64(m,1H),1.6 1-1.35(m,15H),1.31-1.21(m,8H),1.16(d,J=6.9Hz,3H),0.95-0.81(m,7H),0.78(d,J=5.7Hz,3H).

[0216] Preparation of Compound I-5 Compound I-5 (yield 41.9 mg, 83%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(prop-2-yn-1-yl)hydroxyamine hydrochloride was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.88-5.78(m,1H),5.77-5.63(m,2H),5.47-5.32(m,2H),5.00-4.87(m,2H),4.76(br d,J=3.44Hz,1H),4.73-4.56(m,5H),3.93(br s,1H),3.87-3.71(m,2H),3.70-3.56(m,2H),3.43(d,J=9.4Hz,6H),3.30 -3.12(m,3H),2.79(dd,J=12.60,2.86Hz,1H),2.68-2.58(m,1H),2.55(br s,1H),2.53-2.44(m,1H),2.43-2.38(m,1H),2.37-2.16(m,5H),1.96-1.78(m,4H),1.77-1.70(m,1H), 1.68-1.63(m,2H),1.58-1.36(m,15H),1.30-1.11(m,15H),0.94-0.74(m,13H);MSm / z950.6138[M+Na] + .

[0217] Preparation of Compound I-6

[0123] Compound I-6 (yield 22.8 mg, 68%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1], except that O-benzylhydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.36-7.27(m,5H),5.89-5.82(m,1H),5.78-5.63(m,2H),5.45-5.38(m,2H),5.20-5. 07(m,2H),4.95(d,J=9.2Hz,1H),4.90(s,0.5H),4.78-4.75(m,1H),4.71-4.54(m,3H),4.00(s,0.5H),3.93(br s,1H),3.86-3.74(m,2H),3.71-3.59(m,2H),3.60-3.45(m,2H),3.45-3.43(m,3H) ,3.42(s,3H),3.26-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.92-2.83(m,1H),2.56(br s,1H),2.53-2.46(m,1H),2.37-2.19(m,5H),1.93-1.85(m,1H),1.78-1.71(m,1H),1.68-1.60(m,2H),1.59-1.38(m,12H),1.3 1-1.21(m,10H),1.15(t,J=7.2Hz,3H),0.92(t,J=7.2Hz,3H),0.85-0.80(m,4H),0.78(d,J=5.7Hz,3H);MSm / z1002.6900[M+Na] + .

[0218] Preparation of Compound I-7 Compound I-7 (yield 25.2 mg, 75%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-benzylhydroxylamine hydrochloride was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.37-7.24(m,5H),5.83(dt,J=10.6,2.4Hz,1H),5.76-5.62(m,2H),5.44-5.35(m,2H),5.13(s,2H),4.99(s,1H),4.94(d,J=10.9Hz,1H),4.76(d,J=3.4Hz,1H),4.68-4.60(m,2H),4.58(s,1H),3.93(br s,1H),3.86-3.74(m,2H),3.70-3.60(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.43(s,3H),3.26-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.79(dd,J=12.6,3.4Hz,1H),2.64-2.56(m,1H),2.55-2.45(m,2H),2.36-2.19(m,4H),1.94-1.80(m,3H),1.78-1.70(m,1H),1.69-1.61(m,1H),1.59-1.37(m,12H),1.29-1.24(m,7H),1.18-1.13(m,6H),0.92(t,J=7.5Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z1002.5565[M+Na] + 。

[0219] Reference Example 1 (1) Preparation of 2-phenoxyisoindoline-1,3-dione 2-phenoxyisoindoline-1,3-dione (yield 1.47 g, 61%) was obtained with reference to the synthesis method described in Journal of Medicinal Chemistry (2005), 48(5), 1576-1587. (2) Preparation of O-phenylhydroxylamine hydrochloride 2-phenoxyisoindoline-1,3-dione (1.47 g, 6.14 mmol) obtained in Reference Example 1-(1) was dissolved in a mixed solvent of chloroform (27 mL) and methanol (3 mL), and then hydrazine monohydrate (1.14 mL, 18.4 mmol) was added and the mixture was stirred at room temperature for 14 hours. The suspension was filtered, and then 4 M hydrogen chloride in 1,4-dioxane (1.84 mL, 7.37 mmol) was added to the filtrate, followed by stirring at room temperature for 30 minutes. After the solvent was removed under reduced pressure, ether was added, and the suspension was filtered to obtain O-phenylhydroxylamine hydrochloride (yield 0.819 g, 92%). 1 H-NMR (500MHz, DMSO-d6, δ): 7.41-7.28 (m, 2H), 7.16-7.11 (m, 2H), 7.02 (t, J = 7.5Hz, 1H).

[0220] Compound I-8: Compound I-8 (yield 30.0 mg, 91%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Production of Compound I-1] except that O-phenylhydroxylamine hydrochloride obtained in Reference Example 1-(2) was used instead of hydroxylamine hydrochloride. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):7.31-7.27(m,2H),7.21-7.14(m,2H),7.02(t,J=7.5Hz,1H),5.89(dt,J=10.2,2.4Hz,1H),5.7 9-5.67(m,2H),5.47-5.39(m,2H),4.96(d,J=10.9Hz,1H),4.77(d,J=4.0Hz,1H),4.76-4.61(m,3H),4.15(s,1H),3.94(br s,1H),3.87-3.74(m,3H),3.72-3.61(m,2H),3.53-3.46(m,1H),3.45(s,3H),3.43-3.40(m,3H),3.28 -3.19(m,2H),3.17(t,J=9.2Hz,1H),2.98-2.93(m,1H),2.61-2.47(m,2H),2.44-2.19(m,5H),1.92(dd ,J=12.0,3.4Hz,1H),1.80-1.74(m,1H),1.71-1.61(m,4H),1.59-1.31(m,14H),1.30-1.24(m,7H),1.1 9-1.14(m,3H),0.93(t,J=7.5Hz,3H),0.88-0.80(m,4H),0.79(d,J=5.7Hz,3H);MSm / z988.5402[M+Na] + .

[0221] Preparation of Compound I-9 Compound I-9 (yield 22.6 mg, 68%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-phenylhydroxylamine hydrochloride obtained in Reference Example 1-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.29-7.25(m,2H),7.20-7.14(m,2H),7.02-6.97(m,1H),5.93-5.83(m,1H),5.80-5.66(m,2H), 5.46-5.36(m,2H),5.15(s,1H),4.95(d,J=9.7Hz,1H),4.77(d,J=3.4Hz,1H),4.72(d,J=2.3Hz,1H),4.65(s,1H),3.94(br s,1H),3.87-3.74(m,2H),3.71-3.60(m,2H),3.53-3.41(m,6H),3.30-3.20(m,2H),3.17(t,J=9.2Hz,1H),2.86(dd,J=12.6,3.4H z,1H),2.82-2.73(m,1H),2.57-2.46(m,2H),2.37-2.19(m,4H),2.03-1.87(m,3H),1.82-1.71(m,1H),1.69-1.64(m,1H),1.62(br s,1H),1.59-1.38(m,13H),1.31(d,J=6.3Hz,3H),1.29-1.23(m,7H),1.16(d,J=6.9Hz,3H ),0.93(t,J=7.2Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z988.5415[M+Na] + .

[0222] Preparation of Compound I-10 Compound I-10 (yield 27.8 mg, 87%) was obtained in the same manner as in [Preparation of Compound I-1] except that 2-(aminooxy)ethan-1-ol was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.88-5.82(m,1H),5.78-5.64(m,2H),5.39(m,2H),4.94(d,J=10.9Hz,1H),4.85(s,0. 5H),4.76(d,J=3.4Hz,1H),4.73-4.54(m,3H),4.22(t,J=4.6Hz,1H),4.20-4.16(m,1H),3.96(s,0.5H),3.93(br s,1H),3.89-3.73(m,4H),3.65(d,J=4.6Hz,2H),3.48(d,J=1.7Hz,2H),3.44(s,3H),3.42(s,3H) ),3.28-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.91-2.74(m,2H),2.49(d,J=2.3Hz,1H),2.38-2.1 6(m,6H),1.93-1.87(m,1H),1.79-1.71(m,1H),1.70-1.62(m,2H),1.59-1.45(m,12H),1.30-1. 20(m,10H),1.15(d,J=6.9Hz,3H),0.95-0.89(m,3H),0.86-0.73(m,7H);MSm / z956.6654[M+Na] + .

[0223] Preparation of Compound I-11 Compound I-11 (yield 177 mg, 87%) was obtained in the same manner as in [Preparation of Compound I-2] except that 2-(aminooxy)ethan-1-ol was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.83(dt,J=10.7,2.1Hz,1H),5.78-5.64(m,2H),5.44-5.35(m,2H),4.97(s, 1H),4.95(d,J=11.5Hz,1H),4.76(d,J=3.44Hz,1H),4.72-4.61(m,2H),4.20(t,J=4.3Hz,2H),3.93(br s,1H),3.88-3.74(m,4H),3.70-3.60(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H), 3.16(t,J=9.2Hz,1H),2.79(dd,J=12.3,3.7Hz,1H),2.63(dt,J=11.9,5.8Hz,1H),2.54-2.45(m,1H),2.38-2.1 7(m,7H),1.95-1.82(m,3H),1.78-1.70(m,1H),1.66(d,J=12.6Hz,1H),1.59-1.36(m,12H),1.29-1.23(m,7H) ,1.16(t,J=6.6Hz,6H),0.92(t,J=7.2Hz,3H),0.84(d,J=6.3Hz,3H),0.81-0.74(m,4H);MSm / z956.5364[M+Na] + .

[0224] Reference Example 2 (1) Preparation of 2,2,2-trichloroethyl(2-hydroxyethyl)carbamate 2-Aminoethan-1-ol (0.611 g, 10.0 mmol) and triethylamine (2.09 mL, 15.0 mmol) were dissolved in methylene chloride (50 mL) and the solution was ice-cooled to 0°C. 2,2,2-trichloroethyl carbonochloridate (1.48 mL, 11.0 mmol) was then added dropwise, and the mixture was stirred at the same temperature for 1 hour. The temperature was raised to room temperature, and the mixture was stirred for an additional 17 hours. Water was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2,2,2-trichloroethyl(2-hydroxyethyl)carbamate (yield 1.85 g, 78%). 1H-NMR (500 MHz, CDCl3, δ): 4.74 (s, 2H), 3.78 (q, J = 5.2 Hz, 2H), 3.42 (q, J = 4.6 Hz, 2H), 1.81 (t, J = 5.2 Hz, 1H). (2) Preparation of 2,2,2-trichloroethyl (2-((1,3-dioxoindolin-2-yl)oxy)ethyl)carbamate 2-Hydroxyisoindoline-1,3-dione (1.25 g, 7.67 mmol), 2,2,2-trichloroethyl (2-hydroxyethyl)carbamate (1.85 g, 7.82 mmol) obtained in Reference Example 2-(1), and triphenylphosphine (4.10 g, 15.7 mmol) were dissolved in THF (39 mL) and the solution was ice-cooled to 0°C. Thereafter, a 2.2 M solution of diethyl (E)-diazene-1,2-dicarboxylate in toluene (7.1 ml, 15.7 mmol) was added dropwise, and the mixture was stirred at room temperature for 14 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2,2,2-trichloroethyl (2-((1,3-dioxoindolin-2-yl)oxy)ethyl)carbamate (yield: 1.32 g, 44%). 1 H-NMR (500 MHz, CDCl3, δ): 7.89-7.84 (m, 2H), 7.81-7.77 (m, 2H), 6.20 (br s, 1H), 4.77 (s, 2H), 4.30 (t, J = 4.6 Hz, 2H), 3.56 (q, J = 4.0 Hz, 2H). (3) Preparation of 2,2,2-trichloroethyl (2-(aminooxy)ethyl)carbamate 2,2,2-trichloroethyl (2-((1,3-dioxoindolin-2-yl)oxy)ethyl)carbamate (1.32 g, 3.46 mmol) obtained in Reference Example 2-(2) was dissolved in methylene chloride (34.6 mL), and then hydrazine monohydrate (0.202 mL, 4.15 mmol) was added and the mixture was stirred at room temperature for 13 hours. The suspension was filtered, and the solvent was distilled off under reduced pressure. The residue was then purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2,2,2-trichloroethyl (2-(aminooxy)ethyl)carbamate (yield 1.02 g, quantitative).1 H-NMR (500MHz, CDCl3, δ): 4.73 (s, 2H), 3.76 (t, J = 4.6Hz, 2H), 3.48 (q, J = 4.6Hz, 2H).

[0225] Preparation of Compound I-12

[0122] Compound I-12 (yield 37.3 mg, 74%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that 2,2,2-trichloroethyl (2-(aminooxy)ethyl)carbamate obtained in Reference Example 2-(3) was used instead of hydroxyamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.90-5.80(m,1H),5.80-5.64(m,2H),5.48-5.31(m ,2H),4.98-4.91(m,1H),4.82(s,0.6H),4.78-4.59(m,6H),4.42-4.26(m,1H), 4.26-4.14(m,4H),3.96(s,0.4H),3.94-3.89(m,1H),3.86-3.72(m,2H),3.70 -3.58(m,2H),3.56-3.45(m,3H),3.44(s,3H),3.43-3.39(m,3H),3.30-3.19(m ,2H),3.16(t,J=9.2Hz,1H),2.91-2.83(m,1H),2.60(s,1H),2.53-2.45(m,1H ),2.38-2.19(m,4H),1.90(dd,J=12.0,5.2Hz,1H),1.78-1.71(m,3H),1.70-1. 61(m,2H),1.59-1.37(m,12H),1.35-1.21(m,8H),1.18-1.14(m,3H),0.92(t,J =7.5Hz,3H),0.83(d,J=6.9Hz,3H),0.81-0.74(m,4H);MSm / z1129.4558[M+Na] + .

[0226] Preparation of Compound I-13 Compound I-13 (yield 35.3 mg, 93%) was obtained in the same manner as in [Preparation of Compound I-2] except that 2,2,2-trichloroethyl (2-(aminooxy)ethyl)carbamate obtained in Reference Example 2-(3) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.87-5.62(m,3H),5.48-5.30(m,2H),4.97-4.91(m,1. 5H),4.80-4.65(m,5.5H),4.31-4.15(m,3H),3.96-3.88(m,1H),3.86-3.72(m,2H) ,3.70-3.55(m,2H),3.54-3.44(m,4H),3.44(s,3H),3.42(s,3H),3.29-3.19(m,2H ),3.16(t,J=9.2Hz,1H),2.79(dd,J=12.0,4.0Hz,1H),2.68-2.59(m,1H),2.57(br s,1H),2.54-2.42(m,1H),2.38-2.18(m,4H),1.94-1.82(m,3H),1.77-1.62(m,4H),1.59-1.37(m,12H), 1.34-1.20(m,6H),1.20-1.07(m,6H),0.92(t,J=7.5Hz,3H),0.89-0.74(m,7H);MSm / z1129.4570[M+Na] + .

[0227] Reference Example 3 (1) Preparation of 2-(3,3,3-trifluoropropoxy)isoindoline-1,3-dione 2-Hydroxyisoindoline-1,3-dione (0.500 g, 3.07 mmol), 3,3,3-trifluoropropan-1-ol (0.269 mL, 3.07 mmol), and triphenylphosphine (0.965 g, 3.68 mmol) were dissolved in THF (15.4 mL) and the solution was ice-cooled to 0°C. Thereafter, a 2.2 M solution of diethyl (E)-diazene-1,2-dicarboxylate in toluene (1.67 mL, 3.68 mmol) was added dropwise, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform / methanol system) to obtain 2-(3,3,3-trifluoropropoxy)isoindoline-1,3-dione (yield: 0.630 g, 79%). 1H-NMR (500 MHz, CDCl3, δ): 7.88-7.83 (m, 2H), 7.80-7.76 (m, 2H), 4.43 (t, J = 6.9 Hz, 2H), 2.76-2.66 (m, 2H). (2) Preparation of O-(3,3,3-trifluoropropyl)hydroxylamine hydrochloride. 2-(3,3,3-Trifluoropropoxy)isoindoline-1,3-dione (0.630 g, 2.43 mmol) obtained in Reference Example 3-(1) was dissolved in ethanol (24.3 mL), and then hydrazine monohydrate (0.163 mL, 2.67 mmol) was added and the mixture was stirred at 65°C for 1 hour. The suspension was filtered, and then a 4 M solution of hydrogen chloride in 1,4-dioxane (1.22 mL, 4.86 mmol) was added to the filtrate, followed by stirring at room temperature for 15 minutes. The solvent was distilled off under reduced pressure to obtain O-(3,3,3-trifluoropropyl)hydroxylamine hydrochloride (yield: 0.339 g, 84%). 1 H-NMR (500MHz, DMSO-d6, δ): 4.14 (t, J=5.7Hz, 2H), 2.82-2.66 (m, 2H).

[0228] Preparation of Compound I-14

[0123] Compound I-14 (yield 16.1 mg, 48%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that O-(3,3,3-trifluoropropyl)hydroxylamine hydrochloride obtained in Reference Example 3-(2) was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.85(dt,J=10.4,2.8Hz,1H),5.77-5.66(m,2H),5.45-5.37(m,2H),4.95( d,J=10.9Hz,1H),4.78-4.75(m,1.6H),4.71-4.55(m,3H),4.33-4.23(m,2H),3.96(s,0.4H),3.93(br s,1H),3.86-3.74(m,2H),3.71-3.60(m,2H),3.52-3.47(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2 H),3.16(t,J=9.2Hz,1H),2.92-2.81(m,2H),2.56-2.44(m,4H),2.37-2.20(m,5H),1.90(dd,J=11.7,4.9Hz ,1H),1.78-1.72(m,1H),1.69-1.60(m,3H),1.59-1.38(m,12H),1.32-1.22(m,8H),1.20(d,J=7.5Hz,1H), 1.19-1.14(m,3H),0.92(t,J=7.2Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.76(m,4H);MSm / z1008.5277[M+Na] + .

[0229] Preparation of Compound I-15 Compound I-15 (yield 21.4 mg, 63%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3,3,3-trifluoropropyl)hydroxylamine hydrochloride obtained in Reference Example 3-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.85-5.80(m,1H),5.77-5.63(m,2H),5.44-5.34(m,2H),4.94(d,J=10.9Hz,1H ),4.88(s,1H),4.76(d,J=2.9Hz,1H),4.65(t,J=2.0Hz,2H),4.60(s,1H),4.29(t,J=6.9Hz,2H),3.93(br s,1H),3.85-3.74(m,2H),3.70-3.60(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H), 2.78(dd,J=12.6,3.4Hz,1H),2.65-2.56(m,1H),2.54-2.45(m,4H),2.36-2.30(m,2H),2.29-2.20(m,2H),1.94-1.81(m,3H),1.73(br s,1H),1.69-1.63(m,1H),1.60(br s,1H),1.59-1.38(m,12H),1.30-1.22(m,7H),1.16(t,J=6.9Hz,5H),0.92(t,J =7.5Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.75(m,4H);MSm / z1008.5268[M+Na] + .

[0230] Reference Example 4 (1) Preparation of 2-(2,2,2-trifluoroethoxy)isoindoline-1,3-dione 2-Hydroxyisoindoline-1,3-dione (1.63 g, 10.0 mmol) was dissolved in methylene chloride (33.3 mL), and then DIPEA (1.91 mL, 11.0 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (1.58 mL, 11.0 mmol) were added sequentially, followed by stirring at room temperature for 16 hours. Water was added to the reaction solution, and the mixture was extracted with methylene chloride. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by short-pad silica gel column chromatography to obtain 2-(2,2,2-trifluoroethoxy)isoindoline-1,3-dione (yield 1.88 g, 77%). 1H-NMR (500 MHz, CDCl3, δ): 7.91-7.85 (m, 2H), 7.82-7.77 (m, 2H), 4.56 (q, J=8.0 Hz, 2H). (2) Preparation of O-(2,2,2-trifluoroethyl)hydroxylamine hydrochloride. 2-(2,2,2-Trifluoroethoxy)isoindoline-1,3-dione (1.88 g, 7.67 mmol) obtained in Reference Example 4-(1) was dissolved in ethanol (76.7 mL), and then hydrazine monohydrate (0.513 mL, 8.44 mmol) was added and the mixture was stirred at 65°C for 30 minutes. The suspension was filtered, and then a 4 M solution of hydrogen chloride in 1,4-dioxane (3.84 mL, 15.3 mmol) was added to the filtrate, followed by stirring at room temperature for 15 minutes. The solvent was distilled off under reduced pressure to obtain O-(2,2,2-trifluoroethyl)hydroxylamine hydrochloride (yield: 1.16 g, 99%). 1 H-NMR (500MHz, DMSO-d6, δ): 4.37 (q, J=9.2Hz, 2H).

[0231] Preparation of Compound I-16

[0123] Compound I-16 (yield 11.3 mg, 34%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that O-(2,2,2-trifluoroethyl)hydroxylamine hydrochloride obtained in Reference Example 4-(2) was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.91-5.82(m,1H),5.79-5.64(m,2H),5.46-5.37(m,2H),4.95(d,J=10.9Hz,1 H),4.81(s,0.6H),4.77(d,J=3.4Hz,1H),4.73-4.56(m,3H),4.51-4.39(m,2H),3.97(s,0.4H),3.94(br s,1H),3.87-3.73(m,2H),3.71-3.57(m,2H),3.52-3.45(m,1H),3.45(s,3H),3.43(s,3H),3.27-3 .20(m,2H),3.17(t,J=9.2Hz,1H),2.92-2.83(m,1H),2.54-2.46(m,2H),2.38-2.17(m,5H),1.95-1 .85(m,1H),1.79-1.71(m,1H),1.70-1.61(m,1H),1.61-1.38(m,14H),1.31-1.23(m,10H),1.20-1 .12(m,3H),0.92(t,J=7.5Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.76(m,4H);MSm / z994.5120[M+Na] + .

[0232] Preparation of Compound I-17 Compound I-17 (yield 14.9 mg, 45%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(2,2,2-trifluoroethyl)hydroxylamine hydrochloride obtained in Reference Example 4-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.91-5.82(m,1H),5.80-5.63(m,2H),5.44-5.35(m,2H),4.94(d,J=10.9Hz,1H ),4.92(s,1H),4.77(d,J=3.4Hz,1H),4.67(d,J=1.7Hz,2H),4.62(s,1H),4.44(q,J=8.6Hz,2H),3.93(br s,1H),3.86-3.73(m,3H),3.71-3.58(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.43-3.39(m,4H),3.2 6-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.79(dd,J=12.3,3.2Hz,1H),2.67-2.58(m,1H),2.55-2.45(m, 2H),2.38-2.19(m,4H),1.98-1.81(m,3H),1.77-1.70(m,1H),1.69-1.62(m,1H),1.60-1.37(m,8H),1 .31-1.21(m,9H),1.20-1.11(m,6H),0.92(t,J=7.5Hz,3H),0.90-0.74(m,7H);MSm / z994.5115[M+Na] + .

[0233] Reference Example 5 (1) Preparation of 2-(2-methoxyethoxy)isoindoline-1,3-dione 2-Hydroxyisoindoline-1,3-dione (1.63 g, 10.0 mmol) was dissolved in DMF (4.35 mL), and then 1-bromo-2-methoxyethane (4.76 mL, 50.0 mmol) and triethylamine (5.12 mL, 36.8 mmol) were added sequentially, followed by stirring at room temperature for 2 hours and then at 50°C for 2 hours. Water was added to the reaction solution, which was then filtered. The residue was then dissolved in ethyl acetate and washed with water and 1N hydrochloric acid. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 2-(2-methoxyethoxy)isoindoline-1,3-dione (yield: 1.20 g, 54%). 1H-NMR (500 MHz, CDCl3, δ): 7.88-7.82 (m, 2H), 7.78-7.71 (m, 2H), 4.40-4.33 (m, 2H), 3.79-3.73 (m, 2H), 3.40-3.38 (m, 3H). (2) Preparation of O-(2-methoxyethyl)hydroxylamine hydrochloride. 2-(2-Methoxyethoxy)isoindoline-1,3-dione (1.00 g, 4.52 mmol) obtained in Reference Example 5-(1) was dissolved in ethanol (45.2 mL), and then hydrazine monohydrate (0.302 mL, 4.97 mmol) was added and the mixture was stirred at 65°C for 1 hour. The suspension was filtered, and then a 4M solution of hydrogen chloride in 1,4-dioxane (2.26 mL, 9.04 mmol) was added to the filtrate and stirred at room temperature for 15 minutes. The solvent was distilled off under reduced pressure to obtain O-(2-methoxyethyl)hydroxylamine hydrochloride (yield: 0.338 g, 59%). 1 H-NMR (500MHz, DMSO-d6, δ): 10.7 (br s, 3H), 4.12-4.07 (m, 2H), 3.57-3.53 (m, 2H), 3.26 (s, 3H).

[0234] Preparation of Compound I-18

[0123] Compound I-18 (yield 14.8 mg, 46%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that O-(2-methoxyethyl)hydroxylamine hydrochloride obtained in Reference Example 5-(2) was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.89-5.81(m,1H),5.77-5.63(m,2H),5.45-5.38(m,2H),4.95(d,J=9.2Hz,1H),4.85(s, 0.4H),4.77(d,J=4.0Hz,1H),4.70-4.55(m,3H),4.26(t,J=4.9Hz,1H),4.24-4.17(m,1H),3.98(s,0.6H),3.93(br s,1H),3.86-3.74(m,2H),3.71-3.54(m,5H),3.52-3.52(m,1H),3.45(s,3H),3.43(s,3H),3.39-3.35(m ,3H),3.26-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.92-2.82(m,1H),2.52-2.46(m,2H),2.37-2.20(m,5H) ,1.93-1.87(m,1H),1.78-1.73(m,1H),1.70-1.64(m,1H),1.40(d,J=7.5Hz,1H),1.62-1.35(m,12H),1. 31-1.19(m,10H),1.16(d,J=6.9Hz,3H),0.92(t,J=7.5Hz,3H),0.90-0.76(m,7H);MSm / z970.5511[M+Na] + .

[0235] Preparation of Compound I-19 Compound I-19 (yield 20.0 mg, 62%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(2-methoxyethyl)hydroxylamine hydrochloride obtained in Reference Example 5-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.86-5.79(m,1H),5.75-5.65(m,2H),5.43-5.34(m,2H),4.96-4.92 (m,2H),4.76(d,J=3.4Hz,1H),4.69-4.60(m,2H),4.56(s,1H),4.23(t,J=5.2Hz,2H),3.93(br s,1H),3.86-3.74(m,2H),3.71-3.58(m,4H),3.52-3.45(m,1H),3.44(s,3H),3.43(s,3H),3.36(s,3H), 3.26-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.79(dd,J=12.6,3.4Hz,1H),2.64-2.56(m,1H),2.52-2.46(m ,2H),2.38-2.19(m,4H),1.95-1.79(m,3H),1.77-1.71(m,1H),1.68-1.62(m,2H),1.59-1.36(m,12H),1 .29-1.24(m,6H),1.16(t,J=7.2Hz,6H),0.92(t,J=7.5Hz,3H),0.86-0.76(m,7H);MSm / z970.5495[M+Na] + .

[0236] Reference Example 6 (1) Preparation of 2-(2-hydroxyethoxy)isoindoline-1,3-dione 2-Hydroxyisoindoline-1,3-dione (1.63 g, 10.0 mmol) was dissolved in acetonitrile (33.3 mL), and then 2-bromoethan-1-ol (1.43 mL, 20.0 mmol) and triethylamine (2.78 mL, 20 mmol) were added sequentially, followed by stirring at room temperature for 4 hours. Water was added to the reaction solution, which was then extracted with chloroform. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2-(2-hydroxyethoxy)isoindoline-1,3-dione (yield 1.80 g, 87%). 1H-NMR (500MHz, CDCl3, δ):7.90-7.85(m,2H),7.81-7.77(m,2H),4.32-4.29(m,2H),3.83-3.78(m,2H),3.46(t,J=7.2Hz,1H). (2) Preparation of 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)isoindoline-1,3-dione 2-(2-hydroxyethoxy)isoindoline-1,3-dione (0.449 g, 2.17 mmol) obtained in Reference Example 6-(1) was dissolved in DMF (21.7 mL), and then imidazole (0.885 g, 13.0 mmol), DMAP (26.5 mg, 0.217 mmol), and tert-butylchlorodimethylsilane (0.981 g, 6.51 mmol) were added sequentially, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, and the mixture was extracted with ether. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was then purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)isoindoline-1,3-dione (yield: 0.704 g, 100%). 1 H-NMR (500 MHz, CDCl3, δ): 7.85-7.80 (m, 2H), 7.75-7.71 (m, 2H), 4.32-4.29 (m, 2H), 4.01-3.98 (m, 2H), 3.46 (t, J=7.2 Hz, 1H), 0.81 (s, 9H), 0.01 (s, 3H). (3) Preparation of O-(2-((tert-butyldimethylsilyl)oxy)ethyl)hydroxylamine hydrochloride 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)isoindoline-1,3-dione (1.00 g, 3.11 mmol) obtained in Reference Example 6-(2) was dissolved in ethanol (31.1 mL), and then hydrazine monohydrate (0.189 mL, 3.11 mmol) was added and the mixture was stirred at 67°C for 30 minutes. The suspension was filtered, and then the residue was washed with ether. The solvent was evaporated under reduced pressure to obtain O-(2-((tert-butyldimethylsilyl)oxy)ethyl)hydroxylamine hydrochloride (yield: 0.577 g, 97%). 1H-NMR (500MHz, DMSO-d6, δ): 5.95 (br s, 2H), 3.73-3.67 (m, 2H), 3.57-3.53 (m, 2H), 0.86 (s, 9H), 0.01 (s, 3H).

[0237] Preparation of Compound I-20

[0123] Compound I-20 (yield 38.5 mg, 64%) was obtained as a mixture of isomers that were difficult to separate in a similar manner to [Preparation of Compound I-1] except that O-(2-((tert-butyldimethylsilyl)oxy)ethyl)hydroxylamine hydrochloride obtained in Reference Example 6-(3) was used instead of hydroxyamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.88-5.79(m,1H),5.78-5.63(m,2H),5.45-5.36(m,2H),4.99-4.93(m,1H),4.82(s,0. 4H),4.76(d,J=2.9Hz,1H),4.70-4.54(m,2.6H),4.54-4.51(m,0.4H),4.20-4.09(m,2H),3.97(s,0.6H),3.93(br s,1H),3.87-3.74(m,4H),3.71-3.59(m,2H),3.56-3.45(m,2H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,J= 9.2Hz,1H),2.91-2.81(m,1H),2.58-2.45(m,2H),2.36-2.27(m,3H),2.27-2.19(m,2H),1.92-1.85(m,1H),1.79-1.72(m ,1H),1.66(d,J=13.2Hz,1H),1.63-1.37(m,12H),1.31-1.23(m,8H),1.21(d,J=6.9Hz,2H),1.15(d,J=7.5Hz,3H),0.92( t,J=7.2Hz,3H),0.89-0.86(m,10H),0.86-0.80(m,4H),0.78(d,J=6.3Hz,3H),0.06-0.02(m,6H);MSm / z1070.6219[M+Na] + .

[0238] Preparation of Compound I-21

[0123] Compound I-21 (yield 51.3 mg, 86%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(2-((tert-butyldimethylsilyl)oxy)ethyl)hydroxylamine hydrochloride obtained in Reference Example 6-(3) was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.85-5.79(m,1H),5.76-5.63(m,2H),5.44-5.34(m ,2H),4.98-4.90(m,2H),4.79-4.73(m,1H),4.67-4.58(m,2H),4.53(s,1H),4 .18-4.09(m,2H),3.95-3.90(m,1H),3.86-3.74(m,4H),3.70-3.59(m,2H),3. 52-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,9.2Hz,1 H),2.81-2.73(m,1H),2.65-2.54(m,1H),2.55-2.45(m,3H),2.36-2.18(m,4H ),1.95-1.78(m,3H),1.77-1.71(m,1H),1.69-1.63(m,1H),1.62-1.36(m,12H) ,1.31-1.23(m,7H),1.18-1.14(m,5H),0.95-0.89(m,3H),0.89-0.86(m,9H), 0.84(d,J=6.9Hz,3H),0.81-0.74(m,4H),0.05(s,6H);MSm / z1070.6221[M+Na] + .

[0239] Preparation of Compound I-22: 3,4β-Dihydro-5-oxo-ivermectin B1a (30.0 mg, 0.034 mmol) was dissolved in methanol (0.69 mL), and then sodium acetate (16.9 mg, 0.206 mmol) and 2-(aminooxy)ethan-1-amine dihydrochloride (10.2 mg, 0.069 mmol) were added sequentially, followed by stirring at room temperature for 3 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform / methanol system) to obtain Compound I-22 (yield 21.3 mg, 67%) as a mixture of isomers that are difficult to separate. 1 H-NMR(500MHz,CD3OD,δ):5.92-5.84(m,2H),5.78-5.68(m,1H),5.34(d,J=3.4Hz,1H),5.28-5.18(m,1H), 5.13(t,J=7.5Hz,1H),4.80(d,J=2.9Hz,1H),4.76(s,0.6H),4.71-4.58(m,2H),4.31-4.18(m,2H),3.99(br s,1H),3.91-3.85(m,1H),3.84(s,0.4H),3.76-3.62(m,3H),3.42(s,3H),3.41(s,3H),3.27(d,J= 8.0Hz,1H),3.22-3.13(m,3H),3.03(t,J=9.2Hz,1H),2.95-2.87(m,1H),2.86-2.78(m,1H),2.68- 2.61(m,1H),2.38-2.24(m,5H),2.04-1.96(m,1H),1.89-1.82(m,1H),1.66-1.36(m,15H),1.34-1 .19(m,12H),1.17(d,J=6.9Hz,3H),0.97(t,J=7.5Hz,3H),0.91-0.78(m,7H);MSm / z933.5685[M+H] + .

[0240] Preparation of Compound I-23 3,4α-Dihydro-5-oxo-ivermectin B1a (30.0 mg, 0.034 mmol) was dissolved in methanol (0.69 mL), and then sodium acetate (16.9 mg, 0.206 mmol) and 2-(aminooxy)ethan-1-amine dihydrochloride (10.2 mg, 0.069 mmol) were added sequentially, followed by stirring at room temperature for 4 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform / methanol system) to obtain Compound I-23 (yield 19.8 mg, 74%). 1 H-NMR(500MHz,CDCl3,δ):5.89-5.81(m,1H),5.77-5.64(m,2H),5.39(d,J=3 .4Hz,1H),5.36-5.27(m,1H),5.02-4.92(m,2H),4.77(d,J=3.4Hz,1H),4.66 (s,2H),4.24-4.14(m,2H),3.98-3.74(m,5H),3.69-3.60(m,2H),3.52-3.45 (m,1H),3.43(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),3 .11-2.99(m,2H),2.77(dd,J=12.6,3.4Hz,1H),2.66-2.58(m,1H),2.54-2.4 6(m,1H),2.36-2.20(m,4H),1.99-1.81(m,5H),1.79-1.72(m,1H),1.68-1.6 1(m,1H),1.60-1.32(m,12H),1.29-1.23(m,7H),1.19-1.12(m,6H),0.92(t, J=7.2Hz,3H),0.83(d,J=6.9Hz,3H),0.81-0.75(m,4H);MSm / z933.5692[M+H] + .

[0241] Preparation of Compound I-24 and Compound I-25 Compound I-20 (33.0 mg, 0.031 mmol) was added to a 3% sulfuric acid methanol solution (0.63 mL) and stirred at room temperature for 2 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by preparative thin-layer chromatography (n-hexane / acetone = 2:1) to give Compound I-24 (yield 16.2 mg, 65%) and Compound I-25 (yield 4.5 mg, 22%), respectively. (Compound I-24) 1 H-NMR(500MHz,CDCl3,δ):5.85-5.79(m,1H),5.77-5.66(m,2H),5.44-5.35( m,1H),5.35-5.28(m,1H),4.70-4.55(m,3H),4.23(t,J=4.3Hz,2H),4.00(br s,1H),3.96(s,1H),3.91-3.83(m,2H),3.73-3.65(m,1H),3.56-3.49(m,1H),3.19(dd,J=9.2,1.7Hz,1H),2.88(dd,J=13.8,2.9Hz,1H),2.51(br s,1H),2.35-2.16(m,4H),1.94-1.84(m,1H),1.77-1.70(m,1H),1.70-1.63(m,1H),1.63-1.39(m,12H), 1.30-1.19(m,4H),1.17(d,J=6.9Hz,3H),0.95(t,J=7.2Hz,3H),0.85-0.77(m,7H);MSm / z646.3950[M+H] + . (Compound I-25) 1H-NMR(500MHz,CDCl3,δ):5.86(dt,J=10.5,2.5Hz,1H),5.78-5.64(m,2H),5.48-5.38(m,1H),4.99 -4.92(m,1H),4.81(d,J=3.4Hz,1H),4.68-4.55(m,3H),4.23(t,J=4.0Hz,2H),3.96(s,1H),3.95(br s,1H),3.90-3.81(m,3H),3.71-3.65(m,1H),3.60-3.52(m,2H),3.49(s,3H),3.22( dd,J=9.2,1.7Hz,1H),3.16(t,J=9.2Hz,1H),2.90(dd,J=13.8,2.9Hz,1H),2.55(br s,1H),2.51-2.45(m,1H),2.37-2.17(m,5H),1.92-1.85(m,1H),1.79-1.73(m,1H),1.70-1.64(m,1H),1.637-1.38(m,12H), 1.30-1.20(m,7H),1.15(d,J=6.9Hz,3H),0.95-0.90(m,3H),0.86-0.80(m,4H),0.79(d,J=5.7Hz,3H);MSm / z790.4744[M+H] + .

[0242] Preparation of Compounds I-26 and I-27 Compound I-26 (yield 22.5 mg, 62%) and Compound I-27 (yield 6.2 mg, 21%) were obtained in the same manner as in [Preparation of Compounds I-24 and I-25] except that Compound I-21 was used instead of Compound I-20. (Compound I-26) 1H-NMR (500 MHz, CDCl3, δ): 5.83 - 5.77 (m, 1H), 5.76 - 5.65 (m, 2H), 5.43 - 5.33 (m, 1H), 5.33 - 5.28 (m, 1H), 4.96 (s, 1H), 4.75 - 4.61 (m, 3H), 4.20 (t, J = 4.3 Hz, 2H), 4.00 (br s, 1H), 3.91 - 3.79 (m, 2H), 3.75 - 3.61 (m, 1H), 3.18 (dd, J = 9.2, 1.7 Hz, 1H), 2.77 (dd, J = 12.0, 3.4 Hz, 1H), 2.67 - 2.57 (m, 1H), 2.55 - 2.46 (m, 1H), 2.36 - 2.24 (m, 2H), 1.94 - 1.80 (m, 3H), 1.75 - 1.69 (m, 1H), 1.68 - 1.45 (m, 12H), 1.44 - 1.37 (m, 2H), 1.20 - 1.13 (m, 6H), 0.95 (t, J = 7.5 Hz, 3H), 0.86 - 0.77 (m, 7H); MS m / z 646.3956 [M + H] + 。(Compound I-27) 1 H-NMR (500 MHz, CDCl3, δ): 5.84 (dt, J = 1*.*3, 2*.*3 Hz, 1H), 5.78 - 5.63 (m, 2H), 5.46 - 5.35 (m, 1H), 4.97 (s, 1H), 4.94 (d, J = 9*.*7 Hz, 1H), 4.81 (d, J = 3*.*4 Hz, 1H), 4.71 - 4.61 (m, 3H), 4.20 (t, J = 4*.*3 Hz, 2H), 3.95 (br s, 1H), 3.90 - 3.80 (m, 3H), 3.71 - 3.63 (m, 1H), 3.60 - 3.53 (m, 1H), 3.48 (s, 3H), 3.21 (d, J = 7*.*5 Hz, 1H), 3.16 (t, J = 9*.*2 Hz, 1H), 2.79 (dd, J = 12*.*0, 3*.*4 Hz, 1H), 2.67 - 2.54 (m, 2H), 2.52 - 2.46 (m, 1H), 2.37 - 2.20 (m, 4H), 1.95 - 1.81 (m, 3H), 1.79 - 1.70 (m, 1H), 1.70 - 1.64 (m, 1H), 1.59 - 1.34 (m, 13H), 1.28 - 1.22 (m, 4H), 1.16 (d, J = 13*.*2 Hz, 3H), 0.95 - 0.89 (m, 3H), 0.86 - 0.75 (m, 7H); MS m / z 790.4737 [M + H] + 。

[0243] Preparation of Compound I-28 Compound I-1 (30 mg, 0.034 mmol) was dissolved in DMF (0.67 mL), and then potassium carbonate (9.32 mg, 0.067 mmol) and iodoethane (10.8 μL, 0.135 mmol) were added sequentially at room temperature, followed by stirring at 70°C for 4 hours. Potassium carbonate (9.32 mg, 0.067 mmol) and iodoethane (10.8 μL, 0.135 mmol) were added to the reaction solution at room temperature, followed by stirring at 70°C for 48 hours. An aqueous ammonium chloride solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain compound I-28 (yield 10.7 mg, 35%) as a mixture of isomers that are difficult to separate. 1 The H-NMR spectrum is the analytical data for the major isomers. 1 H-NMR(500MHz,CDCl3,δ):5.86(dt,J=10.2,2.4Hz,1H),5.78-5.65(m,2H),5.46-5.38(m,2H),4.95( d,J=10.9Hz,1H),4.77(d,J=3.4Hz,1H),4.69-4.55(m,3H),4.19-4.12(m,2H),3.98(s,1H),3.93(br s,1H),3.86-3.74(m,2H),3.72-3.59(m,2H),3.54-3.45(m,2H),3.44(s,3H),3.43(s,3H),3.2 7-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.93-2.87(m,1H),2.53-2.45(m,2H),2.38-2.19(m,5H), 1.93-1.87(m,1H),1.80-1.72(m,1H),1.67(d,J=12.6Hz,1H),1.61-1.38(m,12H),1.33-1.18(m ,14H),1.16(d,J=6.9Hz,3H),0.92(t,J=7.5Hz,3H),0.85-0.76(m,7H);MSm / z935.5800[M+NH4] + .

[0244] Preparation of Compound I-29 Compound I-29 (yield 12.2 mg, 39%) was obtained in the same manner as in [Preparation of Compound I-28] except that compound I-2 was used instead of compound I-1. 1 H-NMR(500MHz,CDCl3,δ):5.84(dt,J=10.3,2.3Hz,1H),5.77-5.65(m,2H),5.45-5.36(m,2H),4.98 -4.92(m,2H),4.77(d,J=3.4Hz,1H),4.66(d,J=2.9Hz,2H),4.62(s,1H),4.18-4.09(m,2H),3.93(br s,1H),3.87-3.72(m,2H),3.72-3.60(m,2H),3.53-3.45(m,2H),3.44(s,3H),3.44-3.41(m,3H),3.27-3.19 (m,2H),3.17(t,J=9.2Hz,1H),2.79(dd,J=12,6,2.9Hz,1H),2.65-2.55(m,1H),2.55-2.45(m,2H),2.37-2. 18(m,4H),1.95-1.79(m,2H),1.78-1.71(m,1H),1.69-1.64(m,1H),1.62-1.37(m,12H),1.30-1.22(m,10H) ,1.20-1.14(m,6H),0.92(t,J=7.2Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z935.5800[M+NH4] + .

[0245] Preparation of Compound I-30: Compound I-30 (yield 7.9 mg, 25%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-28] except that 1-bromopropane was used instead of iodoethane. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.86(dt,J=10.3,2.3Hz,1H),5.77-5.64(m,2H),5.46-5.37(m,2H),4.95( d,J=10.9Hz,1H),4.77(d,J=3.4Hz,1H),4.68-4.54(m,3H),4.10-4.00(m,2H),3.98(s,1H),3.93(br s,1H),3.87-3.73(m,2H),3.72-3.60(m,2H),3.53-3.45(m,1H),3.45(s,3H),3.43(s,3H),3.27-3.20(m,2 H),3.17(t,J=9.2Hz,1H),2.93-2.87(m,1H),2.53-2.46(m,2H),2.37-2.30(m,2H),2.30-2.17(m,3H),1.93 -1.87(m,1H),1.79-1.73(m,1H),1.71-1.63(m,3H),1.61-1.35(m,12H),1.32-1.23(m,7H),1.23-1.18(m,5 H),1.18-1.14(m,3H),0.96-0.89(m,6H),0.87-0.80(m,4H),0.78(d,J=6.3Hz,3H);MSm / z949.5981[M+NH4] + .

[0246] Preparation of Compound I-31 Compound I-31 (yield 9.6 mg, 31%) was obtained in the same manner as in [Preparation of Compound I-28] except that compound I-2 was used instead of compound I-1 and 1-bromopropane was used instead of iodoethane. 1H-NMR(500MHz,CDCl3,δ):5.86-5.80(m,1H),5.76-5.64(m,2H),5.44-5.36(m,2H),4.98-4.93( m,2H),4.77(d,J=3.4Hz,1H),4.66(d,J=2.3Hz,2H),4.60(s,1H),4.03(t,J=6.9Hz,2H),3.93(br s,1H),3.86-3.73(m,2H),3.71-3.60(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.43(s,3H),3.2 6-3.19(m,2H),3.17(t,J=9.2Hz,1H),2.79(dd,J=12.6,2.9Hz,1H),2.63-2.55(m,1H),2.54-2. 45(m,2H),2.38-2.18(m,4H),1.94-1.80(m,3H),1.78-1.70(m,1H),1.70-1.61(m,3H),1.59-1 .38(m,12H),1.29-1.24(m,6H),1.19-1.13(m,6H),0.94-0.76(m,14H);MSm / z949.5981[M+NH4] + .

[0247] Preparation of Compound I-32: Compound I-32 (yield 14.5 mg, 50%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that O-(3-methylphenethyl)hydroxylamine was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.16(t,J=7.1Hz,1H),7.04-6.99(m,3H)5.89-5.82(m,1H)5.78-5.64(m,2H)5.40(d,J=3.4Hz,2H)4. 99-4.92(m,1H)4.83(s,1H)4.77(d,J=3.4Hz,1H)4.70-4.59(m,2H)4.57(s,1H)4.24(t,J=7.5Hz,2H)4.14-4.09(m,1H)3.93(br s,1H)3.88-3.72(m,2H)3.71-3.61(m,2H)3.51-3.40(m,1H)3.45(s,3H)3.43(s,3H)3. 27-3.19(m,2H)3.17(t,J=9.2Hz,1H)2.96-2.84(m,4H)2.49(m,2H)2.39-2.18(m,5H)2 .31(s,3H),1.94-1.83(m,1H)1.79-1.72(m,1H)1.69-1.35(m,16H)1.33-1.22(m,9H)1 .16(d,J=6.9Hz,3H)0.92(t,J=7.2Hz,3H)0.88-0.73(m,7H);MSm / z1025.6306[M+NH4] + .

[0248] Preparation of Compound I-33: Compound I-33 (yield 21.5 mg, 56%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that O-(2-ethylbenzyl)hydroxylamine was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.35-7.30(m,1H)7.24-7.13(m,3H)5.89-5.81(m,1H)5.7 6-5.63(m,2H)5.46-5.38(m,2H)5.24-5.11(m,2H)4.98-4.93(m,1H)4.88-4.86(m,1 H)4.79-4.73(m,1H)4.69-4.52(m,3H)4.01(s,1H)3.95-3.91(m,1H)3.86-3.73(m,2 H)3.71-3.59(m,2H)3.57-3.45(m,2H)3.45-3.43(m,3H)3.43-3.41(m,3H)3.37-3.19 (m,2H)3.16(t,J=8.9Hz,1H)2.93-2.82(m,1H)2.73-2.63(m,2H)2.54-2.45(m,2H)2 .38-2.19(m,5H)1.93-1.86(m,1H)1.78-1.73(m,1H)1.69-1.66(m,1H),1.62-1.35(m ,8H),1.30-1.24(m,11H),1.23-1.18(m,5H),1.15(dd,J=10.3,6.9Hz,3H),0.92(t, J=7.5Hz,3H)0.83(dd,J=6.9,1.7Hz,3H)0.75-0.82(m,4H);MSm / z1025.6304[M+NH4] + .

[0249] Preparation of Compound I-34 Compound I-34 (yield 27.6 mg, 68%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3-fluorophenethyl)hydroxylamine was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.21(dt,J=7.9,6.0Hz,1H),6.96(d,J=7.4Hz,1H),6.9 3-6.85(m,2H),5.83(dt,J=10.3,2.3Hz,1H),5.76-5.65(m,2H),5.43-5.36(m,2H) ),4.95(d,J=9.7Hz,1H),4.91(s,1H),4.76(d,J=3.4Hz,1H),4.69-4.61(m,2H),4 .58(s,1H),4.27(t,J=6.9Hz,2H),4.14-4.11(m,1H),4.11-4.09(m,1H),3.93(br s,1H),3.86-3.80(m,1H),3.80-3.73(m,1H),3.70-3.60(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.45-3.41( m,1H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.97-2.92(m,2H),2.78(dd,J=12.6,3.4Hz,1H),2.64-2.56(m,1H),2.54- 2.45(m,2H),2.37-2.19(m,5H),1.91-1.79(m,1H),1.77-1.72(m,1H),1.68-1.59(m,1H),1.58-1.36(m,9H),1.29-1.23(m, 8H),1.16(dd,J=6.6,1.4Hz,6H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.3Hz,3H),0.82-0.74(m,4H);MSm / z1029.6066[M+NH4] + .

[0250] Preparation of Compound I-35: Compound I-35 (yield 26.1 mg, 66%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that O-(3-methylbenzyl)hydroxylamine was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.25-7.18(m,1H)7.16-7.05(m,3H)5.88-5.82(m,1H )5.77-5.64(m,2H)5.46-5.37(m,2H)5.15-5.04(m,2H)4.98-4.93(m,1H)4.90(s ,0.5H)4.78-4.75(m,1H)4.70-462(m,1H)4.61-4.56(m,1H)4.00(s,0.5H)3.94 -3.91(m,1H)3.86-3.79(m,1H)3.79-3.73(m,1H),3.72-3.52(m,2H),3.52-3.45 (m,1H),3.44(s,3H)3.42(s,3H)3.26-3.19(m,2H)3.16(t,J=9.2Hz,1H)2.93-2 .84(m,1H)2.53-2.45(m,1H)2.34(m,5H)2.30-2.19(m,3H)1.93-1.87(m,1H)1.8 0-1.72(m,1H)1.70-1.64(m,1H)1.64-1.35(m,12H)1.33-1.20(m,12H)1.15(t, J=7.4Hz,3H),0.92(t,J=7.2Hz,3H)0.90-0.75(m,9H);MSm / z1011.6149[M+NH4] + .

[0251] Preparation of Compound I-36 Compound I-36 (yield 14.0 mg, 35%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3-methylbenzyl)hydroxylamine was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.20(t,J=7.2Hz,1H),7.16-7.11(m,2H),7.08(d,J=7.4Hz,1H),5.84-5.79(m,1H),5. 75-5.63(m,2H),5.40(d,J=4.0Hz,2H),5.09(s,2H),4.99(s,1H),4.97-4.91(m,1H),4.78-4.73(m,1H),4.64(br s,2H),4.58(s,1H),3.92(br s,1H),3.87-3.73(m,2H),3.71-3.58(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.19(m,2H),3 .16(t,J=9.2Hz,1H),2.79(dd,J=12.9,3.2Hz,1H),2.66-2.56(m,1H),2.55-2.43(m,2H),2.36-2.33(m,2H),2. 33(s,3H),2.27-2.23(m,2H),1.94-1.79(m,3H),1.77-1.70(m,1H),1.68-1.62(m,1H),1.61-1.34(m,7H),1.32 -1.20(m,9H),1.16(dd,J=14.6,6.6Hz,6H),0.92(t,J=7.4Hz,3H),0.89-0.75(m,8H);MSm / z1011.6145[M+NH4] + .

[0252] Preparation of Compound I-37: Compound I-37 (yield 20.5 mg, 60%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that O-(3-fluorobenzyl)hydroxylamine was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.32-7.26(m,1H),7.13-7.01(m,2H),7.00-6.91(m,1H),5 .85(s,1H),5.71(m,2H),5.40(m,2H),5.13(d,J=5.7Hz,1H),5.10(d,J=8.0Hz,1H),4. 99-4.92(m,1H),4.89(s,0.5H),4.79-4.74(m,1H),4.71-4.63(m,1H),4.62-4.55(m,1 H),3.99(s,0.5H),3.94-3.92(m,1H),3.87-3.73(m,2H),3.71-3.53(m,2H),3.51-3.4 5(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.93-2 .88(m,1H),2.87-2.75(m,1H),2.53-2.45(m,2H),2.37-2.19(m,5H),1.93-1.79(m,2H ),1.79-1.71(m,1H),1.70-1.34(m,15H),1.32-1.17(m,11H),1.17-1.13(m,3H),0.92 (t,J=7.2Hz,3H),0.88(d,J=14.3Hz,1H),0.85-0.74(m,8H);MSm / z1015.5895[M+NH4] + .

[0253] Preparation of Compound I-38 Compound I-38 (yield 17.5 mg, 51%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3-fluorobenzyl)hydroxylamine was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.30-7.23(m,1H),7.09(d,J=8.0Hz,1H),7.07-7.03(m,1H),6.95(dt,J=8.3,2.3Hz,1H),5.83(td,J=10.2,2.4Hz,1H),5. 70(dd,J=13.7,9.7Hz,2H),5.40(d,J=2.9Hz,2H),5.11(s,2H),4.98(s,1H) ),4.97-4.91(m,1H),4.78-4.75(m,1H),4.65(s,2H),4.59(s,1H),3.93(br s,1H),3.86-3.73(m,2H),3.71-3.60(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.23( d,J=9.2Hz,2H),3.16(t,J=9.5Hz,1H),2.79(dd,J=12.6,3.4Hz,1H),2.65-2.57(m,1H),2.48(br s,2H),2.32(br s,2H),2.29-2.19(m,2H),1.89(d,J=12.6Hz,3H),1.77-1.72(m,1H),1.69-1.63(m,1H),1.60-1.34(m,11H),1.30-1.23 (m,7H),1.15(dd,J=6.9,4.0Hz,6H),0.92(t,J=7.4Hz,3H),0.84(m,4H),0.78(d,J=5.7Hz,4H);MSm / z1015.5908[M+NH4] + .

[0254] Preparation of Compound I-39 Compound I-39 (yield 20.0 mg, 53%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(2-ethylbenzyl)hydroxylamine was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.32(dd,J=1.1,7.4Hz,1H),7.23(dd,J=7.2,1.4Hz,1H ),7.20-7.17(m,1H),7.17-7.13(m,1H),5.81(td,J=10.3,2.3Hz,1H),5.75-5.63( m,J=13.2,9.7Hz,2H),5.39(d,J=4.0Hz,2H),5.21-5.12(m,2H),4.96(s,1H),4.9 5(d,J=4.0Hz,1H),4.76(d,J=3.4Hz,1H),4.67-4.57(m,2H),4.52(s,1H),3.92(br s,1H),3.86-3.73(m,2H),3.70-3.59(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,J=9.2Hz) ,1H),2.78(dd,J=12.6,2.6Hz,1H),2.69(q,J=7.4Hz,2H),2.64-2.57(m,1H),2.52-2.43(m,2H),2.37-2.30(m,2H),2.29-2.18 (m,2H),1.94-1.85(m,2H),1.84-1.78(m,1H),1.77-1.72(m,1H),1.68-1.62(m,1H),1.58-1.37(m,15H),1.22-1.22(m,1H),1. 31-1.12(m,19H),0.92(t,J=7.4Hz,3H),0.90-0.86(m,3H),0.83(d,J=6.3Hz,3H),0.82-0.74(m,4H);MSm / z1025.6302[M+NH4] + .

[0255] Preparation of Compound I-40 Compound I-40 (yield 23.2 mg, 75%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3-methylphenethyl)hydroxylamine was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.15(t,J=7.4Hz,1H),7.05-6.95(m,3H),5.83(td,J=10.3,2.3Hz,1H),4.94(s,2H),5.40(d,J=2.9Hz,2H),4.9 5(d,J=10.8Hz,1H),4.94(s,1H),4.77(d,J=3.4Hz,1H),4.69-4.62(m,2H),4.56(s,1H),4.28-4.24(m,2H),4.11(q,J=6.9Hz,1H),3.93(br s,1H),3.87-3.73(m,2H),3.71-3.60(m,2H),3.52-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.27-3. 19(m,2H),3.16(t,J=9.2Hz,1H),2.96-2.90(m,3H),2.82-2.77(m,1H),2.65-2.57(m,1H),2.49(br s,2H),2.37-2.19(m,5H),2.31(s,3H),1.95-1.87(m,2H),1.87-1.80(m,2H),1.77-1.72(m,1H),1.69-1.64(m,1H),1.60-1.3 5(m,15H),1.30-1.24(m,9H),1.17(dd,J=9.6,6.9Hz,6H),0.92(t,J=7.4Hz,3H),0.89-0.74(m,8H);MSm / z1025.6306[M+NH4] + .

[0256] Preparation of Compounds I-41 and I-42 Compound I-41 (yield 8.7 mg, 23%) and Compound I-42 (yield 8.2 mg, 22%) were obtained in the same manner as in [Preparation of Compound I-1] except that O-(3-fluorophenethyl)hydroxylamine was used instead of hydroxyamine hydrochloride. (Compound I-41) 1H-NMR(500 MHz, CDCl3, δ): 7.24 - 7.18 (m, 1H), 6.96 (d, J = 8.0 Hz, 1H), 6.94 - 6.90 (m, 1H), 6.90 - 6.85 (m, 1H), 5.88 - 5.83 (m, 1H), 5.78 - 5.65 (m, 2H), 5.40 (m, 2H), 4.98 - 4.93 (m, 1H), 4.80 (s, 1H), 4.77 (d, J = 4.0 Hz, 1H), 4.71 - 4.59 (m, 2H), 4.57 (s, 1H), 4.25 (t, J = 7.2 Hz, 2H), 3.93 (br s, 1H), 3.87 - 3.74 (m, 2H), 3.72 - 3.60 (m, 2H), 3.51 - 3.45 (m, 1H), 3.45 (s, 3H), 3.42 (s, 4H), 3.26 - 3.20 (m, 2H), 3.16 (t, J = 9.2 Hz, 1H), 2.95 (t, J = 7.2 Hz, 2H), 2.90 (dd, J = 13.2, 2.9 Hz, 1H), 2.87 - 2.82 (m, 1H), 2.53 - 2.45 (m, 2H), 2.38 - 2.19 (m, 5H), 1.93 - 1.87 (m, 1H), 1.79 - 1.73 (m, 1H), 1.69 - 1.60 (m, 2H), 1.49 (s, 8H), 1.30 - 1.23 (m, 11H), 1.16 (d, J = 6.9 Hz, 4H), 0.92 (t, J = 7.4 Hz, 3H), 0.85 - 0.75 (m, 8H); MS m / z 1029.6057 [M + NH4] + . (Compound I-42) 1H-NMR(500MHz,CDCl3,δ):7.23(dt,J=7.7,6.3Hz,1H),6.97(d,J=7.4Hz,1H),6.93-6.86(m,2H),5.86(td,J=10.3,2.6Hz,1H),5.77-5.65(m,2 H),5.46-5.38(m,2H),4.95(d,J=10.9Hz,1H),4.77(d,J=2.9Hz,1H),4.68-4.55(m,2H),4.61(s,1H),4.34-4.23(m,2H),3.99(s,1H),3.93(br s,1H),3.87-3.72(m,2H),3.71-3.60(m,2H),3.52-3.45(m,1H),3.45-3.40(m,2H),3.44(s,3H),3.43(s,3H),3. 27-3.20(m,2H),3.16(t,J=9.2Hz,1H),2.97(t,J=6.9Hz,2H),2.89(dd,J=13.7,2.9Hz,1H),2.52-2.45(m,2H),2. 37-2.18(m,5H),1.92-1.86(m,1H),1.79-1.73(m,1H),1.70-1.64(m,1H),1.60-1.35(m,10H),1.30-1.23(m,8H) ,1.16(d,J=7.4Hz,6H),0.92(t,J=7.4Hz,3H),0.84(d,J=6.3Hz,3H),0.82-0.75(m,5H);MSm / z1029.6050[M+NH4] + .

[0257] Preparation of Compounds I-43 and I-44 Compound I-43 (yield 10.7 mg, 26%) and Compound I-44 (yield 10.2 mg, 25%) were obtained in the same manner as in [Preparation of Compound I-1] except that O-(3-bromophenethyl)hydroxylamine (28.5 mg, 0.132 mmol) was used instead of hydroxyamine hydrochloride. (Compound I-43) 1H-NMR(500 MHz, CDCl3, δ): 7.36 (m, 1H), 7.34 - 7.30 (m, 1H), 7.14 - 7.10 (m, 2H), 5.86 (td, J = 10.3, 2.6 Hz, 1H), 5.79 - 5.65 (m, 2H), 5.46 - 5.37 (m, 2H), 4.99 - 4.92 (m, 1H), 4.79 (s, 1H), 4.77 (d, J = 3.4 Hz, 1H), 4.71 - 4.61 (m, 2H), 4.55 (s, 1H), 4.29 - 4.21 (m, 2H), 3.94 (br s, 1H), 3.87 - 3.73 (m, 2H), 3.71 - 3.60 (m, 2H), 3.52 - 3.46 (m, 1H), 3.45 (s, 3H), 3.43 (s, 3H), 3.27 - 3.19 (m, 2H), 3.16 (t, J = 9.2 Hz, 1H), 2.96 - 2.81 (m, 4H), 2.53 - 2.45 (m, 2H), 2.39 - 2.19 (m, 5H), 1.94 - 1.87 (m, 1H), 1.79 - 1.73 (m, 1H),​​​H-NMR(500MHz,CDCl3,δ):7.37-7.35(m,1H),7.33(td,J=7.0,2.2Hz,1H),7.13(s,2H),5.88-5.84(m,1H),5.78-5.66(m,2H),5 .40(m,2H),4.99-4.91(m,1H),4.77(d,J=3.4Hz,1H),4.68-4.54(m,2H),4.61(s,1H),4.33-4.23(m,2H),3.99(s,1H),3.93(br s,1H),3.86-3.74(m,2H),3.72-3.59(m,2H),3.52-3.41(m,2H),3.44(s,3H),3.42(s,3H),3.27-3.19(m,2H),3.16 (t,J=9.5Hz,1H),2.94(dt,J=6.7,2.0Hz,2H),2.89(dd,J=13.5,2.6Hz,1H),2.52-2.44(m,2H),2.37-2.19(m,6H),1 .93-1.86(m,1H),1.79-1.73(m,1H),1.69-1.63(m,1H),1.59-1.35(m,9H),1.29-1.23(m,9H),1.16(dd,J=6.9,2.9H z,6H),0.92(t,J=7.4Hz,3H),0.90-0.85(m,1H),0.84(d,J=6.3Hz,3H),0.82-0.75(m,4H);MSm / z1089.5254[M+NH4] + .

[0258] Preparation of Compound I-45 Compound I-45 (yield 28.8 mg, 71%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3-bromophenethyl)hydroxylamine was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):7.38-7.35(m,1H),7.34-7.29(m,1H),7.15-7.1 1(m,2H),5.83(td,J=10.3,2.6Hz,1H),5.76-5.65(m,2H),5.44-5.37(m,2 H),4.97-4.92(m,1H),4.91(s,1H),4.77(d,J=3.4Hz,1H),4.66(d,J=2.3H z,2H),4.56(s,1H),4.26(t,J=6.9Hz,2H),4.19(t,J=6.9Hz,1H),3.93(br s,1H),3.87-3.74(m,2H),3.71-3.60(m,2H),3.52-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.43-3.39(m,1H),3.26-3.19 (m,2H),3.16(t,J=9.2Hz,1H),2.94-2.90(m,3H),2.79(dd,J=12.6,3.4Hz,1H),2.65-2.57(m,1H),2.48(m,2H),2.37-2.1 9(m,5H),1.92-1.80(m,1H),1.77-1.72(m,1H),1.68-1.64(m,1H),1.59-1.36(m,7H),1.30-1.24(m,9H),1.15(dd,J=6.9 ,1.7Hz,6H),0.92(t,J=7.2Hz,3H),0.89-0.86(m,1H),0.84(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z1089.5244[M+NH4] + .

[0259] Preparation of Compound I-46 and Compound I-47 Compound I-46 (yield 11.5 mg, 30%) and Compound I-47 (yield 15.5 mg, 41%) were obtained in the same manner as in [Preparation of Compound I-1] except that 2-(aminooxy)acetic acid 1 / 2 hydrochloride was used instead of hydroxyamine hydrochloride. (Compound I-46) 1H-NMR(500MHz, CDCl3, δ): 5.89 - 5.82(m, 1H), 5.77 - 5.62(m, 2H), 5.41 - 5.33(m, 2H), 4.99 - 4.91(m, 1H), 4.79 - 4.75(m, 1H), 4.68 - 4.52(m, 4H), 3.94(d, J = 9.7Hz, 2H), 3.86 - 3.72(m, 3H), 3.71 - 3.6(m, 3H), 3.56(m, 1H), 3.51 - 3.46(m, 1H), 3.44(s, 3H), 3.42(s, 3H), 3.43 - 3.37(m, 1H), 3.26 - 3.19(m, 2H), 3.16(t, J = 8.9Hz, 1H), 2.89 - 2.84(m, 1H), 2.54 - 2.45(m, 1H), 2.38 - 2.19(m, 5H), 1.95 - 1.87(m, 1H), 1.79 - 1.71(m, 1H), 1.69 - 1.63(m, 1H), 1.60 - 1.35(m, 9H), 1.30 - 1.19(m, 11H), 1.15(d, J = 6.9Hz, 4H), 0.92(t, J = 7.2Hz, 3H), 0.89 - 0.86(m, 1H), 0.83(d, J = 6.9Hz, 3H), 0.82 - 0.74(m, 4H); MS m / z 965.5586[M + NH4] + . (Compound I-47) 1H-NMR(500MHz,CDCl3,δ):5.89-5.80(m,1H),5.78-5.64(m,2H),5.42-5.3 0(m,2H),5.01-4.93(m,1H),4.85-4.74(m,2H),4.68-4.42(m,4H),3.93(br s,1H),3.86-3.72(m,2H),3.69-3.60(m,2H),3.58-3.46(m,2H),3.44(s,3H),3.41(s,3H),3.27-3. 19(m,2H),3.16(t,J=8.9Hz,1H),2.90-2.75(m,1H),2.54-2.46(m,1H),2.37-2.19(m,5H),2.00(br s,1H),1.95-1.89(m,1H),1.79-1.73(m,1H),1.68-1.61(m,1H),1.60-1.34(m,12H),1.30-1.24(m,8H),1.22-1.18(m,3H),1 .17-1.12(m,3H),0.92(t,J=7.2Hz,3H),0.89-0.85(m,1H),0.83(d,J=6.3Hz,3H),0.80-0.74(m,4H);MSm / z965.5583[M+NH4] + .

[0260] Preparation of Compound I-48 Compound I-48 (yield 24.7 mg, 65%) was obtained in the same manner as in [Preparation of Compound I-2] except that 2-(aminooxy)acetic acid ½ hydrochloride was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.88-5.81(m,1H),5.79-5.64(m,2H),5.38(d,J=3. 4Hz,1H),5.35-5.27(m,1H),5.00-4.92(m,2H),4.77(d,J=3.4Hz,1H),4.64(br s,2H),4.51(br s,2H),3.93(br s,1H),3.86-3.72(m,2H),3.70-3.59(m,2H),3.52-3.45(m,1H),3.43(s,3H),3.41(s,1H),3.40-3.35(m,1H) ),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.73-2.66(m,1H),2.63-2.47(m,2H),2.37-2.19(m,4H),1.95- 1.86(m,2H),1.82-1.71(m,2H),1.67-1.61(m,1H),1.59-1.37(m,12H),1.30-1.23(m,8H),1.15(d,J=6.9Hz ,6H),0.93(t,J=7.2Hz,3H),0.88(s,1H),0.84(d,J=6.9Hz,3H),0.82-0.71(m,5H);MSm / z965.5586[M+NH4] + .

[0261] Reference Example 7 Production of 2-(aminooxy)-2-methylpropan-1-ol hydrochloride With reference to US20120238599A1 literature, 2-(aminooxy)-2-methylpropan-1-ol hydrochloride (yield 898 mg, quantitative) was obtained by a three-step conversion using tert-butyl hydroxycarbamate and ethyl 2-bromo-2-methylpropionate as raw materials. 1 H-NMR (500MHz, CDCl3, δ): 3.39 (s, 1H), 3.38 (s, 1H), 1.71-1.66 (m, 1H), 1.19 (s, 6H).

[0262] Preparation of Compound I-49

[0123] Compound I-49 (yield 27.4 mg, 71%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that 2-(aminooxy)-2-methylpropan-1-ol hydrochloride obtained in Reference Example 7 was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.87-5.84(m,1H),5.77-5.64(m,2H),5.46-5.37 (m,2H),4.97-4.91(m,1H),4.85(s,1H),4.76(d,J=3.4Hz,1H),4.70-4.55(m ,3H),3.94-3.91(m,1H),3.87-3.72(m,2H),3.71-3.58(m,4H),3.45(s,2H), 3.44(s,3H),3.42(s,3H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.89(dd ,J=3.2,13.5Hz,1H),2.87-2.81(m,1H),2.53-2.45(m,2H),2.37-2.18(m,5 H),1.93-1.87(m,1H),1.79-1.73(m,1H),1.69-1.35(m,10H),1.31-1.22(m, 17H),1.20(d,J=7.4Hz,1H),1.17-1.11(m,3H),0.92(t,J=7.2Hz,3H),0.89- 0.85(m,2H),0.84(d,J=6.3Hz,3H),0.82-0.75(m,4H);MSm / z962.5841[M+H] + .

[0263] Preparation of Compound I-50 Compound I-50 (yield 24.7 mg, 64%) was obtained in the same manner as in [Preparation of Compound I-2] except that 2-(aminooxy)-2-methylpropan-1-ol hydrochloride obtained in Reference Example 7 was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.83(td,J=10.5,2.5Hz,1H),5.76-5.64(m,2H),5.43-5.35( m,2H),4.96(s,1H),4.94(d,J=9.7Hz,1H),4.76(d,J=3.4Hz,1H),4.66(s,2H),3.93(br s,1H),3.86-3.73(m,2H),3.70-3.57(m,4H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16( t,J=9.2Hz,1H),2.79(dd,J=11.7,4.3Hz,1H),2.67-2.58(m,1H),2.54-2.45(m,2H),2.37-2.30(m,2H),2.29-2.19( m,2H),1.92-1.82(m,3H),1.78-1.71(m,1H),1.69-1.63(m,1H),1.59-1.32(m,11H),1.29-1.22(m,14H),1.15(t,J= 7.2Hz,6H),0.92(t,J=7.4Hz,3H),0.89-0.85(m,1H),0.83(d,J=6.9Hz,3H),0.81-0.73(m,4H);MSm / z962.5833[M+H] + .

[0264] Preparation of Compound I-51 To a solution of compound I-1 (21 mg, 0.024 mmol) obtained in [Preparation of Compound I-1] in DMF (0.24 mL) were added potassium carbonate (13 mg, 0.094 mmol) and 2-bromoacetamide (7.1 μL, 0.094 mmol), and the mixture was stirred overnight at 50°C. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (ethyl acetate) to obtain compound I-51 (yield 14.5 mg, 65%) as a mixture of isomers that are difficult to separate. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):6.08(br s,1H),5.86(td,J=10.5,2.5Hz,1H),5.78-5.63(m,3H),5.46-5.40(m,1H),5.39(d,J=4.0Hz,1H),4.98-4.92(m ,1H),4.76(d,J=3.4Hz,1H),4.68-4.63(m,1H),4.60(d,J=2.3Hz,1H),4.60-4.55(m,2H),3.97(s,1H),3.93(br s,1H),3.85-3.79(m,1H),3.78-3.72(m,1H),3.70-3.59(m,2H),3.58-3.52(m,1H),3.50-3.45(m,1H),3.44(s, 3H),3.41(s,3H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.90(dd,J=13.7,2.9Hz,1H),2.53-2.45(m,1H),2.3 7-2.19(m,5H),1.93-1.88(m,1H),1.79-1.72(m,1H),1.69-1.63(m,1H),1.61-1.35(m,15H),1.29-1.23(m,10H) ,1.15(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z964.5757[M+NH4] + .

[0265] Preparation of Compound I-52 Compound I-52 (yield 14.6 mg, 68%) was obtained in the same manner as in [Preparation of Compound I-51] except that compound I-2 was used instead of compound I-1. 1H-NMR(500MHz,CDCl3,δ):6.40(br s,1H),5.86-5.80(m,1H),5.78-5.71(m,1H),5.70-5.60(m,2H),5.43-5.35(m,2H),4.97(s,1H), 4.95(d,J=10.9Hz,1H),4.76(d,J=3.4Hz,1H),4.71-4.63(m,2H),4.58(d,J=1.7Hz,2H),3.93(br s,1H),3.86-3.79(m,1H),3.78-3.71(m,1H),3.70-3.58(m,2H),3.51-3.46(m,1H),3.43(s,3H),3.41(s,3H),3.27-3.1 9(m,2H),3.16(t,J=9.2Hz,1H),2.80-2.73(m,1H),2.68-2.60(m,1H),2.52-2.46(m,1H),2.37-2.30(m,2H),2.29-2.17( m,2H),1.93-1.83(m,3H),1.75-1.69(m,1H),1.68-1.62(m,1H),1.59-1.36(m,13H),1.27(d,J=6.3Hz,3H),1.26-1.23(m ,4H),1.15(d,J=6.9Hz,6H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.78(d,J=5.7Hz,4H);MSm / z964.5746[M+NH4] + .

[0266] Reference Example 8 Production of 3-(aminooxy)propan-1-ol hydrochloride With reference to European Journal of Organic Chemistry (2018), 2018(29), 3920-3927, the target 3-(aminooxy)propan-1-ol hydrochloride (yield 447 mg, 87%) was obtained using 2-hydroxyisoindoline-1,3-dione (891 mg, 4.03 mmol) as a starting material. 1 H-NMR (500MHz, D2O, δ): 4.06 (t, J = 6.0 Hz, 2H), 3.59 (t, J = 6.3 Hz, 2H), 3.48 (t, J = 6.6 Hz, 2H), 1.83-1.79 (m, 2H).

[0267] Preparation of Compound I-53 Compound I-53 (yield 9.5 mg, 25%) was obtained in the same manner as in [Preparation of Compound I-1] except that 3-(aminooxy)propan-1-ol hydrochloride obtained in Reference Example 8 was used instead of hydroxyamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.87-5.84(dt,J=10.7,2.4Hz,1H),5.76-5.65(m,2H),5.45-5.40(m ,2H),4.95(d,J=10.9Hz,1H),4.77-4.76(m,2H),4.69-4.60(m,3H),4.27-4.19(m,2H),3.93(br s,1H),3.86-3.61(m,6H),3.51-3.42(m,7H),3.26-3.15(m,3H),2.88-2.85(m,2H),2.50-2.49(m,2H),2.36-2.20(m,4H),1.94-1.8 4(m,3H),1.76-1.73(m,1H),1.68-1.36(m,17H),1.28-1.25(m,9H),1.16-1.14(m,2H),0.935-0.756(m,10H);MSm / z970.5552[M+Na] + .

[0268] Preparation of Compound I-54 Compound I-54 (yield 19.4 mg, 51%) was obtained in the same manner as in [Preparation of Compound I-2] except that 3-(aminooxy)propan-1-ol hydrochloride obtained in Reference Example 8 was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.84-5.81(dt,J=10.3,2.3Hz,1H),5.75-5.64(m,2H),5.43-5.36(m,2H),4.95(d,J=10.9 Hz,1H),4.91(s,1H),4.76(d,J=2.9Hz,1H),4.68-4.61(m,3H),4.25(t,J=5.7Hz,2H),4.18(t,J=5.7Hz,1H),3.93(br s,1H),3.85-3.60(m,7H),3.50-3.42(m,7H),3.25-3.14(m,3H),2.79(dd,J=1 2.6,3.4Hz,1H),2.63-2.57(m,1H),2.51-2.47(m,2H),2.35-2.20(m,4H),1.93 -1.81(m,9H),1.74-1.73(m,1H),1.67-1.65(m,1H),1.58-1.36(m,12H),1.28 -1.24(m,6H),1.18-1.14(m,6H),0.931-0.739(m,10H);MSm / z970.5623[M+Na] + .

[0269] Reference Example 9 (1) Preparation of 2-(2,2-difluoroethoxy)isoindoline-1,3-dione 2-(2,2-Difluoroethoxy)isoindoline-1,3-dione (yield 1.94 g, 85%) was obtained in the same manner as in the preparation of Reference Example 1-(2), except that 2,2-difluoroethan-1-ol was used instead of cyclopropylmethanol in the preparation of Reference Example 1-(2). 1H-NMR (500 MHz, CDCl3, δ): 7.89-7.85 (m, 2H), 7.82-7.76 (m, 2H), 6.23 (tt, J = 55.0, 4.3 Hz, 1H), 4.38 (td, J = 12.7, 4.3 Hz, 2H). (2) Preparation of O-(2,2-difluoroethyl)hydroxylamine hydrochloride 2-(2,2-Difluoroethoxy)isoindoline-1,3-dione (1.94 g, 8.54 mmol) obtained in Reference Example 9-(1) was dissolved in methylene chloride (34.2 mL), and then hydrazine hydrate (0.415 mL, 8.54 mmol) was added and the mixture was stirred at room temperature for 14 hours. The suspension was filtered, and then a 4 M solution of hydrogen chloride in 1,4-dioxane (2.24 mL, 8.97 mmol) was added to the filtrate, followed by stirring at room temperature for 15 minutes. The solvent was evaporated under reduced pressure, and then ether was added and the suspension was filtered to obtain O-(2,2-difluoroethyl)hydroxylamine hydrochloride (yield: 1.55 g, 95%). 1 H-NMR (500MHz, DMSO-d6, δ): 6.51-6.19 (m, 1H), 4.33-4.16 (m, 2H).

[0270] Preparation of Compound I-55: Compound I-55 (yield 20.4 mg, 62%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that O-(2,2-difluoroethyl)hydroxylamine hydrochloride obtained in Reference Example 9-(2) was used instead of hydroxyamine hydrochloride. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):6.10-5.94(m,1H),5.89-5.82(m,1H),5.79-5.63(m,2H),5.46-5.38(m,2H),4 .95(d,J=10.9Hz,1H),4.81(s,1H),4.77(d,J=3.4Hz,1H),4.71-4.56(m,3H),4.30-4.19(m,2H),3.93(br s,1H),3.86-3.74(m,2H),3.71-3.60(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.43(s,3H),3.26- 3.19(m,2H),3.17(t,J=9.2Hz,1H),2.92-2.81(m,2H),2.54-2.46(m,2H),2.37-2.20(m,5H),1.9 0(dd,J=12.0,4.6Hz,1H),1.79-1.71(m,1H),1.69-1.63(m,1H),1.63-1.38(m,12H),1.32-1.21( m,11H),1.16(d,J=6.9Hz,3H),0.92(t,J=7.2Hz,3H),0.86-0.76(m,7H);MSm / z971.5892[M+NH4] + .

[0271] Preparation of Compound I-56 Compound I-56 (yield 30.9 mg, 94%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(2,2-difluoroethyl)hydroxylamine hydrochloride obtained in Reference Example 9-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):6.12-5.85(tt,J=55.0,4.3Hz,1H),5.83(dt,J=10.5,2.5Hz,1H),5.77-5.65(m,2H),5.44-5.36(m,2 H),4.94(d,J=11.5Hz,1H),4.91(s,1H),4.76(d,J=2.9Hz,1H),4.66(s,2H),4.62(s,1H),4.24(td,J=13.3,4.3Hz,2H),3.93(br s,1H),3.87-3.73(m,2H),3.71-3.59(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.28-3.1 9(m,2H),3.16(t,J=8.9Hz,1H),2.79(dd,J=12.6,2.9Hz,1H),2.65-2.56(m,1H),2.56-2.45(m,2H), 2.37-2.19(m,4H),1.95-1.81(m,3H),1.78-1.70(m,1H),1.68-1.64(m,1H),1.59-1.37(m,12H),1.2 9-1.24(m,7H),1.19-1.12(m,6H),0.92(t,J=7.5Hz,3H),0.85-0.76(m,7H);MSm / z971.5892[M+NH4] + .

[0272] Reference Example 10 (1) Preparation of 2-(3,3-difluoropropyl)isoindoline-1,3-dione

[0123] 2-(3,3-Difluoropropyl)isoindoline-1,3-dione (yield 418 mg, 94%) was obtained in the same manner as in the preparation of Reference Example 1-(2), except that 3,3-difluoropropan-1-ol was used instead of cyclopropylmethanol in the preparation of Reference Example 1-(2). 1H-NMR (500 MHz, CDCl3, δ): 7.88-7.82 (m, 2H), 7.78-7.73 (m, 2H), 6.27 (tt, J = 55.0, 4.9 Hz 1H), 4.38 (t, J = 6.3 Hz, 2H), 2.39-2.27 (m, 2H). (2) Preparation of O-(3,3-difluoropropyl)hydroxylamine hydrochloride O-(3,3-difluoropropyl)hydroxylamine hydrochloride (yield 254 mg, 69%) was obtained in the same manner as in the preparation of Reference Example 4-(2), except that 2-(3,3-difluoropropyl)isoindoline-1,3-dione obtained in Reference Example 5-(1) was used instead of 2-(2,2-difluoroethoxy)isoindoline-1,3-dione in the preparation of Reference Example 10-(2). 1 H-NMR (500MHz, DMSO-d6, δ): 6.16 (tt, J=55.0, 4.6Hz 1H), 4.17-4.04 (m, 2H), 2.31-2.14 (m, 2H).

[0273] Preparation of Compound I-57: Compound I-57 (yield 23.1 mg, 70%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that O-(3,3-difluoropropyl)hydroxylamine hydrochloride obtained in Reference Example 10-(2) was used instead of hydroxyamine hydrochloride. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.93(t,J=55.0,4.9Hz,1H),5.89-5.83(m,1H),5.78-5.64(m,2H),5.47-5.37(m,2 H),4.96(d,J=11.5Hz,1H),4.78(s,1H),4.77(d,J=3.4Hz,1H),4.71-4.55(m,3H),4.30-4.17(m,2H),3.94(br s,1H),3.87-3.73(m,2H),3.71-3.58(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.20 (m,2H),3.16(t,J=9.2Hz,1H),2.92-2.77(m,2H),2.55-2.44(m,2H),2.38-2.13(m,7H),1.90(dd,J=12 .0,4.6Hz,1H),1.80-1.71(m,1H),1.71-1.38(m,16H),1.31-1.24(m,7H),1.21(d,J=7.5Hz,1H),1.19 -1.14(m,3H),0.93(t,J=7.2Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.75(m,4H);MSm / z985.6105[M+NH4] + .

[0274] Preparation of Compound I-58 Compound I-58 (yield 31.0 mg, 93%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(3,3-difluoropropyl)hydroxylamine hydrochloride obtained in Reference Example 10-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.95(tt,J=55.0,4.9Hz,1H),5.86-5.80(m,1H),5.77-5.63(m,2H),5.45-5.34(m,2H),4.95 (d,J=10.9Hz,1H),4.89(s,1H),4.77(d,J=3.4Hz,1H),4.70-4.62(m,2H),4.61(s,1H),4.23(t,J=6.3Hz,2H),3.93(br s,1H),3.87-3.72(m,2H),3.71-3.59(m,2H),3.52-3.44(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2 H),3.16(t,J=9.2Hz,1H),2.79(dd,J=12.3,3.7Hz,1H),2.65-2.56(m,1H),2.54-2.46(m,2H),2.37-2.13(m ,6H),1.93-1.81(m,3H),1.77-1.71(m,1H),1.69-1.63(m,1H),1.61-1.36(m,12H),1.30-1.23(m,7H),1.1 6(t,J=6.3Hz,6H),0.92(t,J=7.5Hz,3H),0.84(d,J=6.3Hz,3H),0.80-0.74(m,4H);MSm / z985.6105[M+NH4] + .

[0275] Preparation of Compound I-59: To a solution of a mixture of Compound I-46 and Compound I-47 (30 mg, 0.0352 mmol) obtained in [Preparation of Compound I-46 and Compound I-47] in dichloromethane (0.32 mL), DIPEA (0.022 mL, 0.141 mmol), 2 M dimethylamine THF solution (63 μL, 0.141 mmol), and HATU (24.0 mg, 0.070 mmol) were added, and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-59 (yield 24.0 mg, 78%). 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.88-5.82(m,1H),5.77-5.64(m,2H),5.46-5.31(m,2H),4. 95(d,J=10.3Hz,1H),4.82-4.72(m,3H),4.67-4.57(m,2H),3.97-3.95(m,1H),3.93(br s,1H),3.86-3.73(m,2H),3.71-3.58(m,3H),3.52-3.46(m,1H),3.44(s,3H),3 .42(s,3H),3.27-3.13(m,3H),2.97(dd,J=17.2,3.2Hz,6H),2.53-2.44(m,2H), 2.37-2.18(m,5H),1.96-1.80(m,2H),1.78-1.72(m,1H),1.70-1.33(m,16H),1. 32-1.21(m,9H),1.18-1.11(m,3H),0.96-0.72(m,11H);MSm / z992.6049[M+NH4] + .

[0276] Preparation of Compound I-60: To a solution of compound I-48 (30 mg, 0.0352 mmol) obtained in [Preparation of Compound I-48] in dichloromethane (0.32 mL), DIPEA (0.016 mL, 0.106 mmol), 2 M dimethylamine THF solution (0.048 mL, 0.106 mmol), and HATU (15.6 mg, 0.0458 mmol) were added, and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction solution to quench the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (ethyl acetate) to obtain compound I-60 (yield 26.0 mg, 84%). 1H-NMR(500MHz,CDCl3,δ):5.87-5.82(m,1H),5.75-5.64(m,2H),5.41-5.30( m,2H),5.03(d,J=1.7Hz,1H),4.98-4.92(m,1H),4.79-4.71(m,3H),4.65(br s,2H),3.92(br s,1H),3.86-3.79(m,1H),3.78-3.72(m,1H),3.70-3.59(m,2H),3.51-3.45(m,1H),3.43(s,3H),3.42(s,3H),3 .41-3.38(m,1H),3.26-3.13(m,3H),2.98(d,J=2.3Hz,3H),2.92(d,J=1.7Hz,3H),2.80-2.73(m,1H),2.65-2.5 7(m,1H),2.55-2.45(m,2H),2.37-2.18(m,5H),1.96-1.79(m,2H),1.77-1.71(m,1H),1.68-1.60(m,1H),1.59- 1.33(m,9H),1.30-1.21(m,8H),1.18-1.10(m,6H),0.94-0.86(m,4H),0.85-0.71(m,8H);MSm / z975.5793[M+H] + .

[0277] Preparation of Compound I-61: Compound I-61 (yield 28.1 mg, 87%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-59] except that morpholine was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):5.88-5.82(m,1H),5.78-5.63(m,2H),5.46-5.33(m,2H),4. 98-4.90(m,0.5H),4.78-4.75(m,2H),4.84-4.52(m,5H),3.97-3.94(m,0.5H),3.92(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.71-3.54(m,9H),3.53-3.46(m,3H),3.45-3.43 (m,3H),3.43-3.41(m,3H),3.27-3.14(m,3H),2.92-2.86(m,1H),2.81-2.75(m,1H),2.54-2.4 4(m,2H),2.37-2.20(m,5H),1.94-1.80(m,2H),1.78-1.73(m,1H),1.68-1.64(m,1H),1.62-1. 35(m,10H),1.30-1.22(m,11H),1.18-1.12(m,4H),0.96-0.74(m,8H);MSm / z1034.6150[M+NH4] + .

[0278] Preparation of Compound I-62 Compound I-62 (yield 26.9 mg, 84%) was obtained in the same manner as in [Preparation of Compound I-60] except that morpholine was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):5.86-5.81(m,1H),5.77-5.63(m,2H),5.42-5.3 3(m,2H),4.98-4.91(m,2H),4.79-4.71(m,3H),4.71-4.59(m,3H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.72(m,1H),3.70-3.56(m,9H),3.54-3.45(m,3H),3.43(s,3H),3.4 2(s,3H),3.27-3.12(m,3H),2.81-2.74(m,1H),2.66-2.58(m,1H),2.56-2.43(m,2H),2.37-2.30(m,2 H),2.29-2.18(m,2H),1.95-1.81(m,3H),1.78-1.68(m,2H),1.68-1.62(m,1H),1.60-1.34(m,9H),1 .30-1.22(m,7H),1.18-1.11(m,6H),0.91(t,J=7.2Hz,3H),0.89-0.73(m,8H);MSm / z1017.5884[M+H] + .

[0279] Preparation of Compound I-63: Compound I-63 (yield 13.2 mg, 43%) was obtained as a mixture of isomers that were difficult to separate in the same manner as in [Preparation of Compound I-59] except that 2 M methylamine THF solution was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):6.12-6.07(m,1H),5.89-5.83(m,1H),5.79-5.64(m,2H),5.46-5.37 (m,2H),4.97-4.91(m,0.5H),4.76(d,J=3.4Hz,1H),4.74-4.54(m,4H),3.97(s,0.5H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.72(m,1H),3.71-3.59(m,2H),3.58-3.51(m,1H),3.44(s,3H),3.42(s,3H),3.27 -3.19(m,2H),3.16(t,J=9.2Hz,1H),2.93-2.88(m,1H),2.86(d,J=5.2Hz,2H),2.81(d,J=4.6Hz,1H),2.55-2.45(m ,2H),2.37-2.18(m,4H),1.93-1.85(m,1H),1.78-1.71(m,1H),1.69-1.35(m,16H),1.32-1.22(m,10H),1.17-1.14 (m,3H),0.92(t,J=7.2Hz,3H),0.89-0.85(m,1H),0.83(d,J=6.3Hz,3H),0.82-0.74(m,4H);MSm / z978.5889[M+NH4] + .

[0280] Preparation of Compound I-64 Compound I-64 (yield 23.1 mg, 76%) was obtained in the same manner as in [Preparation of Compound I-60] except that 2M methylamine THF solution was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):6.44-6.38(m,1H),5.87-5.81(m,1H),5.79-5.64(m,2H),5.45-5.36(m,2H),4.99(s, 1H),4.95(d,J=10.3Hz,1H),4.82(s,1H),4.76(d,J=3.4Hz,1H),4.73-4.65(m,2H),4.64-4.54(m,2H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.72(m,1H),3.71-3.59(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.23(m, 2H),3.16(t,J=8.9Hz,1H),2.81(d,J=4.6Hz,3H),2.80-2.76(m,1H),2.69-2.61(m,1H),2.54-2.46(m,2H),2.37-2.31( m,2H),2.30-2.18(m,2H),1.92-1.82(m,3H),1.77-1.70(m,1H),1.69-1.35(m,11H),1.30-1.24(m,8H),1.15(t,J=6.6 Hz,6H),0.92(t,J=7.4Hz,3H),0.87(t,J=6.6Hz,1H),0.84(d,J=6.9Hz,3H),0.81-0.74(m,4H);MSm / z978.5902[M+NH4] + .

[0281] Preparation of Compound I-65 Compound I-65 (yield 28.0 mg, 86%) was obtained in the same manner as in [Preparation of Compound I-59] except that cyclohexylamine was used instead of dimethylamine. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.95(d,J=8.0Hz,1H),5.89-5.83(m,1H),5.79-5.6 4(m,2H),5.48-5.37(m,2H),4.97-4.92(m,1H),4.79-4.71(m,1H),4.70-4.63( m,1H),4.61-4.51(m,3H),3.97(s,1H),3.95-3.91(m,1H),3.87-3.73(m,3H), 3.72-3.59(m,2H),3.58-3.52(m,1H),3.51-3.46(m,1H),3.44(s,3H),3.42(s, 3H),3.27-3.20(m,2H),3.16(t,J=9.2Hz,1H),2.94-2.88(m,1H),2.53-2.44( m,2H),2.38-2.17(m,4H),1.93-1.81(m,3H),1.74(d,J=4.6Hz,1H),1.79-1.32 (m,19H),1.30-1.21(m,10H),1.21-1.11(m,7H),0.92(t,J=7.2Hz,3H),0.89-0 .86(m,1H),0.84(d,J=6.3Hz,3H),0.81-0.74(m,4H);MSm / z1046.6510[M+NH4] + .

[0282] Preparation of Compound I-66 Compound I-66 (yield 25.5 mg, 78%) was obtained in the same manner as in [Preparation of Compound I-60] except that cyclohexylamine was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):6.28(d,J=8.0Hz,1H),5.88-5.83(m,1H),5.80-5.65(m,2H),5.46-5.37(m,2H),4.9 9(s,1H),4.96-4.92(m,1H),4.76(d,J=3.4Hz,1H),4.74(s,1H),4.73-4.64(m,2H),4.60-4.51(m,2H),3.93(br s,1H),3.86-3.79(m,2H),3.78-3.73(m,1H),3.71-3.60(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.2 8-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.79(dd,J=11.5,4.6Hz,1H),2.68-2.60(m,1H),2.53-2.45(m,2H),2.36-2. 30(m,2H),2.30-2.19(m,2H),1.92-1.81(m,5H),1.68(m,5H),1.63-1.30(m,10H),1.29-1.23(m,9H),1.21-1.09( m,10H),0.92(t,J=7.2Hz,3H),0.87(t,J=6.9Hz,1H),0.85-0.81(m,3H),0.82-0.74(m,4H);MSm / z1029.6263[M+H] + .

[0283] Reference Example 11: Using 4-bromobutan-1-ol instead of 2-bromoethan-1-ol in Reference Example 6-(1), O-(4-((tert-butyldimethylsilyl)oxy)butyl)hydroxylamine (yield 966 mg, three-step yield 41%) was obtained in the same manner as in the three steps of Reference Example 6-(1), (2), and (3). 1 H-NMR (500MHz, DMSO-d6, δ): 5.84 (br s, 1H), 3.55 (t, J=6.0Hz, 2H), 3.48 (t, J=6.6Hz, 2H), 1.50-1.38 (m, 4H), 0.823 (s, 9H), 0.823 (s, 6H).

[0284] Preparation of Compound I-67

[0123] Compound I-67 (yield 30.6 mg, 71%) was obtained in a similar manner except that O-(4-((tert-butyldimethylsilyl)oxy)butyl)hydroxylamine obtained in Reference Example 11-(3) was used instead of hydroxyamine hydrochloride in [Preparation of Compound I-1]. 1 H-NMR(500MHz,CDCl3,δ):5.86-5.84(m,1H),5.75-5.65(m,2H),5.44-5.38(m,2H),4.95(d,J=10.9Hz,1H),4. 76(d,J=3.4Hz,1H),4.69-4.55(m,3H),4.13-3.93(m,4H),3.85-3.73(m,2H),3.69-3.58(m,5H),3.52-3.42(m ,8H),3.25-3.14(m,3H),2.91(dt,J=13.6,3.0Hz,1H),2.53-2.47(m,2H),2.35-2.20(m,5H),1.91-1.88(m,1H) ),1.76-1.36(m,24H),1.28-1.14(m,13H),0.930-0.742(m,25H),0.034-0.022(m,8H);MSm / z1076.6895[M+H] + .

[0285] Preparation of Compound I-68: Compound I-67 (30.6 mg, 0.028 mmol) obtained in [Preparation of Compound I-67] was dissolved in THF (1.12 mL), and then a hydrogen fluoride pyridine solution (0.378 mL) was added and stirred at room temperature for 10 minutes. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane / ethyl acetate = 1:2) to obtain Compound I-68 (yield 13.1 mg, 49%). 1H-NMR(500MHz,CDCl3,δ):5.86-5.84(m,1H),5.75-5.65(m,2H),5.44-5.39(m,2H),4.95(d,J= 10.9Hz,1H),4.76(d,J=3.4Hz,1H),4.66-4.56(m,3H),4.16-4.09(m,2H),3.97(s,1H),3.93(br s,1H),3.85-3.73(m,2H),3.69-3.60(m,4H),3.50-3.42(m,8H),3.25-3.14(m,3H),2.90(dd,J=13.5,2.6Hz,1H),2.53-2.47(m,2H), 2.35-2.20(m,4H),1.91(dd,J=12.3,4.9Hz,1H),1.77-1.36(m,24H),1.28-1.14(m,13H),0.931-0.771(m,11H);MSm / z962.5991[M+H] + .

[0286] Preparation of Compound I-69

[0222] Compound I-69 (yield 25.2 mg, 59%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(4-((tert-butyldimethylsilyl)oxy)butyl)hydroxylamine obtained in Reference Example 11-(3) was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.84-5.81(m,1H),5.74-5.65(m,2H),5.42-5.36(m,2H),4.94-4.93( m,2H),4.76(d,J=3.4Hz,1H),4.65(d,J=1.1Hz,1H),4.59(s,1H),4.09(t,J=6.6Hz,2H),3.92(br s,1H),3.85-3.74(m,2H),3.68-3.59(m,4H),3.50-3.42(m,7H),3.25-3. 14(m,3H),2.80(dd,J=12.6,3.4Hz,1H),2.62-2.55(m,1H),2.51-2.47(m ,2H),2.36-2.20(m,4H),1.92-1.79(m,3H),1.75-1.34(m,21H),1.28-1. 14(m,12H),0.929-0.769(m,21H),0.026(s,6H);MSm / z1093.7158[M+NH4] + .

[0287] Preparation of Compound I-70: Compound I-69 (25.2 mg, 0.023 mmol) obtained in [Preparation of Compound I-69] was dissolved in THF (0.920 mL), and then a hydrogen fluoride pyridine solution (0.311 mL) was added and stirred at room temperature for 10 minutes. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane / ethyl acetate = 1:2) to obtain Compound I-70 (yield 15.8 mg, 71%). 1 H-NMR(500MHz,CDCl3,δ):5.84(dd,J=8.0,2.3Hz,1H),5.76-5.65(m,2H),5.43-5.36(m,2H ),4.95-4.93(m,2H),4.77(d,J=3.4Hz,1H),4.66-4.62(m,3H),4.17-4.10(m,2H),3.93(br s,1H),3.86-3.75(m,2H),3.69-3.61(m,4H),3.51-3.43(m,7H),3.28-3.15(m,3H),2.80(dd,J=12.3,3.2Hz,1H),2.62-2.57(m,1H),2.51 -2.48(m,2H),2.36-2.20(m,4H),1.93-1.80(m,3H),1.77-1.36(m,22H),1.28-1.15(m,12H),0.935-0.776(m,10H);MSm / z984.5617[M+Na] + .

[0288] Reference Example 12 (1) Preparation of 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethoxy)isoindoline-1,3-dione In accordance with the method described in WO 2013 / 186632, 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethoxy)isoindoline-1,3-dione (yield 340 mg, 36%) was obtained by conversion through three steps using 2,2′-oxybis(ethan-1-ol) (1.73 mL, 18.3 mmol) as a starting material. 1H-NMR (500 MHz, CDCl3, δ): 7.85-7.82 (m, 2H), 7.76-7.73 (m, 2H), 4.37-4.36 (m, 2H), 3.88-3.86 (m, 2H), 3.68 (t, J = 5.2 Hz, 2H), 3.56 (t, J = 5.2 Hz, 2H), 0.85 (s, 9H), 0.01 (s, 6H). (2) Preparation of 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-ol 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethoxy)isoindoline-1,3-dione (292 mg, 1.16 mmol) obtained in Reference Example 12-(1) was dissolved in ethanol (11.6 mL, 11.6 mmol). To the solution was added hydrazine monohydrate (0.062 mL, 1.28 mmol), and the mixture was heated to reflux and stirred for 0.5 hours. After the reaction was completed, the mixture was filtered and the solvent was distilled off under reduced pressure to obtain 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-ol (yield: 185 mg, 68%). 1 H-NMR(500MHz,DMSO-d6,δ):5.97(s,2H),3.69(t,J=5.2Hz,2H),3.63-3.61 (m,2H),3.54-3.53(m,2H),3.45(t,J=5.2Hz,2H),0.86(s,9H),0.04(s,6H).

[0289] Preparation of Compound I-71 Compound I-71 (yield 4.1 mg, 14%) was obtained in a similar manner to [Preparation of Compound I-67] and [Preparation of Compound I-68], except that 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-ol obtained in Reference Example 12-(2) was used instead of O-(4-((tert-butyldimethylsilyl)oxy)butyl)hydroxylamine in [Preparation of Compound I-67]. 1H-NMR(500MHz,CDCl3,δ):5.87-5.85(m,1H),5.76-5.66(m,2H),5.45-5.39(m,2H),4.96(d,J= 9.2Hz,1H),4.77(d,J=4.0Hz,1H),4.68-4.57(m,3H),4.31-4.24(m,2H),3.98(s,1H),3.93(br s,1H),3.86-3.58(m,19H),3.26-3.15(m,3H),2.91(dd,J=13.2,2.9Hz, 1H),2.51-2.49(m,2H),2.36-2.18(m,5H),1.92(dd,J=11.7,3.7Hz,1H) ,1.77-1.74(m,1H),1.68-1.66(m,1H),1.58-1.37(m,21H),1.29-1.15( m,12H),0.94(t,J=7.2Hz,3H),0.85-0.80(m,7H);MSm / z978.5771[M+H] + .

[0290] Preparation of Compound I-72 Compound I-72 (yield 12.0 mg, 42%) was obtained in a similar manner to [Preparation of Compound I-69] and [Preparation of Compound I-70], except that 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-ol obtained in Reference Example 12-(2) was used instead of O-(4-((tert-butyldimethylsilyl)oxy)butyl)hydroxylamine in [Preparation of Compound I-69]. 1H-NMR(500MHz,CDCl3,δ):5.84(dd,J=8.0,2.3Hz,1H),5.76-5.65(m,2H),5.41-5.34(m,2H ),4.97-4.93(m,2H),4.77(d,J=3.4Hz,1H),4.68-4.65(m,3H),4.26-4.24(m,2H),3.93(br s,1H),3.86-3.54(m,11H),3.51-3.43(m,8H),3.26-3.15(m,3H),2.80(dd,J=12.6,3.4Hz,1H),2.64-2.47(m,4H),2.36-2.20(m,4H),1 .94-1.82(m,3H),1.75-1.73(m,1H),1.66(s,3H),1.58-1.34(m,13H),1.28-1.15(m,13H),0.93-0.78(m,11H);MSm / z995.6039[M+NH4] + .

[0291] Preparation of Compound I-73 Compound I-73 (yield 11.7 mg, 37%) was obtained in the same manner as in [Preparation of Compound I-59] except that 2-aminoethan-1-ol was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):6.52(t,J=5.7Hz,1H),5.90-5.81(m,1H),5.79-5.62(m,2H),5.45-5.35(m, 2H),4.99-4.90(m,1H),4.86-4.74(m,2H),4.71-4.62(m,2H),4.62-4.56(m,2H),3.97(s,1H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.72-3.59(m,4H),3.59-3.54(m,1H),3.52-3.45(m,2H),3.44(s,3H),3. 42(s,3H),3.27-3.19(m,2H),3.16(t,J=8.9Hz,1H),2.92-2.84(m,2H),2.57-2.46(m,1H),2.37-2.30(m,2H),2.30-2.1 7(m,2H),1.93-1.87(m,1H),1.78-1.69(m,1H),1.68-1.64(m,1H),1.63-1.34(m,14H),1.33-1.21(m,11H),1.15(d,J=6 MSm / z1008.6011[M+NH4] + .

[0292] Preparation of Compound I-74 Compound I-74 (yield 13.5 mg, 43%) was obtained in the same manner as in [Preparation of Compound I-60] except that 2-aminoethan-1-ol was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):6.82(t,J=5.4Hz,1H),5.85(d,J=9.7Hz,1H),5.79-5.64(m,2H),5.43 -5.34(m,2H),5.00(s,1H),4.99-4.90(m,2H),4.76(d,J=4.0Hz,1H),4.73-4.54(m,4H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.74(m,1H),3.72-3.60(m,4H),3.52-3.34(m,3H),3.43(s,3H),3.41(s,3H),3.26-3.19( m,2H),3.16(t,J=8.9Hz,1H),2.87-2.85(m,1H),2.82-2.75(m,3H),2.70-2.63(m,1H),2.54-2.45(m,1H),2.37-2.30(m,2H) ),2.29-2.18(m,2H),1.93-1.82(m,3H),1.76-1.69(m,1H),1.68-1.62(m,1H),1.59-1.35(m,5H),1.33-1.21(m,10H),1.18 -1.11(m,6H),0.92(t,J=7.2Hz,3H),0.87(t,J=6.3Hz,2H),0.83(d,J=6.3Hz,3H),0.80-0.74(m,4H);MSm / z991.5743[M+H] + .

[0293] Preparation of Compound I-75: To a solution of compound I-22 (30 mg, 0.0321 mmol) obtained in [Preparation of Compound I-22] in dichloromethane (0.32 mL), 37% formalin (23.8 μL, 0.32 mmol) and sodium cyanoborohydride (16.2 mg, 0.252 mmol) were added sequentially, and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (chloroform:methanol=10:1) to obtain compound I-75 (yield 6.5 mg, 21%) as a mixture of isomers that are difficult to separate. 1H-NMR(500MHz,CDCl3,δ):5.88-5.82(m,1H),5.76-5.64(m,2H),5.44-5.36(m,2H),4.97-4.92(m,1H ),4.83(s,0.67H),4.78-4.75(m,1H),4.70-4.54(m,2H),4.26-4.15(m,2H),3.97(s,0.33H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.60(m,2H),3.53-3.46(m,1H),3.45(s,3H),3.42(s,3H),3.26-3.19(m,2H) ,3.16(t,J=8.9Hz,1H),2.91-2.81(m,2H),2.71-2.59(m,2H),2.52-2.45(m,1H),2.30(s,6H),2.38-2.18(m,6H),1.94-1.87(m,1 H),1.78-1.73(m,1H),1.69-1.60(m,2H),1.59-1.35(m,12H),1.27(d,J=6.9Hz,5H),1.25(d,J=6.3Hz,4H),1.20(d,J=6.9Hz,1H) ,1.15(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.89-0.85(m,1H),0.83(d,J=6.3Hz,3H),0.81-0.75(m,4H);MSm / z961.6001[M+H] + .

[0294] Preparation of Compound I-76 Compound I-76 (yield 101 mg, 33%) was obtained in the same manner as in [Preparation of Compound I-75] except that compound I-23 was used instead of compound I-22. 1H-NMR(500MHz,CDCl3,δ):5.86-5.81(m,1H),5.76-5.64(m,2H),5.40(d,J=2.9Hz,1H),5.39-5.32(m,1H) ,4.98-4.93(m,1H),4.93(s,1H),4.76(d,J=3.4Hz,1H),4.68-4.60(m,2H),4.21(t,J=6.0Hz,2H),3.92(br s,1H),3.86-3.80(m,1H),3.80-3.72(m,1H),3.70-3.59(m,2H),3.52-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.18(m, 2H),3.16(t,J=9.2Hz,1H),2.77(dd,J=3.4,12.6Hz,1H),2.69-2.56(m,3H),2.52-2.45(m,1H),2.37-2.18(m,4H),2.28(s,6H) ),1.94-1.85(m,2H),1.85-1.79(m,1H),1.77-1.70(m,1H),1.68-1.61(m,1H),1.59-1.35(m,13H),1.30-1.23(m,7H),1.15( t,J=6.9Hz,6H),0.91(t,J=7.4Hz,3H),0.87(t,J=6.9Hz,1H),0.83(d,J=6.3Hz,3H),0.80-0.73(m,4H);MSm / z961.6001[M+H] + .

[0295] Preparation of Compound I-77: Triethylamine (11.1 μL, 0.0803 mmol) was added to a solution of compound I-22 (25 mg, 0.0267 mmol) obtained in [Preparation of Compound I-22] in dichloromethane (0.27 mL), and then phenylsulfonyl chloride (4.11 μL, 0.0321 mmol) was added, followed by stirring at room temperature for 1.5 hours. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (n-hexane / ethyl acetate system) to obtain compound I-77 (yield 18.9 mg, 66%). 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):7.87-7.82(m,2H),7.58-7.52(m,1H),7.52-7.44(m,2H),5.9 0-5.83(m,1H),5.79-5.66(m,2H),5.53(t,J=6.0Hz,1H),5.46-5.36(m,2H),4.99-4.92( m,1H),4.76(d,J=3.4Hz,1H),4.72(s,1H),4.70-4.65(m,1H),4.64-4.54(m,1H),4.14- 4.02(m,2H),3.95-3.91(m,1H),3.87-3.80(m,1H),3.80-3.73(m,1H),3.71-3.59(m,2H) ,3.52-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.29-3.13(m,5H),2.84-2.76(m,1H),2. 56-2.45(m,2H),2.38-2.17(m,5H),1.94-1.86(m,1H),1.79-1.72(m,1H),1.70-1.62(m, 3H),1.61-1.35(m,12H),1.29-1.24(m,8H),1.20-1.13(m,6H),0.92(t,J=7.4Hz,3H),0 .87(t,J=6.9Hz,2H),0.84(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z1090.5881[M+NH4] + .

[0296] Preparation of Compound I-78 Compound I-78 (yield 19.2 mg, 67%) was obtained in the same manner as in [Preparation of Compound I-77] except that compound I-23 was used instead of compound I-22. 1H-NMR(500MHz,CDCl3,δ):7.86-7.83(m,2H),7.57-7.53(m,1H),7.51-7.46(m,2H),5.84(td,J=2.4,10.7Hz,1H),5.79-5.64(m,2H),5.46-5.36(m,3H),4.97-4.92(m,1H),4.85(s,1H),4.76(d,J=3.4Hz,1H),4.72(s,1H),4.71-4.62(m,2H),4.12-4.04(m,2H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.71-3.60(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.41(s,3H),3.22(s,4H),3.16(t,J=9.2Hz,1H),2.76(dd,J=4.0,12.0Hz,1H),2.61-2.46(m,3H),2.37-2.30(m,2H),2.30-2.18(m,2H),1.93-1.87(m,1H),1.86-1.78(m,2H),1.76-1.71(m,1H),1.70-1.64(m,3H),1.59-1.35(m,7H),1.30-1.22(m,9H),1.16(d,J=6.9Hz,3H),1.08(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.89-0.85(m,2H),0.84(d,J=6.9Hz,3H),0.80-0.75(m,4H);MSm / z1090.5879[M+NH4] + 。

[0297] Reference Example 13 (1) Preparation of O-(oxetan-3-ylmethyl)hydroxylamine Oxetan-3-ylmethanol (0.75 mL, 9.28 mmol) was dissolved in THF (93 mL), and then a toluene solution of bis(2-methoxyethyl)(E)-diazene-1,2-dicarboxylate (2.28 mL, 10.6 mmol), 2-hydroxyisoindoline-1,3-dione (1.44 g, 8.84 mmol), and triphenylphosphine (2.78 g, 10.6 mmol) were added sequentially, followed by stirring at room temperature for 1 hour. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2-(oxetan-3-ylmethoxy)isoindoline-1,3-dione (yield: 1.96 g, 95%). 1 H-NMR (500 MHz, CDCl3, δ): 7.86-7.81 (m, 2H), 7.78-7.73 (m, 2H), 4.89-4.84 (m, 2H), 4.59 (dt, J = 4.0, 6.0 Hz, 2H), 4.47 (dd, J = 3.7, 7.2 Hz, 2H), 3.49-3.38 (m, 1H). (2) O-(Oxetan-3-ylmethyl)hydroxylamine 2-(Oxetan-3-ylmethoxy)isoindoline-1,3-dione (400 mg, 1.71 mmol) obtained in Reference Example 13-(1) was dissolved in ethanol (17 mL). To the solution was added hydrazine monohydrate (91.7 μL, 1.89 mmol), and the mixture was stirred at 60°C for 30 minutes. The reaction mixture was cooled to 0°C, and the resulting precipitate was removed by filtration. The solvent was removed from the filtrate under reduced pressure to give O-(oxetan-3-ylmethyl)hydroxylamine (yield: 166 mg, 93%). MS m / z 104.0706 [M+H] + C4H10NO2(FAB) 1 H-NMR(500MHz,DMSO-d6,δ):4.58(d,J=6.3Hz,1H),4.57(d,J=6.3Hz,1H),4.25(t,J=6.3Hz,2H),3.71(d,J=6.3Hz,2H),3.18-3.09(m,1H).

[0298] Preparation of Compound I-79

[0123] Compound I-79 (yield 255 mg, 77%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that O-(oxetan-3-ylmethyl)hydroxylamine (14.1 mg, 0.141 mmol) obtained in Reference Example 13-(2) was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.88-5.83(m,1H),5.78-5.64(m,2H),5.46-5.37(m,2H),4.94(d,J=10.9Hz,1H),4.80 -4.75(m,3H),4.70-4.56(m,3H),4.53-4.46(m,2H),4.35-4.27(m,2H),4.02-4.00(m,1H),3.95(s,1H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.71-3.60(m,2H),3.52-3.45(m,2H),3.44(s,3H),3.42(s,3H),3.38-3.29(m,1 H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.88(dd,J=2.9,13.7Hz,1H),2.85-2.78(m,1H),2.53-2.45(m,2H),2.37-2.28( m,3H),2.28-2.18(m,2H),1.93-1.87(m,1H),1.78-1.72(m,1H),1.69-1.35(m,22H),1.29-1.23(m,10H),1.20(d,J=7.4Hz,1H ),1.17-1.12(m,4H),0.92(t,J=7.4Hz,3H),0.89-0.85(m,1H),0.83(d,J=6.3Hz,3H),0.81-0.75(m,5H);MSm / z960.5689[M+H] + .

[0299] Preparation of Compound I-80 Compound I-80 (yield 25.5 mg, 77%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-(oxetan-3-ylmethyl)hydroxylamine obtained in Reference Example 13-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.83(td,J=2.3,10.3Hz,1H),5.76-5.63(m,2H),5.43-5.35(m,2H),4.93(d,J=11.5Hz,1 H),4.88(s,1H),4.81-4.74(m,3H),4.70-4.60(m,3H),4.50(dt,J=1.4,6.2Hz,2H),4.32(d,J=6.9Hz,2H),3.92(br s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.59(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.37-3.29( m,1H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.77(dd,J=3.4,12.0Hz,1H),2.62-2.54(m,1H),2.53-2.44(m,2H),2.37- 2.30(m,2H),2.29-2.18(m,2H),1.93-1.80(m,3H),1.77-1.70(m,1H),1.68-1.60(m,3H),1.59-1.34(m,10H),1.31-1.23(m ,7H),1.14(dd,J=2.6,6.6Hz,6H),0.91(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.81-0.71(m,4H);MSm / z977.5950[M+NH4] + .

[0300] Preparation of Compound I-81: Compound I-81 (yield 3.1 mg, 11%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-77] except that isopropylsulfonium chloride was used instead of phenylsulfonyl chloride. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.86(td,J=10.5,2.5Hz,1H),5.78-5.65(m,2H),5.45-5.37(m,2H),5.01-4.97(m,1 H),4.94(d,J=10.3Hz,1H),4.79(s,1H),4.76(d,J=3.4Hz,1H),4.71-4.55(m,3H),4.24-4.16(m,2H),3.93(br s,1H),3.86-3.80(m,1H),3.80-3.73(m,1H),3.71-3.60(m,2H),3.52-3.45(m,2H),3.44(s,3H),3.42(s,3H),3.4 1-3.35(m,2H),3.27-3.19(m,2H),3.19-3.11(m,2H),2.91-2.83(m,2H),2.54-2.45(m,1H),2.37-2.28(m,3H),2. 28-2.18(m,2H),1.93-1.88(m,1H),1.78-1.72(m,1H),1.70-1.33(m,12H),1.31-1.23(m,11H),1.16(d,J=6.9Hz, 3H),0.92(t,J=7.2Hz,3H),0.89-0.86(m,2H),0.84(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z1056.6042[M+NH4] + .

[0301] Preparation of Compound I-82 Compound I-82 (yield 6.3 mg, 23%) was obtained in the same manner as in [Preparation of Compound I-78] except that isopropylsulfonium chloride was used instead of phenylsulfonyl chloride. 1H-NMR(500MHz,CDCl3,δ):5.83(td,J=2.5,10.5Hz,1H),5.78-5.63(m,2H),5.44-5.35(m,2 H),4.98-4.91(m,3H),4.76(d,J=3.4Hz,1H),4.72-4.59(m,3H),4.24-4.16(m,2H),3.93(br s,1H),3.87-3.80(m,1H),3.80-3.73(m,1H),3.71-3.59(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.41-3. 37(m,2H),3.27-3.19(m,2H),3.19-3.10(m,2H),2.81-2.75(m,1H),2.66-2.59(m,1H),2.53-2.45(m,2H),2.37-2.31( m,2H),2.30-2.18(m,2H),1.93-1.83(m,3H),1.76-1.70(m,1H),1.69-1.38(m,8H),1.35(d,J=6.9Hz,6H),1.29-1.23( m,7H),1.18-1.14(m,6H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.3Hz,3H),0.78(d,J=5.7Hz,4H);MSm / z1056.6042[M+NH4] + .

[0302] Reference Example 14 (1) Production of 2-((1-((tert-butyldimethylsilyl)oxy)cycloprop)methoxy)isoindoline-1,3-dione In accordance with the method described in WO 2020 / 260857, 2-((1-((tert-butyldimethylsilyl)oxy)cycloprop)methoxy)isoindoline-1,3-dione (yield 1.17 g, 42%) was obtained using methyl 1-hydroxycyclopropane-1-carboxylate (3 g, 25.8 mmol) as a starting material. 1H-NMR (500 MHz, CDCl3, δ): 7.81 (dd, J = 5.5, 3.0 Hz, 2H), 7.73 (dd, J = 5.5, 3.0 Hz, 2H), 4.18 (s, 2H), 0.90-0.87 (m, 2H), 0.83 (s, 9H), 0.85-0.82 (m, 2H), 0.17 (s, 6H). (2) Preparation of 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-ol 2-((1-((tert-butyldimethylsilyl)oxy)cycloprop)methoxy)isoindoline-1,3-dione (500 mg, 1.43 mmol) obtained in Reference Example 14-(1) was dissolved in ethanol (14 mL). To this solution, hydrazine monohydrate (76.9 μL, 1.52 mmol) was added, and the mixture was stirred at 60°C for 30 minutes. After completion of the reaction, the reaction solution was cooled to 0°C, and the resulting precipitate was removed by filtration. The solvent was removed from the filtrate by distillation under reduced pressure, yielding 2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethan-1-ol (yield: 261 mg, 83%). 1 H-NMR (500MHz, DMSO-d6, δ): 3.52 (s, 2H), 0.77 (d, J = 1.1 Hz, 9 H), 0.55 (s, 4 H), 0.05 (d, J = 1.1 Hz, 6 H).

[0303] Preparation of Compound I-83 and Compound I-84 Compound I-83 (yield 12.7 mg, 34%) and Compound I-84 (yield 16.7 mg, 45%) were obtained in the same manner as in [Preparation of Compound I-1], except that O-((1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methyl)hydroxylamine obtained in Reference Example 14-(2) was used instead of hydroxylamine hydrochloride in [Preparation of Compound I-1], and purification was carried out by preparative thin-layer silica gel column chromatography (n-hexane / ethyl acetate system) instead of silica gel chromatography. (Compound I-83) 1H-NMR(500 MHz, CDCl3, δ): 5.87 - 5.81 (m, 1H), 5.77 - 5.66 (m, 2H), 5.45 - 5.37 (m, 2H), 4.98 - 4.93 (m, 1H), 4.83 (s, 1H), 4.77 (d, J = 3.4 Hz, 1H), 4.69 - 4.49 (m, 3H), 4.25 - 4.18 (m, 1H), 4.14 - 4.00 (m, 1H), 3.93 (br s, 1H), 3.86 - 3.80 (m, 1H), 3.79 - 3.73 (m, 1H), 3.71 - 3.60 (m, 2H), 3.52 - 3.45 (m, 1H), 3.44 (s, 3H), 3.42 (s, 3H), 3.26 - 3.20 (m, 2H), 3.16 (t, J = 9.2 Hz, 1H), 2.93 - 2.86 (m, 1H), 2.86 - 2.75 (m, 1H), 2.53 - 2.45 (m, 2H), 2.37 - 2.30 (m, 3H), 2.30 - 2.19 (m, 2H), 1.93 - 1.87 (m, 1H), 1.79 - 1.73 (m, 1H), 1.69 - 1.64 (m, 1H), 1.63 - 1.36 (m, 12H), 1.30 - 1.23 (m, 10H), 1.18 - 1.13 (m, 3H), 0.92 (t, J = 7.4 Hz, 3H), 0.86 - 0.80 (m, 14H), 0.78 (d, J = 6.3 Hz, 3H), 0.74 - 0.61 (m, 4H), 0.10 (s, 3H), 0.10 (s, 3H); MS m / z 1091.6815 [M + NH4] + 。(Compound I-84) 1H-NMR(500MHz,CDCl3,δ):5.85(td,J=2.3,10.3Hz,1H),5.76-5.64(m,2H),5.46-5.38(m,2H),4.95(d,J=9.7Hz,1H),4.76(d,J=3.4Hz,1H),4.60(s,1H),4.67-4.55(m,2H),4.23(d,J=11.5Hz,1H),4.06(d,J=11.5Hz,1H),3.96(s,1H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.71-3.60(m,2H),3.60-3.53(m,1H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.20(m,2H),3.16(t,J=9.2Hz,1H),2.90(dd,J=2.9,13.7Hz,1H),2.49(d,J=2.3Hz,2H),2.34(dd,J=4.3,12.3Hz,2H),2.23(d,J=5.7Hz,3H),1.93-1.87(m,1H),1.79-1.72(m,1H),1.69-1.64(m,1H),1.61-1.36(m,10H),1.26(dd,J=6.3,12.0Hz,8H),1.22(d,J=6.9Hz,3H),1.15(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.89-0.85(m,1H),0.85-0.81(m,13H),0.80-0.77(m,4H),0.74-0.62(m,3H),0.10(s,3H),0.10(s,3H);MSm / z1091.6815[M+NH4] + 。

[0304] Preparation of Compound I-85 and Compound I-86 Compound I-83 (12.7 mg, 0.0118 mmol) obtained in [Preparation of Compound I-83 and Compound I-84] was dissolved in THF (0.24 mL) and then cooled to 0°C on ice. A hydrogen fluoride pyridine solution (0.108 mL, 1.18 mmol) was added thereto, and the mixture was stirred at room temperature for 20 minutes. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-85 (yield 4.4 mg, 55%) and Compound I-86 (yield 1.8 mg, 19%). (Compound I-85) 1 H-NMR(500MHz,CDCl3,δ):5.85-5.79(m,1H),5.77-5.67(m,2H),5.43-5.35(m,1H), 5.33-5.27(m,1H),4.69-4.54(m,3H),4.21-4.18(m,1H),4.17-4.04(m,2H),3.99(br s,1H),3.96(s,1H),3.72-3.64(m,1H),3.59-3.52(m,1H),3.20-3.16(m,1H),2.88(dd, J=2.9,13.7Hz,1H),2.55-2.46(m,1H),2.36-2.21(m,3H),1.92-1.83(m,1H),1.76-1.7 1(m,1H),1.69-1.46(m,15H),1.46-1.37(m,4H),1.28-1.21(m,5H),1.17(d,J=6.9Hz,4 H),0.95(t,J=7.4Hz,3H),0.85-0.77(m,10H),0.67-0.60(m,2H);MSm / z672.4112[M+H] + . (Compound I-86) 1H-NMR(500MHz,CDCl3,δ):5.89-5.84(m,1H),5.77-5.64(m,2H),5.47-5.3 7(m,1H),4.97-4.92(m,1H),4.82-4.79(m,1H),4.69-4.54(m,3H),4.21-4. 17(m,1H),4.13-4.09(m,1H),3.97(s,1H),3.96-3.93(m,1H),3.89-3.83(m ,1H),3.73-3.64(m,1H),3.60-3.53(m,2H),3.49(s,3H),3.42-3.32(m,1H) ,3.24-3.19(m,1H),3.18-3.14(m,1H),2.93-2.88(m,1H),2.53-2.45(m,2H ),2.37-2.22(m,5H),1.93-1.86(m,2H),1.80-1.74(m,2H),1.71-1.34(m,9 H),1.32-1.22(m,8H),1.14(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.86-0 .83(m,5H),0.78(d,J=6.3Hz,4H),0.67-0.59(m,2H);MSm / z816.4898[M+H] + .

[0305] Preparation of Compound I-87 and Compound I-88 Compound I-87 (yield 5.9 mg, 56%) and Compound I-88 (yield 3.3 mg, 26%) were obtained in the same manner as in [Preparation of Compound I-85 and Compound I-86] except that Compound I-84 was used instead of Compound I-83. (Compound I-87) 1H-NMR(500 MHz, CDCl3, δ): 5.85 - 5.80 (m, 1H), 5.76 - 5.67 (m, 2H), 5.43 - 5.35 (m, 1H), 5.32 - 5.27 (m, 1H), 4.68 - 4.56 (m, 3H), 4.22 - 4.17 (m, 1H), 4.16 - 4.04 (m, 2H), 4.00 (br s, 1H), 3.96 (s, 1H), 3.72 - 3.64 (m, 1H), 3.59 - 3.51 (m, 1H), 3.21 - 3.17 (m, 1H), 2.88 (dd, J = 2.9, 13.7 Hz, 1H), 2.54 - 2.45 (m, 1H), 2.37 - 2.21 (m, 3H), 1.91 - 1.86 (m, 1H), 1.77 - 1.70 (m, 1H), 1.69 - 1.63 (m, 2H), 1.61 - 1.44 (m, 9H), 1.44 - 1.37 (m, 3H), 1.30 - 1.21 (m, 7H), 1.17 (d, J = 6.9 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H), 0.87 (s, 1H), 0.85 - 0.74 (m, 10H), 0.67 - 0.58 (m, 2H); MS m / z 672.4112 [M + H] + . (Compound I-88) 1H-NMR(500MHz,CDCl3,δ):5.86(td,J=2.4,10.2Hz,1H),5.77-5.64(m,2H),5.47-5.38(m,1H),4.96-4.91(m,1H),4.8 1(d,J=3.4Hz,1H),4.68-4.61(m,2H),4.60-4.55(m,1H),4.21-4.17(m,1H),4.15-4.08(m,1H),3.97(s,1H),3.95(br s,1H),3.90-3.83(m,1H),3.72-3.65(m,1H),3.60-3.54(m,2H),3.49(s,3H),3.42-3.30(m,1H),3.24-3.19 (m,1H),3.16(t,J=9.2Hz,1H),2.90(dd,J=2.9,13.2Hz,1H),2.56-2.44(m,2H),2.38-2.22(m,4H),1.93-1.8 7(m,1H),1.79-1.73(m,1H),1.70-1.64(m,1H),1.62-1.35(m,10H),1.27(d,J=6.3Hz,4H),1.26-1.22(m,4H ),1.14(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.87-0.76(m,10H),0.68-0.58(m,2H);MSm / z816.4898[M+H] + .

[0306] Preparation of Compound I-89

[0222] Compound I-89 (yield 17.5 mg, 48%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-((1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methyl)hydroxylamine obtained in Reference Example 14-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.85-5.79(m,1H),5.76-5.64(m,2H),5.43-5.35(m,2H),4.97-4.92(m,1H),4.94(s,1H) ),4.76(d,J=3.4Hz,1H),4.68-4.56(m,2H),4.51(s,1H),4.20(d,J=11.5Hz,1H),4.07(d,J=11.5Hz,1H),3.93(br s,1H),3.86-3.80(m,1H),3.80-3.73(m,1H),3.70-3.60(m,2H),3.51-3 .45(m,1H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m, 2H),3.16(t,J=9.2Hz,1H),2.78(dd,J=2.9,12.6Hz,1H),2.64-2.55(m, 1H),2.53-2.45(m,2H),2.37-2.19(m,4H),1.93-1.86(m,2H),1.85-1.7 8(m,1H),1.77-1.72(m,1H),1.68-1.63(m,1H),1.57-1.35(m,6H),1.27 (d,J=6.3Hz,4H),1.25(d,J=6.3Hz,4H),1.16(d,J=3.4Hz,3H),1.15(d, J=2.9Hz,3H),0.92(t,J=7.2Hz,3H),0.88-0.82(m,8H),0.82-0.76(m,12H),0.73-0.64(m,4H),0.09(d,J=5.2Hz,6H);MSm / z1091.6815[M+NH4] + .

[0307] Preparation of Compound I-90 and Compound I-91 Compound I-90 (yield 6.5 mg, 59%) and Compound I-91 (yield 2.6 mg, 20%) were obtained in the same manner as in [Preparation of Compound I-85 and Compound I-86] except that Compound I-89 was used instead of Compound I-83. (Compound I-90) 11H-NMR (500 MHz, CDCl3, δ): 5.82 - 5.77 (m, 1H), 5.73 - 5.69 (m, 2H), 5.40 - 5.33 (m, 1H), 5.32 - 5.27 (m, 1H), 5.03 (s, 1H), 4.76 (s, 1H), 4.72 - 4.63 (m, 2H), 4.18 - 4.14 (m, 1H), 4.08 - 4.04 (m, 1H), 3.99 (br s, 1H), 3.71 - 3.64 (m, 1H), 3.20 - 3.16 (m, 1H), 2.77 (dd, J = 4.0, 12.0 Hz, 1H), 2.68 - 2.61 (m, 1H), 2.54 - 2.47 (m, 1H), 2.36 - 2.23 (m, 2H), 2.17 (s, 1H), 1.91 - 1.83 (m, 3H), 1.74 - 1.69 (m, 1H), 1.69 - 1.46 (m, 7H), 1.44 - 1.36 (m, 4H), 1.27 - 1.23 (m, 2H), 1.17 (dd, J = 1.7, 6.9 Hz, 6H), 0.95 (t, J = 7.4 Hz, 3H), 0.83 (d, J = 6.9 Hz, 4H), 0.80 - 0.76 (m, 6H), 0.66 - 0.56 (m, 2H); MS m / z 672.4112 [M + H] + 。(Compound I-91) 1H-NMR(500MHz,CDCl3,δ):5.84(td,J=2.4,10.6Hz,1H),5.77-5.64(m,2H),5.44-5.36(m,1H),5.04(s,1 H),4.96-4.91(m,1H),4.81(d,J=4.0Hz,1H),4.67(s,2H),4.18-4.14(m,1H),4.10-4.05(m,1H),3.95(br s,1H),3.90-3.83(m,1H),3.72-3.65(m,1H),3.60-3.54(m,1H),3.49(s,3H),3.23-3.19(m,1H),3.16(t, J=9.2Hz,1H),2.80(dd,J=4.6,11.5Hz,1H),2.69-2.62(m,1H),2.54-2.47(m,2H),2.37-2.31(m,2H),2.2 9-2.22(m,2H),1.92-1.86(m,4H),1.77-1.72(m,2H),1.68-1.65(m,3H),1.59-1.36(m,10H),1.29-1.24( m,5H),1.19-1.11(m,3H),0.94-0.91(m,3H),0.86-0.76(m,6H),0.67-0.54(m,2H);MSm / z816.4907[M+H] + .

[0308] Preparation of Compound I-92: Compound I-83 (15.0 mg, 0.0140 mmol) obtained in [Preparation of Compound I-83 and Compound I-84] was dissolved in THF (0.23 mL), and the reaction solution was cooled to -10°C. Pyridine (0.75 mL) and a hydrogen fluoride pyridine solution (0.125 mL) were added, and the mixture was stirred at the same temperature for 30 minutes. A hydrogen fluoride pyridine solution (62.5 μL) was then added, and the mixture was stirred at the same temperature for 30 minutes. Thereafter, a hydrogen fluoride pyridine solution (0.11 mL) was added again, and the mixture was heated to 0°C and stirred for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-92 (yield 10.8 mg, 81%). 1H-NMR(500MHz,CDCl3,δ):5.88-5.83(m,1H),5.78-5.65(m,2H),5.44-5.37(m,2H),4.97-4.92(m,1H),4.91(s,1H) ),4.76(d,J=3.4Hz,1H),4.71-4.62(m,3H),4.16-4.13(m,1H),4.11(d,J=6.9Hz,1H),4.08-4.04(m,1H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.71-3.59(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s, 3H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.91-2.85(m,2H),2.57-2.46(m,2H),2.39-2.19(m,5H),2. 13(s,2H),1.92-1.85(m,2H),1.79-1.71(m,2H),1.71-1.35(m,9H),1.30-1.23(m,12H),1.20-1.13(m,4H) ,0.92(t,J=7.4Hz,3H),0.84(d,J=6.9Hz,2H),0.82-0.75(m,6H),0.65-0.57(m,2H);MSm / z960.5684[M+H] + .

[0309] Preparation of Compound I-93 Compound I-93 (yield 14.1 mg, 95%) was obtained in the same manner as in [Preparation of Compound I-92] except that compound I-84 was used instead of compound I-83. 1H-NMR(500MHz,CDCl3,δ):5.88-5.83(m,1H),5.77-5.65(m,2H),5.47-5.38(m,2H),4.97-4.92(m,1H),4.76(d,J=3.4H) z,1H),4.64(s,1H),4.68-4.62(m,1H),4.61-4.56(m,1H),4.21-4.17(m,1H),4.13-4.09(m,1H),3.97(s,1H),3.93(br s,1H),3.87-3.80(m,1H),3.80-3.73(m,1H),3.71-3.54(m,3H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3. 26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.90(dd,J=13.7,2.9Hz,1H),2.58-2.45(m,2H),2.36-2.19(m,5H),2.13 (s,1H),1.93-1.86(m,1H),1.79-1.72(m,1H),1.70-1.35(m,13H),1.27(d,J=6.3Hz,4H),1.24(dd,J=6.9,4.6Hz ,6H),1.16(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.88-0.76(m,10H),0.67-0.59(m,2H);MSm / z960.5684[M+H] + .

[0310] Preparation of Compound I-94 Compound I-94 (yield 14.8 mg, 85%) was obtained in the same manner as in [Preparation of Compound I-92] except that compound I-89 was used instead of compound I-83. 1H-NMR(500MHz,CDCl3,δ):5.83(td,J=10.6,2.4Hz,1H),5.77-5.64(m,2H),5.44-5.36(m,2H),5.04(s,1H),4.97- 4.92(m,1H),4.76(d,J=3.4Hz,1H),4.75(s,1H),4.69-4.66(m,2H),4.18-4.13(m,1H),4.09-4.04(m,1H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.59(m,3H),3.44(s,3H),3.42(s,3H),3.51-3.38(m,2H),3.27-3.19( m,2H),3.16(t,J=9.2Hz,1H),2.80(dd,J=11.7,4.3Hz,1H),2.69-2.61(m,1H),2.54-2.45(m,2H),2.37-2.18(m,5H),2.13( s,1H),1.92-1.84(m,3H),1.76-1.71(m,1H),1.68-1.35(m,10H),1.27(d,J=5.7Hz,4H),1.25(d,J=6.3Hz,4H),1.16(dd,J= MSm / z960.5684[M+H] + .

[0311] Preparation of Compound I-95: To a solution of compound I-23 (20 mg, 0.0214 mmol) obtained in [Preparation of Compound I-23] in DMF (0.21 mL), DIPEA (22.4 μL, 0.129 mmol), isobutyric acid (11.9 μL, 0.129 mmol), and HATU (16.3 mg, 0.0428 mmol) were added, and the mixture was stirred at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction solution to quench the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (n-hexane / ethyl acetate system) to obtain compound I-95 (yield 17.7 mg, 82%). 1H-NMR(500MHz,CDCl3,δ):6.14-6.09(m,1H),5.84(td,J=10.7,2.4Hz,1H),5.77-5.65(m,2H),5.44-5.35(m ,2H),4.95(s,1H),4.95-4.91(m,1H),4.76(d,J=2.9Hz,1H),4.71-4.62(m,2H),4.20-4.11(m,2H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.60(m,2H),3.56-3.44(m,4H),3.44(s,3H),3.42(s,3H),3.26-3.19( m,2H),3.16(t,J=9.2Hz,1H),2.82-2.77(m,1H),2.67-2.59(m,1H),2.53-2.45(m,1H),2.36-2.19(m,6H),1.92-1.84(m,4 H),1.76-1.71(m,1H),1.59-1.34(m,7H),1.27(d,J=6.3Hz,5H),1.25(d,J=6.3Hz,5H),1.16(t,J=6.9Hz,7H),1.13(dd,J= MSm / z1003.6106[M+H] + .

[0312] Preparation of Compound I-96 Compound I-96 (yield 17.1 mg, 80%) was obtained in the same manner as in [Preparation of Compound I-95] except that glycolic acid was used instead of isobutyric acid. 1H-NMR(500MHz,CDCl3,δ):5.83(td,J=10.9,2.3Hz,1H),5.78-5.63(m,2H),5.44-5.36(m,2H),4.94(s,1 H),4.97-4.91(m,1H),4.76(d,J=3.4Hz,1H),4.70-4.62(m,2H),4.28-4.15(m,2H),4.04(s,2H),3.93(br s,1H),3.87-3.79(m,1H),3.79-3.72(m,1H),3.71-3.59(m,2H),3.56(q,J=4.8Hz,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3. 27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.79(dd,J=4.9,11.2Hz,1H),2.66-2.58(m,1H),2.53-2.45(m,1H),2.36-2.31(m,2H),2.30-2. 19(m,3H),1.93-1.81(m,3H),1.75-1.69(m,1H),1.69-1.63(m,1H),1.59-1.34(m,12H),1.27(d,J=6.3Hz,4H),1.25(d,J=6.3Hz,4H),1 .16(dd,J=3.7,6.6Hz,6H),0.92(t,J=7.2Hz,3H),0.87(t,J=6.9Hz,1H),0.83(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z991.5743[M+H] + .

[0313] Preparation of Compound I-97 Compound I-97 (yield 16.3 mg, 75%) was obtained in the same manner as in [Preparation of Compound I-95] except that cyclopropylacetic acid was used instead of isobutyric acid. 1H-NMR(500MHz,CDCl3,δ):5.83(td,J=10.7,2.4Hz,1H),5.77-5.65(m,2H),5.43-5.35(m,2H),4.9 4(s,1H),4.98-4.91(m,1H),4.76(d,J=3.4Hz,1H),4.70-4.61(m,2H),4.23-4.14(m,2H),3.93(br s,1H),3.87-3.79(m,1H),3.79-3.73(m,1H),3.70-3.45(m,6H),3.44(s,3 H),3.42(s,3H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.81-2.76(m,1H ),2.67-2.57(m,1H),2.53-2.45(m,1H),2.36-2.33(m,1H),2.32(d,J=3.4 Hz,1H),2.29-2.18(m,2H),2.12(d,J=6.9Hz,2H),1.92-1.83(m,3H),1.76- 1.71(m,1H),1.66(d,J=12.6Hz,1H),1.60-1.33(m,10H),1.27(d,J=5.7Hz ,4H),1.25(d,J=6.3Hz,4H),1.16(dd,J=3.7,6.6Hz,6H),0.99-0.94(m,1H) ,0.92(t,J=7.2Hz,3H),0.89-0.85(m,2H),0.83(d,J=6.9Hz,3H),0.81-0. 73(m,5H),0.60-0.53(m,2H),0.16(q,J=5.2Hz,2H);MSm / z1015.6102[M+H] + .

[0314] Preparation of Compound I-98 Compound I-98 (yield 36.3 mg, 67%) was obtained in the same manner as in [Preparation of Compound I-60] except that 2,2,2-trifluoroethylamine hydrochloride was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):7.04(t,J=6.3Hz,1H),5.86(dt,J=10.9,2.6Hz,1H),5.78-5.65(m,2H),5.44-5.37 (m,2H),5.00(s,1H),4.95-4.84(m,2H),4.76(d,J=3.4Hz,1H),4.72-4.60(m,4H),4.13-4.02(m,1H),3.93(br s,1H),3.85-3.60(m,5H),3.50-3.40(m,7H),3.25-3.14(m,3H),2.78(dd ,J=12.3,3.7Hz,1H),2.70-2.63(m,1H),2.52-2.47(m,1H),2.34-2.19(m, 4H),1.91-1.80(m,3H),1.74-1.71(m,1H),1.67-1.64(m,1H),1.58-1.35( m,12H),1.27-1.13(m,12H),0.93-0.74(m,10H);MSm / z1046.5906[M+NH4] + .

[0315] Reference Example 15 Production of O-(azetidin-3-yl)hydroxyamine dihydrochloride With reference to Journal of Medicinal Chemistry (2008), 51(15), 4601-4608, a crude product of O-(azetidin-3-yl)hydroxyamine dihydrochloride (yield 648 mg) was obtained using tert-butyl 3-hydroxyazetidine-1-carboxylate (1.34 g, 7.72 mmol) as a starting material. 1 H-NMR(500MHz,DMSO-d6,δ):9.68-9.16(m,2H),4.66(br s,1H),4.22-3.82(m,4H);MSm / z89.0723[M+H] + .

[0316] Preparation of Compound I-99

[0123] Compound I-99 (yield 4.2 mg, 13%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-1], except that the crude product of O-(azetidin-3-yl)hydroxyamine dihydrochloride obtained in Reference Example 15 was used instead of hydroxyamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.89-5.83(m,1H),5.78-5.65(m,2H),5.43-5.36(m,2H),5.12-5.06(m,1H),5.12-5.00(m,1H),4.98-4. 92(m,1H),4.81(s,0.5H),4.76(d,J=3.4Hz,1H),4.70-4.56(m,2H),4.33-4.23(m,2H),4.21-4.13(m,2H),3.98(s,0.5H),3.93(br s,1H),3.86-3.72(m,3H),3.70-3.59(m,3H),3.44(s,3H),3.42(s,3H),3.53-3.40(m,1H), 3.27-3.19(m,2H),3.16(t,J=9.2Hz,2H),2.94-2.86(m,2H),2.53-2.46(m,2H),2.37-2.19 (m,5H),1.95-1.87(m,2H),1.78-1.73(m,1H),1.69-1.63(m,2H),1.60-1.33(m,9H),1.30- 1.21(m,10H),1.16(d,J=6.9Hz,4H),0.92(s,3H),0.89-0.76(m,8H);MSm / z945.5688[M+H] + .

[0317] Preparation of Compound I-100: Compound I-100 (yield 10.7 mg, 33%) was obtained as a mixture of isomers that are difficult to separate in a similar manner to [Preparation of Compound I-2], except that the crude product of O-(azetidin-3-yl)hydroxyamine dihydrochloride obtained in Reference Example 15 was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.84(td,J=10.7,2.4Hz,1H),5.78-5.64(m,2H),5.39(br s,1H),5.38-5.30(m,1H),5.10-5.03(m,1H),4.98-4.93(m,1H),4.92(s,1H),4.78-4.75(m,1H),4.66(s,2H),4.28-4.13(m,4H),3.93(br s,1H),3.86-3.73(m,3H),3.69-3.61(m,2H),3.43(s,3H),3.41(s,3H),3.51-3.38(m,2H),3.26-3.18(m,2H),3.1 8-3.13(m,1H),2.80-2.75(m,1H),2.67-2.60(m,1H),2.53-2.45(m,1H),2.36-2.30(m,2H),2.28-2.19(m,2H),1.9 7-1.83(m,3H),1.77-1.71(m,1H),1.67-1.62(m,1H),1.58-1.34(m,12H),1.28-1.23(m,8H),1.16(dd,J=6.6,10. 0Hz,6H),0.91(t,J=7.4Hz,3H),0.89-0.85(m,1H),0.82(d,J=6.9Hz,3H),0.80-0.75(m,4H);MSm / z945.5688[M+H] + .

[0318] Preparation of Compound I-101 Compound I-101 (yield 21.8 mg, 70%) was obtained in the same manner as in [Preparation of Compound I-60] except that ethylamine hydrochloride was used instead of dimethylamine. 1H-NMR(500MHz,CDCl3,δ):6.45(t,J=5.7Hz,1H),5.85(dd,J=8.6,2.3Hz,1H),5. 44-5.33(m,2H),4.99(s,1H),4.95(d,J=10.9Hz,1H),4.76-4.53(m,6H),3.93(br s,1H),3.85-3.72(m,2H),3.69-3.60(m,2H),3.50-3.41(m,8H),3.38-3.14(m ,3H),2.80(dd,J=11.7,3.7Hz,1H),2.68-2.61(m,1H),2.51-2.47(m,1H),2.34 -2.19(m,4H),1.90-1.81(m,3H),1.74-1.72(m,1H),1.67-1.65(m,1H),1.58- 1.35(m,13H),1.27-1.10(m,17H),0.93-0.75(m,11H);MSm / z992.6066[M+NH4] + .

[0319] Preparation of Compound I-102 Compound I-102 (yield 23.1 mg, 73%) was obtained in the same manner as in [Preparation of Compound I-60] except that 2-fluoroethylamine hydrochloride was used instead of dimethylamine. 1 H-NMR(500MHz,CDCl3,δ):6.98(t,J=6.0Hz,1H),5.86(dt,J=10.9,2.3Hz,1H),5.78-5.65(m,2H),5. 44-5.36(m,2H),5.00(s,1H),4.95(d,J=10.9Hz,1H),4.76-4.50(m,6H),4.46-4.40(m,1H),3.93(br s,1H),3.85-3.60(m,5H),3.54-3.42(m,8H),3.25-3.14(m,3H),2.81-2.77(m,1H),2.70-2.63(m,1H),2.51-2.46 (m,1H),2.35-2.19(m,4H),1.92-1.34(m,19H),1.28-1.13(m,12H),0.93-0.742(m,10H);MSm / z1010.6110[M+NH4] + .

[0320] Preparation of Compound I-103 Compound I-103 (yield 24.2 mg, 76%) was obtained in the same manner as in [Preparation of Compound I-60] except that isopropylamine was used instead of dimethylamine. 1 H-NMR(500MHz,CDCl3,δ):6.29(d,J=8.6Hz,1H),5.85(dd,J=8.6,2.3Hz,1H),5.78-5.65(m,2H),5.44-5.38(m,2H) ,4.99(s,1H),4.95(d,J=10.9Hz,1H),4.76-4.65(m,4H),4.58(dd,J=25.8,16.0Hz,2H),4.17-4.09(m,1H),3.93(br s,1H),3.85-3.72(m,2H),3.69-3.61(m,2H),3.50-3.41(m,7H),3.25-3.14(m,3H),2.80(dd,J=12.0,4.0Hz,1H),2.68-2.61(m,1H),2.51 -2.46(m,1H),2.34-2.19(m,4H),1.99-1.65(m,6H),1.58-1.34(m,13H),1.27-1.10(m,19H),0.93-0.75(m,10H);MSm / z1006.6337[M+NH4] + .

[0321] Reference Example 16 Preparation of 2-((5-hydroxypentyl)oxy)isoindoline-1,3-dione (MM10-18)

[0123] Using 5-bromopentan-1-ol instead of 1-bromo-2-methoxyethane in Reference Example 5-(1), 5-(aminooxy)pentan-1-ol hydrochloride (yield 368 mg, 88%) was obtained in the same manner as in Reference Examples 5-(1) and (2). 1 H-NMR (500MHz, DMSO-d6, δ): 5.84 (br s, 1H), 3.55 (t, J=6.0Hz, 2H), 3.48 (t, J=6.6Hz, 2H), 1.50-1.38 (m, 4H), 0.823 (s, 9H), 0.823 (s, 6H).

[0322] Preparation of Compound I-104 Compound I-104 (yield 9.3 mg, 28%) was obtained in the same manner as in [Preparation of Compound I-2] except that 5-(aminooxy)pentan-1-ol hydrochloride obtained in Reference Example 16 was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.84-5.82(m,1H),5.75-5.64(m,2H),5.42-5.36(m,2H),4.9 4-4.93(m,2H),4.76(d,J=6.9Hz,1H),4.654-4.650(m,2H),4.12-4.06(m,2H),3.93(br s,1H),3.86-3.74(m,2H),3.68-3.60(m,4H),3.52-3.41(m,8H),3.26-3.15(m,3H),2.80(dd,J=12.6,3.4Hz,1H),2.6 2-2.57(m,1H),2.50-2.47(m,1H),2.36-2.20(m,4H),1.92-1.14(m,51H),0.93-0.77(m,10H);MSm / z998.5876[M+Na] + .

[0323] Preparation of Compound I-105 Compound I-105 (yield 17.4 mg, 62%) was obtained in the same manner as in [Preparation of Compound I-1], except that 1-(aminooxy)-2-methylpropan-2-ol was used instead of hydroxylamine hydrochloride in [Preparation of Compound I-1]. 1H-NMR(500MHz,CDCl3,δ):5.87-5.84(m,1H),5.77-5.65(m,2H),5.45-5.39(m,2H),4.97-4.93(m,1H),4 .76(d,J=3.4Hz,1H),4.70-4.56(m,2H),4.03-3.93(m,4H),3.85-3.74(m,2H),3.69-3.60(m,2H),3.50-3 .41(m,7H),3.25-3.14(m,3H),2.91-2.84(m,1H),2.51-2.47(m,1H),2.35-2.20(m,5H),1.93-1.89(m,1 H),1.76-1.74(m,1H),1.68-1.34(m,15H),1.28-1.14(m,20H),0.93-0.77(m,10H);MSm / z962.5615[M+H] + .

[0324] Preparation of Compound I-106 Compound I-106 (yield 19.2 mg, 69%) was obtained in the same manner as in [Preparation of Compound I-2] except that 1-(aminooxy)-2-methylpropan-2-ol was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.85-5.83(m,1H),5.76-5.65(m,2H),5.43-5.36(m,2H),4. 97-4.93(m,2H),4.76(d,J=3.4Hz,1H),4.69-4.63(m,2H),4.01-3.95(m,2H),3.92(br s,1H),3.85-3.73(m,2H),3.69-3.60(m,2H),3.50-3.41(m,7H),3.25-3.14(m, 3H),2.80-2.77(dd,J=12.6,3.4Hz,1H),2.65-2.60(m,1H),2.50-2.47(m,1H),2 .35-2.20(m,5H),1.93-1.82(m,3H),1.74-1.73(m,1H),1.67-1.65(m,1H),1.58 -1.36(m,13H),1.28-1.14(m,20H),0.93-0.77(m,10H);MSm / z979.5811[M+NH4] + .

[0325] Preparation of Compound I-107: Compound I-107 (yield 94.6 mg, 86%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-1] except that 3-(aminooxy)propanoic acid hydrochloride was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.88-5.83(m,1H),5.77-5.65(m,2H),5.40(d,J= 3.4Hz,1H),5.45-5.38(m,1H),4.95(d,J=10.9Hz,1H),4.77(s,1H),4.76(br s,0.6H),4.70-4.56(m,3H),4.30(t,J=5.7Hz,2H),3.96(s,0.4H),3.94-3.92(br s,1H),3.87-3.80(m,1H),3.80-3.73(m,1H),3.71-3.65(m,1H),3.65-3.60(m,1H),3.52-3.46(m,2H),3.44(s,3H),3.4 2(s,3H),3.26-3.20(m,2H),3.17(t,J=9.2Hz,1H),2.91-2.82(m,2H),2.77-2.73(m,2H),2.52-2.46(m,1H),2.37-2.20( m,5H),1.92-1.87(m,3H),1.78-1.72(m,1H),1.69-1.65(m,1H),1.59-1.36(m,14H),1.29-1.24(m,6H),1.20-1.18(m,1 H),1.15(dd,J=1.4,7.2Hz,3H),0.92(t,J=7.4Hz,3H),0.84(d,J=6.9Hz,3H),0.82-0.75(m,5H);MSm / z979.5597[M+NH4] + .

[0326] Preparation of Compound I-108 Compound I-108 (yield 85.5 mg, 78%) was obtained in the same manner as in [Preparation of Compound I-2] except that 3-(aminooxy)propanoic acid hydrochloride was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):6.14(br s,1H),5.84-5.81(m,1H),5.78-5.64(m,2H),5.44-5.36(m,2H),4.94(brd,J=9.7Hz,1 H),4.89(s,1H),4.78-4.74(m,1H),4.70-4.60(m,1H),4.35(t,J=5.7Hz,2H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.59(m,2H),3.51-3.45(m,1H),3.45-3.43(m,3H),3.42-3.4 1(m,3H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.80-2.74(m,4H),2.62(d,J=8.6Hz,1H),2.55-2.45(m,3H),2 .36-2.18(m,5H),1.92-1.83(m,3H),1.76-1.70(m,1H),1.68-1.64(m,1H),1.60-1.34(m,10H),1.28-1.23(m,6H) ),1.16(t,J=5.7Hz,6H),0.92(t,J=7.2Hz,3H),0.83(d,J=6.3Hz,3H),0.80-0.74(m,4H);MSm / z979.5597[M+NH4] + .

[0327] Preparation of Compound I-109: To a solution of compound I-107 (25 mg, 0.026 mmol) obtained in [Preparation of Compound I-107] in DMF (0.26 mL), DIPEA (45 μL, 0.260 mmol), 2 M methylamine THF solution (0.065 mL, 0.065 mmol), and HATU (29.7 mg, 0.078 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Saturated aqueous sodium bicarbonate was added to the reaction solution to quench the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (ethyl acetate) to obtain compound I-109 (yield 16.2 mg, 64%) as a mixture of isomers that are difficult to separate. 1H-NMR(500MHz,CDCl3,δ):6.16(br s,0.4H),5.88-5.83(m,1H),5.82(br s,0.6H),5.78-5.64(m,2H),5.45-5.37(m,2H),4.94(brd,J=10.9Hz,1H),4.77(s, 0.6H),4.76(s,1H),4.71-4.55(m,2H),4.39-4.29(m,2H),3.96(s,0.4H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.71-3.59(m,2H),3.50-3.46(m,1H),3.44(s,3H),3.42-3.41(m,3H),3.26-3.19 (m,2H),3.16(t,J=9.2Hz,1H),2.91-2.81(m,2H),2.78(d,J=5.2Hz,1.2H),2.76(d,J=5.2Hz,1.8H),2.57(t,J=6.0Hz,1H),2.53 -2.47(m,2H),2.37-2.16(m,6H),1.92-1.88(m,1H),1.77-1.72(m,1H),1.68-1.64(m,1H),1.59-1.34(m,15H),1.28-1.23(m,8 H),1.19-1.17(m,1H),1.16(d,J=6.9Hz,3H),0.92(t,J=7.2Hz,3H),0.85-0.82(m,3H),0.80-0.75(m,4H);MSm / z975.5660[M+H] + .

[0328] Preparation of Compound I-110: To a solution of compound I-108 (25 mg, 0.026 mmol) obtained in [Preparation of Compound I-108] in DMF (0.26 mL), DIPEA (45 μL, 0.260 mmol), 2 M methylamine THF solution (0.065 mL, 0.065 mmol), and HATU (29.7 mg, 0.078 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Saturated aqueous sodium bicarbonate was added to the reaction solution to quench the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (ethyl acetate) to obtain compound I-110 (yield 16.2 mg, 64%). 1H-NMR(500MHz,CDCl3,δ):6.14(br s,1H),5.85-5.81(m,1H),5.77-5.63(m,2H),5.44-5.35(m,2H),4.94(brd,J=9.7Hz,1 H),4.90(s,1H),4.78-4.75(m,1H),4.70-4.59(m,2H),4.35(t,J=5.7Hz,2H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.72(m,1H),3.70-3.59(m,2H),3.50-3.45(m,1H),3.45-3.43(m,3H),3.42-3.41(m, 3H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.80-2.77(m,1H),2.76-2.74(m,3H),2.65-2.59(m,1H),2.55-2.47(m ,3H),2.36-2.18(m,5H),1.92-1.84(m,3H),1.76-1.70(m,1H),1.68-1.63(m,1H),1.59-1.36(m,13H),1.28-1.23(m, 7H),1.16(t,J=5.7Hz,6H),0.92(t,J=7.2Hz,3H),0.83(d,J=6.3Hz,3H),0.80-0.76(m,4H);MSm / z1046.5776[M+NH4] + .

[0329] Preparation of Compound I-111 Compound I-111 (yield 22.5 mg, 83%) was obtained in the same manner as in [Preparation of Compound I-110] except that 2,2,2-trifluoroethylamine hydrochloride was used instead of methylamine. 1H-NMR(500MHz,CDCl3,δ):6.47(t,J=6.3Hz,1H),5.82(td,J=2.6,10.9Hz,1H),5.78-5.63(m,2H),5.44-5.37(m,1H),5.40(d,J=4.6Hz,1H),4 .94(brd,J=11.5Hz,1H),4.88(s,1H),4.76(d,J=3.4Hz,1H),4.64(dq,J=2.3,14.1Hz,2H),4.38(t,J=5.4Hz,2H),4.04-3.96(m,1H),3.93(br s,1H),3.87-3.80(m,1H),3.80-3.71(m,2H),3.70-3.60(m,2H),3.50-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.2 0(m,2H),3.16(t,J=8.9Hz,1H),2.80-2.75(m,1H),2.68-2.62(m,1H),2.60-2.56(m,2H),2.53-2.47(m,1H),2.36-2.31( m,2H),2.29-2.20(m,2H),1.93-1.84(m,4H),1.76-1.71(m,2H),1.68-1.64(m,1H),1.60-1.36(m,12H),1.28-1.24(m,7H) ),1.17(dd,J=4.9,6.6Hz,6H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.3Hz,3H),0.80-0.76(m,4H);MSm / z1010.6110[M+NH4] + .

[0330] Preparation of Compound I-112: Compound I-112 (yield 14.0 mg, 67%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-109] except that dimethylamine was used instead of methylamine. 1H-NMR(500MHz,CDCl3,δ):5.87-5.83(m,1H),5.77-5.65(m,2H),5.40(d,J=4.0Hz,1H),5.46-5.37(m,1H),4.94(brd ,J=1.7Hz,1H),4.78(s,0.6H),4.76(d,J=3.4Hz,1H),4.69-4.55(m,2H),4.44-4.36(m,2H),3.96(s,0.4H),3.93(br s,1H),3.85-3.80(m,1H),3.79-3.73(m,1H),3.71-3.60(m,2H),3.51-3.45(m,2H),3.44(s,3H),3.42(s,3H),3.27-3. 20(m,2H),3.16(t,J=9.2Hz,1H),3.01-2.92(m,6H),2.91-2.86(m,1H),2.75-2.70(m,2H),2.52-2.46(m,1H),2.36-2.1 9(m,6H),1.93-1.87(m,1H),1.78-1.74(m,1H),1.68-1.60(m,2H),1.59-1.35(m,12H),1.29-1.23(m,10H),1.19(d,J=7 .4Hz,2H),1.15(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.3Hz,3H),0.82-0.75(m,4H);MSm / z989.6359[M+H] + .

[0331] Preparation of Compound I-113 Compound I-113 (yield 17.5 mg, 85%) was obtained in the same manner as in [Preparation of Compound I-110] except that dimethylamine hydrochloride was used instead of methylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.85-5.80(m,1H),5.76-5.64(m,2H),5.43-5.35(m,2H),4.94(brd,J =10.9Hz,1H),4.89(s,1H),4.78-4.74(m,1H),4.68-4.59(m,2H),4.40(t,J=7.2Hz,2H),3.93(br s,1H),3.86-3.80(m,1H),3.79-3.73(m,1H),3.70-3.59(m,2H),3.51-3.45(m,1 H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.99(br s,3H),2.93(br s,3H),2.80-2.75(m,1H),2.72(q,J=6.9Hz,2H),2.63-2.54(m,1H),2.52-2.45(m,1H),2.3 6-2.18(m,5H),1.93-1.86(m,2H),1.85-1.79(m,1H),1.76-1.72(m,1H),1.68-1.63(m,1H) ,1.59-1.36(m,13H),1.27(d,J=6.3Hz,3H),1.25(d,J=6.3Hz,4H),1.15(dd,J=2.6,7.2Hz, 6H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.79-0.75(m,4H);MSm / z989.6359[M+H] + .

[0332] Preparation of Compound I-114 5-Oxo-ivermectin B1a (50.0 mg, 0.057 mmol) was dissolved in methanol (0.57 mL), and then sodium acetate (28.2 mg, 0.344 mmol) and O-(prop-2-yn-1-yl)hydroxylamine hydrochloride (37.0 mg, 0.344 mmol) were added sequentially, followed by stirring at room temperature for 24 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-114 (yield 45.4 mg, 86%). 1H-NMR(500MHz,CDCl3,δ):5.94-5.90(m,1H),5.83-5.81(m,1H),5.79-5.70( m,2H),5.42-5.36(m,2H),4.96(d,J=10.9Hz,1H),4.78(d,J=2.9Hz,2H),4.7 7-4.64(m,3H),4.58(s,1H),4.00-3.90(m,2H),3.85-3.73(m,2H),3.69-3.5 9(m,2H),3.50-3.46(m,1H),3.43(s,3H),3.42(s,3H),3.38(t,J=2.3Hz,1H), 3.26-3.19(m,2H),3.16(t,J=9.17Hz,1H),2.55-2.47(m,1H),2.45-2.40(m, 1H),2.35-2.18(m,4H),1.99-1.91(m,4H),1.79-1.73(m,1H),1.68-1.62(m, 1H),1.59-1.34(m,13H),1.29-1.22(m,7H),1.16(d,J=6.9Hz,3H),0.92(t,J =7.5Hz,3H),0.86-0.81(m,4H),0.78(d,J=5.2Hz,3H);MSm / z948.5490[M+Na] + .

[0333] Preparation of Compound I-115 5-Oxo-ivermectin B1a (50.0 mg, 0.057 mmol) was dissolved in methanol (1.14 mL), and then sodium acetate (28.2 mg, 0.344 mmol), cesium chloride heptahydrate (25.6 mg, 0.069 mmol), and O-allylhydroxylamine hydrochloride (37.0 mg, 0.344 mmol) were added sequentially at 0°C, followed by stirring at the same temperature for 3 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-115 (yield 34.0 mg, 64%). 1H-NMR(500MHz,CD3OD,δ):6.04-5.96(m,1H),5.96-5.87(m,3H),5.80-5.69( m,1H),5.34(d,J=2.9Hz,1H),5.32-5.27(m,1H),5.21-5.08(m,3H),4.81(d,J =2.9Hz,1H),4.71-4.59(m,4H),4.51(s,1H),4.01-3.96(m,1H),3.91-3.85(m ,1H),3.75-3.60(m,3H),3.44-3.41(m,4H),3.40(s,3H),3.34(t,J=2.3Hz,1H ),3.27(d,J=8.0Hz,1H),3.19(t,J=8.9Hz,1H),3.03(t,J=9.2Hz,1H),2.70- 2.61(m,1H),2.34-2.26(m,4H),2.15(dd,J=12.6Hz,2.9Hz,1H),1.94-1.84(m ,4H),1.69-1.37(m,14H),1.30-1.20(m,8H),1.17(d,J=6.9Hz,3H),0.97(t,J =7.5Hz,3H),0.89(d,J=6.9Hz,3H),0.87-0.78(m,4H);MSm / z950.5767[M+Na] + .

[0334] Reference Example 17 (1) Preparation of 2-(cyclopropylmethoxy)isoindoline-1,3-dione 2-Hydroxyisoindoline-1,3-dione (3.26 g, 20.0 mmol), cyclopropylmethanol (1.44 g, 20.0 mmol), and triphenylphosphine (6.30 g, 24.0 mmol) were dissolved in THF (100 mL) and the solution was ice-cooled to 0°C. Then, a 2.2 M solution of diethyl (E)-diazene-1,2-dicarboxylate in toluene (10.9 ml, 24.0 mmol) was added dropwise, and the mixture was stirred at room temperature for 14 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain 2-(cyclopropylmethoxy)isoindoline-1,3-dione (yield 3.82 g, 88%). 1H-NMR (500 MHz, CDCl3, δ): 7.86-7.82 (m, 2H), 7.77-7.73 (m, 2H), 4.04 (d, J=7.5 Hz, 2H), 1.33-1.24 (m, 1H), 0.65-0.61 (m, 2H), 0.34-0.31 (m, 2H). (2) Preparation of O-(cyclopropylmethyl)hydroxyamine hydrochloride. 2-(Cyclopropylmethoxy)isoindoline-1,3-dione (3.82 g, 17.6 mmol) obtained in Reference Example 17-(1) was dissolved in methylene chloride (35.2 mL), and then methylhydrazine (1.11 mL, 21.1 mmol) was added and the mixture was stirred at room temperature for 2 hours. The suspension was filtered, and the organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine, and then dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, ether and a 4 M solution of hydrogen chloride in 1,4-dioxane (5.28 mL, 21.1 mmol) were added and stirred at room temperature for 15 minutes. The suspension was filtered, and the resulting solid was washed with ether to give O-(cyclopropylmethyl)hydroxyamine hydrochloride (yield: 0.992 g, 46%). 1 H-NMR (500MHz, DMSO-d6, δ): 10.9-10.6 (m, 3H), 3.81-3.78 (m, 2H), 1.10-1.02 (m, 1H), 0.58-0.55 (m, 2H), 0.31-0.27 (m, 2H).

[0335] Preparation of Compound I-116 Compound I-116 (yield 45.0 mg, 83%) was obtained in the same manner as in [Preparation of Compound I-115] except that O-(cyclopropylmethyl)hydroxylamine hydrochloride obtained in Reference Example 17-(2) was used instead of O-allylhydroxylamine hydrochloride. 1H-NMR(500MHz,CD3OD,δ):5.97-5.86(m,3H),5.78-5.70(m,1H),5.34(d,J=2. 86Hz,1H),5.21-5.06(m,2H),4.81(d,J=3.4Hz,1H),4.74-4.58(m,2H),4.52( s,1H),4.01-3.98(m,1H),3.98-3.94(m,2H),3.93-3.85(m,1H),3.75-3.63(m ,3H),3.45-3.41(m,4H),3.40(s,3H),3.35-3.32(m,1H),3.27(d,J=8.6Hz,1H) ,3.19(t,J=8.9Hz,1H),3.03(t,J=9.2Hz,1H),2.70-2.63(m,1H),2.34-2.23( m,4H),2.18-2.11(m,1H),1.94-1.88(m,4H),1.96-1.86(m,1H),1.68-1.38(m ,14H),1.31-1.13(m,11H),0.97(t,J=7.5Hz,3H),0.89(d,J=6.9Hz,3H),0.87 -0.79(m,4H),0.56-0.49(m,2H),0.30(q,J=5.5Hz,2H);MSm / z964.5845[M+Na] + .

[0336] Preparation of Compound I-117 5-Oxo-ivermectin B1a (50.0 mg, 0.057 mmol) was dissolved in methanol (1.14 mL), and then sodium acetate (28.2 mg, 0.344 mmol), lanthanum chloride heptahydrate (25.5 mg, 0.069 mmol), and O-isobutylhydroxylamine hydrochloride (43.2 mg, 0.344 mmol) were added sequentially at 0°C, followed by stirring at room temperature for 4 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) and preparative thin-layer chromatography (n-hexane / acetone = 2:1) to obtain Compound I-117 (yield 45.0 mg, 83%). 1H-NMR(500MHz,CD3OD,δ):5.95-5.88(m,3H),5.78-5.69(m,1H),5.35(d,J=3.44Hz,1H) ,5.19-5.07(m,2H),4.81(d,J=2.9Hz,1H),4.66(q,J=13.9Hz,2H),4.50(s,1H),4.00(br s,1H),3.91(d,J=6.9Hz,2H),3.90-3.84(m,1H),3.75-3.62(m,3H),3.46-3.41(m,4H),3.41-3.37(m,3H) ,3.33(t,J=2.3Hz,1H),3.27(d,J=8.0Hz,1H),3.19(t,J=8.9Hz,1H),3.03(t,J=9.2Hz,1H),2.71-2.61(m ,1H),2.34-2.25(m,4H),2.18-2.11(m,1H),2.05-1.96(m,1H),1.94-1.87(m,4H),1.68-1.38(m,14H),1. 30-1.20(m,7H),1.17(d,J=6.9Hz,3H),0.99-0.83(m,13H),0.81(d,J=5.7Hz,4H);MSm / z966.6112[M+Na] + .

[0337] Preparation of Compound I-118 and Compound I-119 Compound I-114 (80.0 mg, 0.086 mmol) was added to a 3% aqueous solution of sulfuric acid in methanol (1.7 mL) and stirred at room temperature for 3 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) and preparative thin-layer chromatography (chloroform / ethyl acetate = 2:1) to give Compound I-118 (yield 17.0 mg, 31%) and Compound I-119 (yield 33.4 mg, 49%), respectively. (Compound I-118) 1H-NMR(500 MHz, CDCl3, δ): 5.90 - 5.85 (m, 1H), 5.82 - 5.81 (m, 1H), 5.77 - 5.68 (m, 2H), 5.39 - 5.29 (m, 2H), 4.78 (d, J = 2.3 Hz, 2H), 4.75 - 4.70 (m, 1H), 4.68 (d, J = 2.3 Hz, 1H), 4.58 (s, 1H), 4.01 (br s, 1H), 3.91 (s, 1H), 3.70 - 3.64 (m, 1H), 3.36 (q, J = 2.4 Hz, 1H), 3.19 (dd, J = 9.2, 1.7 Hz, 1H), 2.52 (ddd, J = 9.3, 7.0, 2.6 Hz, 1H), 2.45 - 2.44 (m, 1H), 2.34 - 2.26 (m, 2H), 1.99 - 1.93 (m, 4H), 1.77 - 1.73 (m, 1H), 1.67 - 1.59 (m, 4H), 1.57 - 1.40 (m, 8H), 1.34 (t, J = 11.7 Hz, 1H), 1.17 (d, J = 6.9 Hz, 3H), 0.96 (t, J = 7.5 Hz, 3H), 0.87 - 0.78 (m, 7H); MS m / z 660.4483 [M + Na] + . (Compound I-119) 1H-NMR(500MHz,CDCl3,δ):5.93-5.89(m,1H),5.82(dd,J=2.3,1.2Hz,1H),5.79-5.68(m,2H),5.38(t,J=4.9Hz,1H), 4.96(dt,J=10.9,1.7Hz,1H),4.81(d,J=3.4Hz,1H),4.78(d,J=2.3Hz,2H),4.76-4.63(m,2H),4.58(s,1H),3.95(br s,1H),3.92(s,1H),3.86(dd,J=9.2,6.3Hz,1H),3.70-3.63(m,1H),3.59-3.51(m,1H),3 .48(s,3H),3.38(t,J=2.3Hz,1H),3.22(d,J=7.5Hz,1H),3.16(t,J=9.2Hz,1H),2.60(br s,1H),2.56-2.48(m,1H),2.45-2.43(m,1H),2.36-2.20(m,3H),2.12(s ,1H),2.03-1.92(m,4H),1.80-1.74(m,1H),1.70-1.61(m,1H),1.57-1. 36(m,12H),1.27(d,J=6.3Hz,3H),1.15(d,J=6.9Hz,3H),0.93(t,J=7.2Hz,3H),0.87-0.80(m,4H),0.78(d,J=5.7Hz,3H);MSm / z804.5444[M+Na] + .

[0338] Preparation of Compound I-120 Compound I-120 (yield 11.7 mg, 20%) was obtained in the same manner as in [Preparation of Compound I-117] except that O-ethylhydroxylamine was used instead of O-isobutylhydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.93-5.91(dd,J=8.0,2.3Hz,1H),5.831-5.827(m,1H),5.79-5.69(m,2H),5.42-5. 36(m,2H),4.98(d,J=11.5Hz,1H),4.77-4.65(m,3H),4.64(s,1H),4.31(t,J=2.3Hz,2H),3.99(s,1H),3.94(br s,1H),3.87-3.74(m,4H),3.69-3.59(m,2H),3.50-3.42(m,7H),3.67- 3.36(m,1H),3.26-3.14(m,3H),2.53-2.94(m,2H),2.35-2.20(m,4H), 1.98-1.94(m,4H),1.77-1.75(m,1H),1.67-1.35(m,16H),1.27-1.25( m,7H),1.17-1.15(m,2H),0.94-0.78(m,11H);MSm / z949.5826[M+NH4] + .

[0339] Preparation of Compound I-121 Compound I-121 (yield 21.9 mg, 58%) was obtained in the same manner as in [Preparation of Compound I-117] except that O-(2-hydroxyethyl)hydroxylamine hydrochloride obtained in Reference Example 5-(2) was used instead of O-isobutylhydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.93-5.88(m,1H),5.79-5.77(m,1H),5.76-5.70(m,2H),5.42-5.35(m,2H) ,5.00-4.94(m,1H),4.77(d,J=3.4Hz,1H),4.74-4.63(m,2H),4.60(s,1H),4.39-4.29(m,2H),3.94(br s,1H),3.91(s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.59(m,4H),3.51-3.45(m,1H),3.43(s,3H),3.42(s,3 H),3.39-3.37(m,1H),3.36(s,3H),3.26-3.20(m,2H),3.16(t,J=9.2Hz,1H),2.55-2.46(m,2H),2.36-2.30(m,2H),2.3 0-2.18(m,2H),2.00-1.95(m,1H),1.93(d,J=2.3Hz,3H),1.80-1.73(m,1H),1.67-1.63(m,1H),1.68-1.33(m,7H),1.32 -1.23(m,9H),1.16(d,J=6.9Hz,3H),0.93(t,J=7.2Hz,3H),0.90-0.83(m,6H),0.82-0.75(m,4H);MSm / z946.5528[M+H] + .

[0340] Preparation of Compound I-122 Compound I-122 (yield 21.9 mg, 58%) was obtained in the same manner as in [Preparation of Compound I-117] except that O-(2-methoxyethyl)hydroxylamine hydrochloride obtained in Reference Example 5-(2) was used instead of O-isobutylhydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.93-5.88(m,1H),5.79-5.77(m,1H),5.76-5.70(m,2H),5.42-5.35(m,2H) ,5.00-4.94(m,1H),4.77(d,J=3.4Hz,1H),4.74-4.63(m,2H),4.60(s,1H),4.39-4.29(m,2H),3.94(br s,1H),3.91(s,1H),3.86-3.79(m,1H),3.79-3.73(m,1H),3.70-3.59(m,4H),3.51-3.45(m,1H),3.43(s,3H),3.42(s,3 H),3.39-3.37(m,1H),3.36(s,3H),3.26-3.20(m,2H),3.16(t,J=9.2Hz,1H),2.55-2.46(m,2H),2.36-2.30(m,2H),2.3 0-2.18(m,2H),2.00-1.95(m,1H),1.93(d,J=2.3Hz,3H),1.80-1.73(m,1H),1.67-1.63(m,1H),1.68-1.33(m,7H),1.32 -1.23(m,9H),1.16(d,J=6.9Hz,3H),0.93(t,J=7.2Hz,3H),0.90-0.83(m,6H),0.82-0.75(m,4H);MSm / z946.5528[M+H] + .

[0341] Preparation of Compound I-123 Compound I-123 (yield 15.9 mg, 49%) was obtained in the same manner as in [Preparation of Compound I-117] except that 3-(aminooxy)propan-1-ol hydrochloride obtained in Reference Example 8 was used instead of O-isobutylhydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.93-5.88(m,1H),5.81-5.78(m,1H),5.77-5.66(m,2H),5.42-5.34(m,2H),4.99 -4.92(m,1H),4.76(d,J=2.9Hz,1H),4.73-4.68(m,1H),4.66-4.61(m,1H),4.54(s,1H),4.36(t,J=5.7Hz,2H ),3.98-3.94(m,1H),3.94-3.91(m,1H),3.86-3.79(m,1H),3.78-3.72(m,3H),3.70-3.59(m,2H),3.51-3.4 4(m,1H),3.42(s,3H),3.41(s,3H),3.34(t,J=2.3Hz,1H),3.26-3.19(m,2H),3.15(t,J=9.2Hz,1H),2.59(br s,1H),2.54-2.47(m,1H),2.36-2.18(m,4H),2.00-1.91(m,6H),1.77-1.72(m,2H),1.67-1.62(m,1H),1.58-1.33(m,11H),1.29-1.23( m,7H),1.15(d,J=6.9Hz,3H),0.92(t,J=7.2Hz,3H),0.86-0.83(m,1H),0.84(d,J=6.9Hz,3H),0.81-0.75(m,4H);MSm / z968.5347[M+Na] + .

[0342] Preparation of 5-[(carboxymethoxy)imino]-ivermectin B1a 5-[(carboxymethoxy)imino]-ivermectin B1a (yield 108 mg, 83%) was obtained in the same manner as in [Preparation of compound I-117] except that 2-(aminooxy)acetic acid ½ hydrochloride was used instead of O-isobutylhydroxylamine hydrochloride. 1H-NMR(500MHz,CD3OD,δ):6.27-6.22(m,1H),6.23-6.16(m,1H),6.01-5.85(m,2H),5 .78-5.66(m,1H),5.33(d,J=3.4Hz,1H),5.29-5.21(m,1H),5.20-4.98(m,2H),4.81- 4.74(m,1H),4.71-4.54(m,4H),4.00-3.96(m,1H),3.95-3.92(m,1H),3.92-3.82(m, 1H),3.75-3.60(m,3H),3.43-3.41(m,1H),3.40(s,3H),3.38(s,3H),3.34-3.31(m,1H ),3.30-3.27(m,2H),3.26-3.21(m,1H),3.17(t,J=8.9Hz,1H),3.01(t,J=8.9Hz,1H) ,2.69-2.62(m,1H),2.60-2.50(m,1H),2.33-2.23(m,4H),2.16-2.09(m,1H),1.92-1. 87(m,3H),1.85-1.80(m,1H),1.68-1.36(m,9H),1.35-1.26(m,1H),1.26-1.22(m,4H ),1.21(d,J=6.3Hz,4H),1.16(d,J=6.9Hz,3H),0.98-0.91(m,3H),0.91-0.76(m,7H).

[0343] Preparation of Compound I-124 5-[(carboxymethoxy)imino]-ivermectin B1a (24 mg, 0.025 mmol) was dissolved in dichloromethane (0.25 mL), DIPEA (22 μL, 0.127 mmol) and HATU (14.5 mg, 0.038 mmol) were added, and the mixture was stirred at room temperature for 15 minutes. Then, 2 M methylamine THF solution (38 μL, 0.076 mmol) was added, and the mixture was stirred overnight at room temperature. Saturated aqueous sodium bicarbonate was added to the reaction mixture to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (chloroform / methanol system) to obtain Compound I-124 (yield 6.2 mg, 25%). 1H-NMR(500MHz,CDCl3,δ):7.05(br s,1H),5.89-5.83(m,1H),5.82-5.66(m,2H),5.46-5.35(m,2H),5.00-4.9 3(m,1H),4.80-4.70(m,4H),4.68-4.59(m,2H),4.16-4.02(m,1H),3.94(br s,1H),3.88-3.79(m,1H),3.79-3.72(m,1H),3.70-3.58(m,2H),3.50-3.45(m,1H),3.44-3.42(m,3H),3.42-3.41(m,3H),3.38-3.32( m,1H),3.28-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.83-2.76(m,3H),2.59-2.48(m,2H),2.38-2.18(m,4H),2.01-1.95(m,1H),1.92(br s,3H),1.80-1.72(m,2H),1.71-1.34(m,8H),1.29-1.21(m,9H),1.16(d,J =5.7Hz,4H),0.95-0.91(m,3H),0.87-0.76(m,9H);MSm / z976.5746[M+NH4] + .

[0344] Preparation of Compound I-125 Compound I-125 (yield 3.3 mg, 12%) was obtained in the same manner as in [Preparation of Compound I-124] except that ammonium chloride was used instead of methylamine. 1H-NMR(500MHz,CDCl3,δ):7.04(q,J=4.6Hz,1H),5.97-5.92(m,1H),5.87-5.84(m,1H),5.81-5.68(m,2H), 5.43-5.34(m,2H),5.00-4.93(m,1H),4.79-4.60(m,6H),4.13-4.06(m,1H),4.10(d,J=6.9Hz,1H),3.93(br s,1H),3.85-3.78(m,1H),3.77-3.71(m,1H),3.70-3.57(m,2H),3.49-3.43(m,1H),3.42-3.41(m,3H),3.41-3.39 (m,3H),3.35-3.32(m,1H),3.25-3.18(m,2H),3.17-3.11(m,1H),2.55-2.47(m,1H),2.36-2.17(m,5H),2.03-2.0 1(m,2H),2.00-1.94(m,1H),1.91(s,3H),1.79-1.73(m,1H),1.67-1.62(m,1H),1.59-1.31(m,12H),1.28-1.21(m ,9H),1.15(d,J=6.9Hz,3H),0.92(t,J=7.4Hz,2H),0.84(d,J=6.9Hz,3H),0.82-0.76(m,4H);MSm / z962.5589[M+H] + .

[0345] Preparation of Compound I-126 Compound I-126 (yield 5.5 mg, 13%) was obtained in the same manner as in [Preparation of Compound I-117] except that O-(oxetan-3-ylmethyl)hydroxylamine obtained in Reference Example 13-(2) was used instead of O-isobutylhydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.95-5.86(m,1H),5.81-5.77(m,1H),5.77-5.69(m,2H),5.43-5.34(m,2H),5.00-4. 93(m,1H),4.80-4.75(m,3H),4.74-4.63(m,2H),4.57-4.49(m,3H),4.43(d,J=6.9Hz,2H),4.01(s,1H),3.94(br s,1H),3.86-3.79(m,1H),3.78-3.73(m,1H),3.69-3.59(m,2H),3.51-3.46(m,1H),3.43(s,3H),3.42(s,3H),3.40-3 .34(m,2H),3.27-3.19(m,2H),3.16(t,J=9.2Hz,1H),2.55-2.47(m,2H),2.37-2.31(m,2H),2.29-2.18(m,2H),1.99- 1.94(m,1H),1.90(s,3H),1.79-1.74(m,1H),1.68-1.40(m,7H),1.40-1.33(m,2H),1.27(d,J=6.3Hz,4H),1.26-1.24 (m,5H),1.16(d,J=6.9Hz,3H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,4H),0.83-0.76(m,5H);MSm / z958.5528[M+H] + .

[0346] Preparation of Compound I-127 Compound I-127 (yield 4.0 mg, 15%) was obtained in the same manner as in [Preparation of Compound I-89] and [Preparation of Compound I-92], except that 5-oxo-ivermectin B1a was used instead of 3,4α-dihydro-5-oxo-ivermectin B1a in [Preparation of Compound I-89]. 1H-NMR(500MHz,CDCl3,δ):5.93(td,J=2.4,10.6Hz,1H),5.84-5.82(m,1H),5.80-5.68(m,2H),5.44-5.36(m,2H),4.97(b rd,J=9.7Hz,1H),4.79-4.73(m,2H),4.69(s,1H),4.68-4.64(m,1H),4.37-4.33(m,1H),4.10(d,J=12.0Hz,1H),3.94(br s,1H),3.86-3.80(m,1H),3.80-3.74(m,1H),3.71-3.59(m,2H),3.51-3.44(m,2H),3.43(s,3H),3.42(s,3H),3.40-3.3 6(m,1H),3.27-3.20(m,2H),3.16(t,J=8.9Hz,1H),2.56-2.49(m,1H),2.37-2.19(m,5H),2.00-1.93(m,5H),1.79-1.74 (m,1H),1.68-1.64(m,1H),1.60-1.34(m,9H),1.27(d,J=6.3Hz,4H),1.25(d,J=6.3Hz,5H),1.16(d,J=6.9Hz,3H),1.19 -1.14(m,1H),0.93(t,J=7.4Hz,3H),0.88-0.84(m,4H),0.84-0.75(m,7H),0.63-0.60(m,2H);MSm / z1089.6658[M+NH4] + .

[0347] Preparation of Compound I-128 Compound I-128 (yield 9.7 mg, 34%) was obtained in the same manner as in [Preparation of Compound I-78], except that trifluoromethylsulfonic anhydride was used instead of phenylsulfonyl chloride. 1H-NMR(500MHz,CDCl3,δ):6.61(t,J=5.4Hz,1H),5.86(d,J=10.9Hz,1H),5. 81-5.74(m,1H),5.72-5.65(m,1H),5.46-5.38(m,2H),5.00(s,1H),4.96(br d,J=11.5Hz,1H),4.78(d,J=3.4Hz,1H),4.74-4.65(m,2H),4.32-4.19(m,2H),3.95(br s,1H),3.88-3.81(m,1H),3.81-3.75(m,1H),3.72-3.61(m,2H),3.56-3.47(m,3H),3.46(s,3H),3.44(s,3H),3.28-3.20(m,2 H),3.18(t,J=9.2Hz,1H),2.80(dd,J=12.0,3.4Hz,1H),2.73-2.64(m,1H),2.55-2.47(m,1H),2.35(dd,J=12.3,4.3Hz,2H),2. 32-2.20(m,2H),1.96-1.82(m,4H),1.77-1.71(m,1H),1.68(d,J=11.5Hz,1H),1.60-1.39(m,13H),1.29(d,J=5.7Hz,3H),1.28 -1.25(m,4H),1.18(t,J=6.0Hz,6H),0.94(t,J=7.2Hz,3H),0.85(d,J=6.9Hz,3H),0.82-0.77(m,4H);MSm / z1082.5459[M+NH4] + .

[0348] Preparation of Compound I-129: Compound I-64 (0.180 g, 0.187 mmol) obtained in [Preparation of Compound I-64] was dissolved in dichloromethane (3.7 mL), and then dimethyl sulfoxide (1.33 mL, 18.7 mmol) and triethylamine (0.470 mL, 3.37 mmol) were added sequentially. Sulfur trioxide pyridine complex (0.268 g, 1.69 mmol) was then added, and the mixture was stirred at room temperature for 19 hours. Water was added to the reaction solution, which was then extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-129 (yield 0.167 g, 93%). 1H-NMR(500MHz,CDCl3,δ):6.49-6.39(m,1H),5.97-5.83(m,1H),5.82-5.67(m,2H),5.54(s,1H),5.48-5.37(m,1H),5.00(s,1H),4.97(d ,J=9.7Hz,1H),4.80(d,J=3.4Hz,1H),4.76-4.66(m,2H),4.68-4.57(m,2H),4.43(q,J=6.3Hz,1H),4.21(dd,J=11.5,6.3Hz,1H),3.96(br s,1H),3.94-3.86(m,1H),3.78-3.64(m,2H),3.53(s,3H),3.47(s,3H),3.35(t,J=9.2Hz,1H),3.23(d,J=7.5Hz,1 H),2.88-2.77(m,4H),2.74-2.64(m,1H),2.64-2.55(m,1H),2.52(m,1H),2.40-2.32(m,1H),2.32-2.22(m,2H),2 .19-2.10(m,1H),1.98-1.81(m,3H),1.80-1.72(m,1H),1.68(d,J=12.6Hz,1H),1.62-1.39(m,13H),1.34-1.23(m ,6H),1.20-1.14(m,6H),0.94(t,J=7.5Hz,3H),0.85(d,J=6.9Hz,3H),0.83-0.77(m,4H);MSm / z976.5746[M+NH4] + .

[0349] Preparation of Compound I-130: Compound I-2 (50.0 mg, 0.056 mmol) obtained in [Preparation of Compound I-2] was dissolved in DMF (1.12 mL), and then potassium carbonate (93.0 mg, 0.674 mmol), (S)-3-chloropropane-1,2-diol (0.0375 mL, 0.449 mmol), and sodium iodide (0.842 mg, 5.62 μmol) were added sequentially at room temperature, followed by stirring at 100°C for 12 days. Aqueous ammonium chloride solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by preparative thin-layer chromatography (chloroform:acetone=2:1) ​​to obtain Compound I-130 (yield 4.60 mg, 5%). 1H-NMR(500MHz,CDCl3,δ):5.87-5.83(m,1H),5.79-5.66(m,2H),5.46-5.38(m,2H),4.99-4.92( m,2H),4.78(d,J=3.4Hz,1H),4.72-4.63(m,2H),4.24-4.14(m,2H),4.04-3.92(m,1H),3.95(br s,1H),3.88-3.81(m,1H),3.78(dq,J=9.5,6.2Hz,1H),3.73-3.60(m,4H),3.53-3.47(m,1H),3.46(s,3H),3.4 4(s,3H),3.28-3.21(m,2H),3.18(t,J=9.2Hz,1H),2.83-2.77(m,1H),2.69-2.61(m,1H),2.55-2.45(m,2H),2 .38-2.20(m,5H),2.15-2.10(m,1H),1.94-1.84(m,3H),1.77-1.73(m,1H),1.70-1.37(m,15H),1.31-1.25(m, 6H),1.21-1.14(m,6H),0.94(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,3H),0.81-0.78(m,4H);MSm / z986.5457[M+Na] + .

[0350] Preparation of Compound I-131: Compound I-129 (0.500 g, 0.521 mmol) obtained in [Preparation of Compound I-129] was dissolved in methanol (10 mL), and then sodium borohydride (0.0592 g, 1.56 mmol) was added and stirred at room temperature for 30 minutes. Aqueous ammonium chloride solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-131 (yield 0.435 g, 89%). 1H-NMR(500MHz,CDCl3,δ):6.42(q,J=4.6Hz,1H),5.90-5.82(m,1H),5.79-5.66(m,2 H),5.46-5.37(m,2H),4.99(s,1H),4.96(d,J=10.9Hz,1H),4.77(d,J=3.4Hz,1H),4. 73-4.65(m,2H),4.65-4.56(m,2H),3.99-3.90(m,2H),3.87-3.79(m,2H),3.72-3.64 (m,1H),3.65-3.56(m,2H),3.44(s,3H),3.42(s,3H),3.25(t,J=9.2Hz,1H),3.22(d, J=9.2Hz,1H),2.89-2.77(m,4H),2.70-2.62(m,1H),2.54-2.46(m,1H),2.38-2.31( m,1H),2.30-2.16(m,2H),2.01-1.94(m,1H),1.93-1.82(m,4H),1.78-1.70(m,1H),1 .67(d,J=12.6Hz,1H),1.62-1.34(m,13H),1.31-1.21(m,7H),1.17-1.11(m,6H),0.9 3(t,J=7.2Hz,3H),0.84(d,J=6.3Hz,3H),0.82-0.74(m,4H);MSm / z978.5912[M+NH4] + .

[0351] Preparation of Compound I-132: Compound I-48 (25 mg, 0.026 mmol) obtained in [Preparation of Compound I-48] was dissolved in DMF (0.53 mL), and then DIPEA (0.037 mL, 0.211 mmol), 5-aminopyrimidine (10 mg, 0.105 mmol), and a 50% propylphosphonic anhydride ethyl acetate solution (0.062 mL, 0.105 mmol) were added, followed by stirring overnight at room temperature. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with a mixed solution of ethyl acetate / hexane, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer silica gel column chromatography (n-hexane:ethyl acetate=1:2) to obtain Compound I-132 (yield 19.5 mg, 72%). 1H-NMR(500MHz,CD3OD,δ):9.07(s,2H),8.88(s,1H),5.93-5.86(m,2H),5.79-5.67(m,1H),5.34 -5.31(m,1H),5.19-5.10(m,2H),4.96(s,1H),4.80-4.77(m,1H),4.71(d,J=5.2Hz,4H),3.98(br s,1H),3.91-3.83(m,1H),3.74-3.61(m,3H),3.40(s,3H),3.39(s,3H),3.44-3.37(m,1H),3.25(br d,J=8.6Hz,1H),3.17(t,J=8.9Hz,1H),3.01(t,J=9.2Hz,1H),2.85-2.80(m,1H),2 .69-2.59(m,2H),2.32-2.25(m,4H),2.04-2.00(m,1H),1.94-1.79(m,3H),1.63-1 .44(m,12H),1.28-1.19(m,8H),1.15(d,J=6.9Hz,3H),1.12(d,J=6.3Hz,3H),0.95 (t,J=7.5Hz,3H),0.86(d,J=6.9Hz,3H),0.83-0.77(m,4H);MSm / z1025.5698[M+H] + .

[0352] Preparation of Compound I-133: Compound I-23 (20 mg, 0.021 mmol) obtained in [Preparation of Compound I-23] was dissolved in dichloromethane (0.45 mL), and then DIPEA (0.011 mL, 0.064 mmol) and 2,5-dioxopyrrolidin-1-yl methylcarbamate (4.4 mg, 0.026 mmol) were added, followed by stirring at room temperature for 4 hours. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with chloroform, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform / methanol system) to obtain Compound I-133 (yield 16.1 mg, 76%). 1H-NMR(500MHz,CDCl3,δ):5.83(dt,J=10.3,2.3Hz,1H),5.77-5.65(m,2H),5.44-5.33(m,2H),4.98-4.91(m,2H),4.76(br d,J=3.4Hz,1H),4.72-4.57(m,2H),4.23-4.09(m,2H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.72(m,1H),3.71-3.57(m,2H),3.43(s,3H),3.41(s,3H),3.52-3.43(m,2H),3.29-3. 18(m,2H),3.16(t,J=9.2Hz,1H),2.85-2.77(m,1H),2.73(s,3H),2.68-2.56(m,1H),2.56-2.42(m,1H),2.37-2.30(m,2 H),2.30-2.16(m,2H),1.96-1.76(m,3H),1.78-1.69(m,1H),1.66(d,J=12.60Hz,1H),1.59-1.35(m,13H),1.31-1.23( m,8H),1.16(d,J=6.87Hz,5H),0.91(t,J=7.45Hz,3H),0.83(d,J=6.87Hz,3H),0.81-0.74(m,4H);MSm / z990.5902[M+H] + .

[0353] Preparation of Compound I-134 Compound I-134 (yield 4.6 mg, 17%) was obtained in the same manner as in [Preparation of Compound I-133], except that compound I-11 obtained in [Preparation of Compound I-11] was used instead of compound I-23 in [Preparation of Compound I-133]. 1H-NMR(500MHz,CDCl3,δ):5.88-5.80(m,1H),5.76-5.63(m,2H),5.43-5.3 3(m,2H),4.98-4.89(m,2H),4.78-4.60(m,4H),4.34-4.20(m,4H),3.93(br s,1H),3.86-3.79(m,1H),3.79-3.72(m,1H),3.71-3.58(m,2H),3.52-3.38(m,8H),3.27-3.1 3(m,3H),2.81-2.73(m,4H),2.64-2.54(m,1H),2.53-2.46(m,1H),2.36-2.30(m,2H),2.28-2 .19(m,2H),1.95-1.78(m,4H),1.78-1.71(m,1H),1.69-1.63(m,1H),1.59-1.34(m,7H),1.31 -1.23(m,8H),1.19-1.10(m,7H),0.96-0.88(m,3H),0.87-0.72(m,8H);MSm / z991.5743[M+H] + .

[0354] Preparation of Compound I-135 Compound I-135 (yield 19.7 mg, 90%) was obtained in the same manner as in [Preparation of Compound I-133], except that 2-isocyanatopropane was used instead of 2,5-dioxopyrrolidin-1-yl methylcarbamate in [Preparation of Compound I-133]. 1H-NMR(500MHz,CDCl3,δ):5.84(dd,J=10.31,2.29Hz,1H),5.76-5.64(m,2H),5.41-5.35(m,2H),4.98-4.90(m,2H),4.76(br s,1H),4.69-4.60(m,2H),4.18-4.09(m,2H),3.93(br s,1H),3.84-3.72(m,3H),3.69-3.59(m,2H),3.49-3.38(m,8H),3.38-3.32(m,1H),3.26-3.12(m,3H) ,2.84-2.77(m,1H),2.66-2.57(m,1H),2.53-2.46(m,1H),2.35-2.18(m,4H),1.94-1.81(m,3H),1.73( d,J=10.31Hz,1H),1.65(d,J=10.31Hz,1H),1.58-1.35(m,11H),1.28-1.22(m,7H),1.18-1.12(m,6H) ,1.12-1.07(m,6H),0.96-0.89(m,3H),0.89-0.80(m,4H),0.80-0.72(m,4H);MSm / z1018.6223[M+NH4] + .

[0355] Reference Example 18 (1) Preparation of (S)-2-((5-oxopyrrolidin-3-yl)oxy)isoindoline-1,3-dione 2-Hydroxyisoindoline-1,3-dione (1.63 g, 10.0 mmol), (R)-4-hydroxypyrrolidin-2-one (1.01 g, 10.0 mmol), and triphenylphosphine (3.66 g, 21.0 mmol) were dissolved in THF (100 mL) and the solution was ice-cooled to 0°C. Thereafter, a 2.2 M solution of diethyl (E)-diazene-1,2-dicarboxylate in toluene (9.55 mL, 21.0 mmol) was added dropwise, and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain (S)-2-((5-oxopyrrolidin-3-yl)oxy)isoindoline-1,3-dione (yield 0.300 g, 12%). 1H-NMR (500 MHz, CDCl3, δ): 7.88-7.85 (m, 2H), 7.80-7.78 (m, 2H), 5.12-5.08 (m, 1H), 3.83-3.81 (m, 1H), 3.74-3.70 (m, 1H), 2.80-2.69 (m, 2H). (2) Preparation of (S)-4-(aminooxy)pyrrolidin-2-one (S)-2-((5-oxopyrrolidin-3-yl)oxy)isoindoline-1,3-dione (yield 0.300 g, 1.22 mmol) obtained in Reference Example 18-(1) was dissolved in dichloromethane (12.2 mL), and then methylhydrazine (0.0710 mL, 1.46 mmol) was added and the mixture was stirred at room temperature for 2 hours. The suspension was filtered, and the solvent was evaporated under reduced pressure to obtain (S)-4-(aminooxy)pyrrolidin-2-one (yield: 0.120 g, 85%). 1 H-NMR (500MHz, CDCl3, δ): 4.43-4.41 (m, 1H), 3.56-3.49 (m, 2H), 2.55-2.50 (m, 1H), 2.41-2.37 (m, 1H).

[0356] Preparation of Compound I-136 Compound I-136 (yield 12.8 mg, 38%) was obtained in the same manner as in [Preparation of Compound I-2] except that (S)-4-(aminooxy)pyrrolidin-2-one obtained in Reference Example 18-(2) was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CDCl3,δ):5.90-5.80(m,1H),5.79-5.65(m,3H),5.45-5.37(m,2H), 4.99-4.93(m,2H),4.90-4.86(m,1H),4.80-4.75(m,1H),4.70-4.58(m,2H),3.94(br s,1H),3.87-3.81(m,1H),3.81-3.73(m,1H),3.71-3.60(m,3H),3.58-3.46(m,2H),3.45(s,3H),3.43(s,3H) ),3.28-3.20(m,2H),3.17(t,J=9.2Hz,1H),2.93-2.76(m,1H),2.69-2.59(m,2H),2.57-2.46(m,2H),2.38- 2.19(m,5H),1.95-1.82(m,4H),1.79-1.72(m,1H),1.69-1.65(m,1H),1.60-1.37(m,12H),1.31-1.24(m,8H ),1.21-1.14(m,5H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,3H),0.81-0.75(m,4H);MSm / z973.5626[M+H] + .

[0357] Reference Example 19 Preparation of O-amino-D-serine dihydrochloride (R)-4-Aminoisoxazolidin-3-one (0.102 g, 1.00 mmol) and a 4N solution of hydrogen chloride in 1,4-dioxane (2.50 mL, 10.0 mmol) were dissolved in water (1 mL) and stirred for 19 hours at 60° C. The solvent was evaporated under reduced pressure to give O-amino-D-serine dihydrochloride (yield 0.222 g, quantitative). 1 H-NMR (500MHz, CDCl3, δ): 4.60-4.51 (m, 2H), 4.49-4.47 (m, 1H).

[0358] Preparation of Compound I-137 Compound I-137 (yield 48.2 mg, 86%) was obtained in the same manner as in [Preparation of Compound I-2] except that O-amino-D-serine dihydrochloride obtained in Reference Example 19 was used instead of hydroxylamine hydrochloride. 1H-NMR(500MHz,CD3OD,δ):5.94-5.82(m,2H),5.78-5.69(m,1H),5.34(d,J=2.9Hz,1H),5.20-5.10(m,2H),4.85 (s,1H),4.80(d,J=2.9Hz,1H),4.67(s,2H),4.51(dd,J=12.0,3.4Hz,1H),4.34(dd,J=12.0,7.5Hz,1H),3.99(br s,1H),3.93-3.83(m,2H),3.79-3.62(m,3H),3.45-3.42(m,4H),3.46-3.41(m,1H),3.42(m,3H),3.40(s,3H),3 .32-3.25(m,3H),3.19(t,J=8.9Hz,1H),3.03(t,J=9.2Hz,1H),2.81(dd,J=12.9,3.2Hz,1H),2.70-2.56(m,2H), 2.34-2.25(m,4H),2.06-2.01(m,1H),1.95-1.79(m,3H),1.43-1.40(m,1H),1.71-1.37(m,13H),1.33-1.20(m,9) H),1.20-1.13(m,6H),0.96(t,J=7.5Hz,3H),0.88(d,J=6.9Hz,3H),0.81(d,J=5.7Hz,4H);MSm / z977.5604[M+H] + .

[0359] Preparation of Compound I-138 Compound I-138 (yield 2.46 mg, 13%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-137 obtained in [Preparation of Compound I-137] was used instead of compound I-48 in [Preparation of Compound I-132], and methylamine hydrochloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CD3OD,δ):5.92-5.82(m,2H),5.76-5.69(m,1H),5.35(d,J=3.4Hz,1H) ,5.20-5.11(m,2H),4.81-4.79(m,1H),4.67-4.63(m,1H),4.34-4.17(m,2H),3.99(br s,1H),3.93-3.84(m,1H),3.75-3.61(m,4H),3.46-3.43(m,1H),3.42(s,3H),3.40(s,3H),3.28-3.24(m,1H),3.19( t,J=8.9Hz,1H),3.03(t,J=9.2Hz,1H),2.83-2.78(m,1H),2.77-2.72(m,3H),2.69-2.52(m,2H),2.34-2.26(m,4H), 2.07-2.01(m,1H),1.92-1.75(m,3H),1.67-1.38(m,12H),1.31-1.24(m,7H),1.22(d,J=6.3Hz,3H),1.17(d,J=6.9H) z,3H),1.14(d,J=6.3Hz,3H),0.96(t,J=7.4Hz,3H),0.88(d,J=6.9Hz,3H),0.83-0.69(m,4H);MSm / z990.5907[M+H] + .

[0360] Reference Example 20 (1) Preparation of methyl (R)-2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate Methyl (R)-2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate (yield 1.91 g, 77%) was obtained in the same manner as in Reference Example 18-(1), except that methyl (S)-2-hydroxypropanoate was used instead of (R)-4-hydroxypyrrolidin-2-one in Reference Example 18-(1). 1H-NMR (500 MHz, CDCl3, δ): 7.86-7.83 (m, 2H), 7.77-7.74 (m, 2H), 4.87 (q, J = 6.9 Hz, 1H), 3.79 (s, 3H), 1.65 (d, J = 6.9 Hz, 3H). (2) Preparation of methyl (R)-2-(aminooxy)propanoate Methyl (R)-2-(aminooxy)propanoate (yield 0.892 g, 98%) was obtained in the same manner as in Reference Example 18-(2), except that methyl (R)-2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate obtained in Reference Example 20-(2) was used instead of (S)-2-((5-oxopyrrolidin-3-yl)oxy)isoindoline-1,3-dione in Reference Example 18-(2). 1 H-NMR (500MHz, CDCl3, δ): 4.45 (q, J = 6.9 Hz, 1H), 3.80 (s, 3H), 1.47 (d, J = 7.4Hz, 3H).

[0361] Preparation of Compound I-139 Compound I-139 (yield 25.8 mg, 46%) was obtained in a similar manner except that methyl (R)-2-(aminooxy)propanoate obtained in Reference Example 20-(2) was used instead of hydroxylamine hydrochloride in [Preparation of Compound I-2]. 1H-NMR (500MHz, CDCl3, δ): 5.91-5.80(m,1H),5.77-5.66(m,2H),5.46-5.36(m,2H),5.01(s,1H),4.98-4.93(m,1H),4.80-4.53(m,5H),3.94(br s,1H),3.88-3.75(m,2H),3.73(s,3H),3.71-3.61(m,2H),3.53-3.46(m,2H),3.45(s,3H),3.43 (s,3H),3.27-3.20(m,2H),3.17(t,J=9.2Hz,1H),2.84-2.78(m,1H),2.68-2.57(m,1H),2.50(br s,1H),2.39-2.20(m,5H),1.98-1.81(m,3H)1.76(br s,1H),1.71-1.62(m,1H)1.59-1.39(m,16H),1.32-1.22(m,12H),1.19-1.14(m,3H), 1.13-1.10(m,2H),0.93(t,J=7.2Hz,3H),0.90-0.75(m,9H);MSm / z993.5910[M+NH4] + .

[0362] Preparation of Compound I-140: Compound I-139 (13.8 mg, 0.0141 mmol) obtained in [Preparation of Compound I-139] and methylamine hydrochloride (5.73 mg, 0.0849 mmol) were dissolved in dichloromethane (0.47 mL), and then DIPEA (0.030 mL, 0.170 mmol) and 1.4 M trimethylaluminum hexane solution (0.061 mL, 0.0849 mmol) were added sequentially and the mixture was stirred at room temperature for 3 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (hexane:ethyl acetate = 1:2) to obtain Compound I-140 (yield 7.35 mg, 53%). 1H-NMR(500MHz,CDCl3,δ):6.52-6.37(m,1H),5.71(s,2H),5.40(d,J=3.4Hz,2H),4.94(s,2H),4.73-4.60(m,4H),3.93(br s,1H),3.86-3.73(m,2H),3.71-3.60(m,2H),3.51-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.28-3.19(m,2H) ),3.17(t,J=9.2Hz,1H),2.79(d,J=5.2Hz,2H),2.85-2.78(m,3H),2.77-2.72(m,1H),2.65-2.56(m,1H),2. 52-2.46(m,1H),2.36-2.19(m,4H),1.91(s,4H),1.81-1.36(m,15H),1.26(dd,J=10.9,6.3Hz,7H),1.16(dd ,J=6.9,4.6Hz,6H),0.92(t,J=7.4Hz,3H),0.84(d,J=6.9Hz,3H),0.81-0.73(m,4H);MSm / z992.6062[M+NH4] + .

[0363] Preparation of Compound I-141: Compound I-48 (25 mg, 0.026 mmol) obtained in [Preparation of Compound I-48] was dissolved in THF (0.53 mL), and then DIPEA (0.033 mL, 0.190 mmol), 2-aminopyrazine (12 mg, 0.127 mmol), DMAP (11.6 mg, 0.095 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (18.20 mg, 0.095 mmol) were added, followed by stirring at room temperature overnight. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with a mixed solution of ethyl acetate / hexane, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-141 (yield 6.1 mg, 19%). 1H-NMR(500MHz,CDCl3,δ):9.55(d,J=2.86Hz,1H),9.04-8.99(m,1H),8.38-8.33(m,1H),8.32-8.26(m,1H),5.93-5 .85(m,1H),5.80-5.68(m,2H),5.43-5.35(m,2H),5.10-5.02(m,2H),4.98-4.92(m,1H),4.80-4.73(m,4H),3.95(br s,1H),3.85-3.71(m,2H),3.69-3.60(m,2H),3.56-3.55(m,1H),3.49-3.38(m,7H), 3.27-3.19(m,2H),3.18-3.12(m,1H),2.85-2.79(m,1H),2.78-2.67(m,1H),2.54-2. 46(m,2H),2.38-2.17(m,5H),1.94-1.82(m,3H),1.79-1.71(m,1H),1.69-1.37(m,6 H),1.30-1.21(m,9H),1.20-1.09(m,7H),0.98-0.73(m,12H);MSm / z1025.5698[M+H] + .

[0364] Preparation of Compound I-142 Compound I-142 (yield 4.0 mg, 6%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-132], except that 3-amino-1,2,4-triazole was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):7.73-7.80(m,0.5H),7.43-7.49(m,0.5H),6.37-6.55(m,1H),5 .81-5.93(m,1H),5.66-5.79(m,2H),5.34-5.46(m,2H),5.27-5.34(m,1H),5.08(d,J=5.7 Hz,1H),4.89-5.02(m,1H),4.81-4.85(m,1H),4.74-4.81(m,2H),4.59-4.74(m,2H),3.89 -3.98(m,1H),3.74-3.85(m,2H),3.60-3.71(m,2H),3.47-3.52(m,1H),3.43-3.47(m,3H) ,3.40-3.42(m,3H),3.19-3.28(m,2H),3.12-3.19(m,1H),2.69-2.84(m,2H),2.59-2.68( m,1H),2.46-2.53(m,1H),2.19-2.36(m,4H),2.03-2.08(m,1H),1.80-1.96(m,2H),1.71- 1.79(m,1H),1.61-1.68(m,1H),1.36-1.59(m,10H),1.23-1.29(m9,H),1.11-1.18(m,6H) ,0.89-0.95(m,3H),0.84(dd,J=6.9,1.7Hz,3H),0.76-0.80(m,4H);MSm / z1014.5651[M+H] + .

[0365] Preparation of Compound I-143 Compound I-143 (yield 31.0 mg, 94%) was obtained in the same manner as in [Preparation of Compound I-132], except that pyridin-3-yl-methylamine was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1H-NMR(500MHz,CDCl3,δ):8.72(br s,1H),8.64(d,J=4.6Hz,1H),7.95(d,J=7.4Hz,1H),7.48(dd,J=6.6Hz,1H),7.30(br s,1H),5.85-5.80(m,1H),5.77-5.63(m,2H),5.38(d,J=3.4Hz,1H),5.35-5.29(m,1H),5.00(s,1H) ,4.98-4.86(m,2H),4.76(d,J=2.9Hz,1H),4.67-4.59(m,5H),4.46(dd,J=15.2,5.4Hz,1H),3.93(br s,1H),3.84-3.74(m,2H),3.68-3.59(m,2H),3.50-3.44(m,1H),3.42(s,3H),3.41(s,3H),3.26-3.19(m,2H),3. 16(t,J=9.2Hz,1H),2.73(dd,J=12.9,3.2Hz,1H),2.66-2.55(m,2H),2.55-2.42(m,2H),2.35-2.18(m,4H),1.94 -1.85(m,1H),1.88-1.70(m,2H),1.66(d,J=12.6Hz,1H),1.57-1.35(m,9H),1.29-1.21(m,10H),1.14(d,J=6.9H) z,3H),1.12-1.09(m,3H),0.91(t,J=7.2Hz,3H),0.84(d,J=6.9Hz,3H),0.79-0.76(m,4H);MSm / z1038.589[M+H] + .

[0366] Preparation of Compound I-144 Compound I-144 (yield 303 mg, 92%) was obtained in the same manner as in [Preparation of Compound I-132], except that pyridin-2-yl-methylamine (0.558 mL, 0.949 mmol) was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1H-NMR(500MHz,CDCl3,δ):8.69-8.65(m,1H),7.98-7.86(m,1H),7.76-7.64 (m,1H),7.63-7.53(m,1H),7.49-7.36(m,1H),5.97-5.91(m,1H),5.81-5.68 (m,2H),5.43-5.39(m,1H),5.36-5.27(m,1H),5.10(s,1H),4.97(d,J=10.6H z,1H),4.87-4.80(m,1H),4.78(d,J=3.5Hz,1H),4.76-4.58(m,4H),3.94(br s,1H),3.88-3.81(m,1H),3.80-3.74(m,1H),3.72-3.60(m,2H),3.54-3.47(m,1H),3.46-3.44(m,3H),3.43(s,3H),3.30 -3.21(m,2H),3.18(t,J=9.2Hz,1H),2.81(dd,J=12.6,3.4Hz,1H),2.70-2.61(m,1H),2.56-2.48(m,2H),2.38-2.17(m,5H) ),2.06-2.04(m,1H),2.02-1.95(m,1H),1.94-1.71(m,2H),1.68-1.65(m,1H),1.59-1.31(m,11H),1.31-1.24(m,9H),1.1 7(d,J=6.9Hz,3H),1.07(d,J=6.9Hz,3H),0.95-0.91(m,3H),0.87-0.84(m,3H),0.82-0.77(m,4H);MSm / z1038.5884[M+H] + .

[0367] Preparation of Compound I-145 Compound I-145 (yield 294 mg, 91%) was obtained in the same manner as in [Preparation of Compound I-132], except that 1-methyl-1H-pyrazol-3-amine (0.929 mL, 1.58 mmol) was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1H-NMR(500MHz,CDCl3,δ):8.95(br s,1H),7.28-7.27(m,1H),6.72(d,J=1.7Hz,1H),5.91(dt,J=10.3,2.3Hz,1H),5.81-5.68(m,2H),5.43-5.34(m,2H),5.08(s,1H),4.99(br d,J=11.0Hz,1H),4.80-4.67(m,5H),3.95(br s,1H),3.88-3.85(m,3H),3.85-3.76(m,2H),3.73-3.60(m,2H),3.53-3.46(m,1H),3.45(s,3H),3.43(s,3H),3.28-3 .20(m,2H),3.18(t,J=8.9Hz,1H),2.85-2.80(m,1H),2.75-2.67(m,1H),2.57-2.48(m,2H),2.38-2.20(m,5H),2.05(s ,1H),1.97-1.86(m,3H),1.81-1.74(m,1H),1.70-1.65(m,1H),1.61-1.36(m,10H),1.31-1.24(m,8H),1.17(d,J=6.9 Hz,3H),1.15(d,J=6.9Hz,3H),0.94(t,J=7.2Hz,3H),0.85(d,J=6.9Hz,3H),0.83-0.77(m,4H);MSm / z1027.5848[M+H] + .

[0368] Reference Example 21: Preparation of 5-(chloromethyl)pyrimidine To a solution of pyrimidin-5-yl-methanol (11 mg, 0.101 mmol) in dichloromethane (0.10 mL) was added thionyl chloride (0.011 mL, 0.152 mmol), and the mixture was stirred for 30 minutes at 0° C. The solvent was evaporated under reduced pressure to give 5-(chloromethyl)pyrimidine as a crude product.

[0369] Preparation of Compound I-146: Compound I-2 (30 mg, 0.034 mmol) obtained in [Preparation of Compound I-2] was dissolved in DMF (0.67 mL), and then 5-(chloromethyl)pyrimidine obtained in Reference Example 21, potassium carbonate (56 mg, 0.034 mmol), and sodium iodide (0.50 mg, 0.003 mmol) were added, followed by stirring at 50°C for 2 hours. The temperature was further raised to 70°C and stirring was continued for 1 hour. Saturated aqueous sodium bicarbonate was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate / methanol system) to obtain Compound I-146 (yield 15.0 mg, 45%). 1 H-NMR(500MHz,CDCl3,δ):9.17(s,1H),8.77(s,2H),5.83(dt,J=10.5,2.5Hz,1H),5.76-5.61(m,2H),5. 42-5.36(m,2H),5.16-5.11(m,2H),4.95-4.90(m,2H),4.76(d,J=2.9Hz,1H),4.71-4.59(m,3H),3.92(br s,1H),3.82(dd,J=9.7,6.3Hz,1H),3.80-3.73(m,1H),3.69-3.58(m,2H),3.51-3.45(m,1H),3.43(s,3H),3.42(s,3H) ),3.28-3.18(m,2H),3.16(t,J=9.2Hz,1H),2.77(dd,J=11.7,3.7Hz,1H),2.64-2.56(m,1H),2.48(ddd,J=9.6,7.0,2 .3Hz,1H),2.36-2.18(m,6H),1.92-1.82(m,3H),1.77-1.69(m,1H),1.68-1.61(m,1H),1.58-1.35(m,9H),1.29-1.23 (m,8H),1.14(t,J=6.9Hz,7H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.79-0.73(m,4H);MSm / z982.5637[M+H] + .

[0370] Preparation of Compound I-147 Compound I-147 (yield 27.7 mg, 88%) was obtained in the same manner as in [Preparation of Compound I-132], except that (1-methyl-1H-pyrazol-4-yl)methanamine (0.015 mL, 0.158 mmol) was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1 H-NMR(500MHz,CDCl3,δ):7.44(s,1H),7.37(s,1H),6.74(t,J=5.7Hz,1H),5.81(dt,J=11.0,2.5Hz,1H),5.79-5.72(m,1H),5.69-5.62(m,1H),5. 43-5.36(m,2H),4.97-4.93(m,2H),4.77(d,J=3.4Hz,1H),4.71-4.55(m, 5H),4.40(dd,J=14.9,6.3Hz,1H),4.21(dd,J=14.9,5.2Hz,1H),3.93(br s,1H),3.90-3.88(m,3H),3.84-3.75(m,2H),3.70-3.60(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.26-3. 19(m,2H),3.16(t,J=9.2Hz,1H),2.74(dd,J=13.2,2.9Hz,1H),2.65-2.58(m,1H),2.53-2.46(m,1H),2.36-2.31(m,2H) ,2.28-2.19(m,2H),1.90-1.82(m,3H),1.79-1.67(m,3H),1.59-1.36(m,12H),1.26(dd,J=10.9,6.3Hz,7H),1.17-1.1 4(m,3H),1.10(d,J=6.9Hz,3H),0.93(t,J=7.4Hz,3H),0.84(d,J=6.9Hz,3H),0.79-0.75(m,4H);MSm / z1041.5997[M+H] + .

[0371] Preparation of Compound I-148 Compound I-148 (yield 5.5 mg, 17%) was obtained in the same manner as in [Preparation of Compound I-132], except that oxazol-2-amine (13 mg, 0.158 mmol) was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1H-NMR(500MHz,CDCl3,δ):9.61(br s,1H),7.45(d,J=1.0Hz,1H),7.03(d,J=1.1Hz,1H),5.90(dt,J=10.9,2.4 Hz,1H),5.82-5.68(m,2H),5.47-5.38(m,2H),5.11-5.03(m,2H),4.96(br d,J=10.3Hz,1H),4.81-4.72(m,4H),3.95(br s,1H),3.87-3.80(m,1H),3.80-3.74(m,1H),3.73-3.60(m,2H),3.52-3.47(m,1H),3.46(s,3H),3.43( s,3H),3.29-3.20(m,2H),3.18(t,J=9.2Hz,1H),2.83-2.78(m,1H),2.77-2.69(m,1H),2.55-2.47(m,2 H),2.38-2.20(m,4H),1.97-1.84(m,3H),1.79-1.73(m,1H),1.70-1.38(m,11H),1.32-1.28(m,4H),1. 28-1.23(m,5H),1.17(t,J=6.9Hz,6H),0.94(t,J=7.4Hz,3H),0.90-0.75(m,8H);MSm / z1014.5522[M+H] + .

[0372] Preparation of Compound I-149: Compound I-139 (0.728 g, 0.746 mmol) obtained in [Preparation of Compound I-139] was dissolved in THF (7.5 mL), and then 1 M aqueous potassium hydroxide solution (2.24 mL, 2.24 mmol) was added and the mixture was stirred at 0°C for 15 minutes. The temperature was then raised to room temperature and the mixture was stirred for 2 hours and 45 minutes. An aqueous ammonium chloride solution was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-149 (yield 0.495 g, 69%). 1H-NMR(500MHz,CDCl3,δ):5.94-5.80(m,1H),5.78-5.62(m,2H),5.47-5.33(m,2H),4.94(s,1H),4.94(d,J=9.0Hz,1H),4.85-4.50(m,5H),3.93(br s,1H),3.86-3.72(m,2H),3.71-3.56(m,2H),3.53-3.45(m,1H),3.45(s,3H),3.42(s,3H),3.32-3.19 (m,2H),3.17(t,J=9.5Hz,1H)2.96-2.85(m,1H),2.81-2.69(m,1H),2.68-2.57(m,1H),2.55-2.42(m,1 H),2.39-2.17(m,4H),1.97-1.81(m,2H),1.78-1.70(m,1H),1.70-1.61(m,1H),1.59-1.34(m,12H),1 .30-1.20(m,10H),1.18-1.10(m,5H),0.92(t,J=7.5Hz,3H),0.83(d,J=7.0Hz,3H),0.80-0.72(m,4H).

[0373] Preparation of Compound I-150 Compound I-150 (yield 0.230 g, 58%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-149 was used instead of compound I-48 and ammonium chloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):6.40(d,J=2.9Hz,1H),5.93-5.79(m,1H),5.78-5.64(m,2H),5.48-5.37(m,3H),4.94(s,1H),4.97-4.92(m,2H),4.76(1br d,J=3.4Hz,1H),4.71-4.63(m,4H),3.93(br s,1H),3.85-3.70(m,2H),3.70-3.58(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t ,J=9.2Hz,1H),2.73(dd,J=12.6,2.9Hz,1H),2.64-2.53(m,2H),2.53-2.46(m,1H),2.36-2.29(m,2H),2.29-2.19(m, 2H),1.97-1.81(m,3H),1.77-1.71(m,1H),1.69-1.63(m,2H),1.58-1.37(1m,6H),1.28-1.23(m,7H),1.17(d,J=6.9H) z,3H),1.15(d,J=6.9Hz,3H),0.92(t,J=7.2Hz,3H),0.83(d,J=6.9Hz,3H),0.81-0.74(m,4H);MSm / z978.592[M+NH4] + .

[0374] Preparation of Compound I-151 Compound I-151 (yield 38.2 mg, 65%) was obtained in the same manner as in [Preparation of Compound I-132], except that 2-(aminomethyl)aniline was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1H-NMR(500MHz,CDCl3,δ):8.09(d,J=6.2Hz,1H),7.41(d,J=7.4Hz,1H),6.96(t, J=6.7Hz,1H),6.53(t,J=6.8Hz,1H),5.83-5.73(m,2H),5.68-5.62(m,1H),5.42- 5.35(m,2H),4.97-4.93(m,2H),4.88-4.83(m,1H),4.76(d,J=4.0Hz,1H),4.69- 4.58(m,4H),4.47(dd,J=14.9,7.4Hz,1H),4.25(dd,J=14.9,5.7Hz,1H),3.93(br s,1H),3.85-3.73(m,2H),3.70-3.59(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.19(m,2H) ),3.16(t,J=9.2Hz,1H),2.75-2.70(m,1H),2.63-2.46(m,3H),2.36-2.14(m,4H),1.92-1.86(m,1H),1.84- 1.79(m,1H),1.74-1.64(m,2H),1.60-1.38(1m,2H),1.26(dd,J=10.3,6.3Hz,7H),1.15(d,J=6.9Hz,3H),1. 07(d,J=6.3Hz,3H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,3H),0.80-0.74(m,4H);MSm / z1053.6022[M+H] + .

[0375] Preparation of Compound I-152 Compound I-152 (yield 29.8 mg, 56%) was obtained in the same manner as in [Preparation of Compound I-132], except that pyrazin-2-yl-methanamine was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1H-NMR(500MHz,CDCl3,δ):8.61(s,1H),8.56(s,1H),8.50(d,J=2.9Hz,1H),7.31(t,J=6.0Hz,1H),5.84(dt,J=10.9,2.3Hz,1H),5.76-5.6 7(m,2H),5.41-5.34(m,2H),5.03(s,1H),4.96-4.92(m,2H),4.81-4.75(m,2H),4.71-4.61(m,4H),4.47(dd,J=15.8,5.4Hz,1H),3.93(br s,1H),3.85-3.73(m,2H),3.69-3.59(m,2H),3.51-3.44(m,1H),3.43(s,3H),3.41(s,3H),3.26-3.19(m,2H),3.16( t,J=9.2Hz,1H),2.80(dd,J=13.2,2.9Hz,1H),2.69-2.62(m,1H),2.56-2.46(m,2H),2.35-2.30(m,2H),2.30-2.18(m ,2H),1.93-1.85(m,2H),1.79-1.69(m,2H),1.69-1.61(m,1H),1.58-1.34(m,1H),1.28-1.23(m,7H),1.15(d,J=6.9H) z,3H),1.11(d,J=6.9Hz,3H),0.91(t,J=7.4Hz,3H),0.84(d,J=6.9Hz,3H),0.80-0.74(m,4H);MSm / z1039.5867[M+H] + .

[0376] Preparation of Compound I-153: Compound I-2 (200 mg, 0.224 mmol) obtained in [Preparation of Compound I-2] was dissolved in DMF (2.2 mL), and then cesium carbonate (370 mg, 1.12 mmol) and ethyl 2-bromo-2-fluoroacetate (0.13 mL, 1.12 mmol) were added, followed by stirring at room temperature for 1 hour. Water was added to the reaction solution to terminate the reaction. After extraction with a mixed solvent of ethyl acetate and hexane, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-153 (yield 81.1 mg, 36%) as a mixture of isomers that are difficult to separate. 1H-NMR(500MHz,CDCl3,δ):6.13-6.08(m,0.5H),6.03-5.94(m,0.5H),5.88-5.82(m,1H),5.78-5.66(m,2H),5.44-5.37(m,2H),4. 96(d,J=12.0Hz,1H),4.92(s,1H),4.78(d,J=3.4Hz,1H),4.68(s,2H),4.66(s,0.5H),4.56(s,0.5H),4.38-4.24(m,2H),3.94(br s,1H),3.89-3.74(m,2H),3.72-3.61(m,2H),3.53-3.47(m,1H),3.45(s,3H),3.44(s,3H),3.28-3.21( m,2H),3.18(t,J=9.2Hz,1H),2.84-2.77(m,1H),2.73-2.62(m,1H),2.53-2.49(m,2H),2.40-2.20(m,4H) ),1.99-1.82(m,3H),1.79-1.50(m,10H),1.47-1.38(m,3H),1.38-1.32(m,3H),1.31-1.25(m,8H),1.22 -1.13(m,6H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.3Hz,3H),0.81-0.76(m,4H);MSm / z1011.5790[M+NH4] + .

[0377] Preparation of Compound I-154 Compound I-153 (77 mg, 0.078 mmol) obtained in [Preparation of Compound I-153] was dissolved in THF (3.4 mL), and then 1 M aqueous potassium hydroxide solution (0.78 mL, 0.78 mmol) was added and stirred at room temperature for 30 minutes. A saturated aqueous ammonium chloride solution was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate / methanol system) to obtain Compound I-154 (yield 66.6 mg, 89%) as a mixture of isomers that are difficult to separate. The following 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.98-5.90(m,1H),5.89-5.79(m,2H),5.76-5.6 4(m,2H),5.41-5.22(m,3H),5.01-4.90(m,2H),4.86-4.80(m,1H),4.76(br s,2H),4.74-4.67(m,1H),4.65-4.58(m,3H),3.96-3.90(m,2H),3.89-3.80(m,2H),3.8 0-3.73(m,2H),3.71-3.62(m,4H),3.54-3.46(m,4H),3.46-3.36(m,3H),3.26-3.09(m,3 H),2.80-2.56(m,3H),2.55-2.45(m,2H),2.38-2.18(m,3H),2.12-1.60(m,4H),1.58-1 .34(m,6H),1.33-1.21(m,3H),1.21-1.08(m,4H),0.97-0.88(m,6H),0.85-0.70(m,9H).

[0378] Preparation of Compound I-155 Compound I-155 (yield 7.1 mg, 21%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-154 obtained in [Preparation of Compound I-154] was used instead of compound I-48 in [Preparation of Compound I-132], and methylamine hydrochloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):6.48-6.43(m,1H),6.12-6.00(m,1H),5.85(dt,J=10.7,2.4Hz,1H),5.78-5.65(m,2 H),5.43-5.36(m,2H),4.96(d,J=10.9Hz,1H),4.91(s,1H),4.78(d,J=3.4Hz,1H),4.71-4.63(m,2H),3.94(br s,1H),3.87-3.75(m,2H),3.72-3.62(m,2H),3.53-3.47(m,1H),3.45(s,3H),3.43(s,3H),3.29-3.20(m,2H),3.18(t,J= 9.2Hz,1H),2.89(d,J=5.2Hz,3H),2.81(dd,J=12.6,3.4Hz,1H),2.75-2.62(m,1H),2.55-2.47(m,1H),2.38-2.32(m,2H), 2.31-2.20(m,2H),2.16-1.98(m,2H),1.96-1.87(m,4H),1.78-1.71(m,1H),1.67(d,J=12.6Hz,1H),1.60-1.38(m,11H),1 .32-1.23(m,7H),1.21-1.14(m,6H),0.93(t,J=7.2Hz,3H),0.88-0.82(m,3H),0.82-0.75(m,4H);MSm / z996.5801[M+NH4] + .

[0379] Preparation of Compound I-156 Compound I-156 (yield 7.0 mg, 20%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-154 obtained in [Preparation of Compound I-154] was used instead of compound I-48 in [Preparation of Compound I-132] and ammonium chloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):6.40(br S,1H),6.11-5.99(m,1H),5.88-5.82(m,1H),5.82-5.66(m,3H),5.45-5.36(m,2H),4 .96(d,J=10.9Hz,1H),4.91(s,1H),4.78(d,J=3.4Hz,1H),4.73-4.63(m,2H),3.94(br s,1H),3.87-3.74(m,2H),3.71-3.57(m,2H),3.53-3.46(m,1H),3.45(s,3H),3.43(s,3H),3.31-3.20(m,2 H),3.18(t,J=9.2Hz,1H),2.81(dd,J=12.6,3.4Hz,1H),2.75-2.61(m,1H),2.59-2.43(m,1H),2.37-2.18( m,4H),2.07-1.78(m,6H),1.77-1.70(m,2H),1.67(d,J=12.6Hz,2H),1.60-1.38(m,10H),1.31-1.24(m,6H ),1.23-1.12(m,6H),0.93(t,J=7.4Hz,3H),0.89-0.82(m,3H),0.82-0.74(m,4H);MSm / z982.5658[M+NH4] + .

[0380] Reference Example 22: Preparation of methyl (S)-2-(p-toluenesulfoxy)butanoate Methyl (S)-2-hydroxybutanoate (300 μL, 2.67 mmol) was dissolved in acetonitrile (5.3 mL), and then triethylamine (0.74 mL, 5.33 mmol), methylamine hydrochloride (25.5 mg, 0.267 mmol), and p-toluenesulfonyl chloride (760 mg, 4.00 mmol) were added sequentially, followed by stirring at room temperature for 1 hour and 30 minutes. Water was added to the reaction solution to terminate the reaction. After extraction with ethyl acetate, the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane:ethyl acetate system) to obtain methyl (S)-2-(p-toluenesulfoxy)butanoate (yield: 712 mg, 98%). 1H-NMR(500MHz,CDCl3,δ):7.86-7.79(m,2H),7.35(d,J=8.0Hz,2H),4.80(dd,J=7. 4,5.2Hz,1H),3.67(s,3H),2.46(s,3H),1.92-1.79(m,2H),0.91(t,J=7.4Hz,3H).

[0381] Preparation of Compound I-157: Compound I-157 (yield 91.0 mg, 82%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-153], except that methyl (S)-2-(p-toluenesulfoxy)butanoate obtained in Reference Example 22 was used instead of ethyl 2-bromo-2-fluoroacetate in [Preparation of Compound I-153]. 1 The H-NMR spectrum is the analytical data for the major isomers. 1 H-NMR(500MHz,CDCl3,δ):5.89-5.79(m,1H),5.79-5.64(m,2H),5.44-5.32(m,2H),5.01(s,1H),4.96( d,J=11.5Hz,1H),4.78(d,J=2.9Hz,1H),4.71-4.65(m,2H),4.64(s,1H),4.57(t,J=6.6Hz,1H),3.95(br s,1H),3.88-3.76(m,2H),3.74(s,3H),3.72-3.61(m,2H),3.53-3.47(m,1H),3.45(s,3H),3. 44(s,3H),3.29-3.14(m,3H),2.85-2.75(m,1H),2.68-2.58(m,2H),2.55-2.47(m,2H),2.39-2 .20(m,5H),1.93-1.81(m,5H),1.77-1.59(m,13H),1.57-1.48(m,6H),1.48-1.40(m,1H),1.31 -1.25(m,6H),1.19-1.09(m,4H),0.98(t,J=7.4Hz,2H),0.96-0.91(m,2H),0.89-0.77(m,4H).

[0382] Preparation of Compound I-158: Compound I-157 obtained in [Preparation of Compound I-157] was used instead of compound I-153 in [Preparation of Compound I-154], and the same method as in [Preparation of Compound I-154] was used to obtain compound I-158 (yield 65.6 mg, 77%) as a mixture of isomers that are difficult to separate. 1 The H-NMR spectrum is the analytical data for the major isomers. 1 H-NMR(500MHz,CD3OD,δ):5.93-5.80(m,2H),5.76-5.69(m,1H),5.35(d,J= 3.4Hz,1H),5.17-5.11(m,2H),4.90(s,1H),4.80(d,J=3.4Hz,1H),4.65(d, J=1.7Hz,2H),4.47(dd,J=6.9,5.7Hz,1H),3.99(s,1H),3.92-3.84(m,1H), 3.75-3.63(m,3H),3.42(s,3H),3.41(s,3H),3.46-3.38(m,7H),3.28-3.24 (m,1H),3.19(t,J=8.9Hz,1H),3.03(t,J=9.2Hz,1H),2.82(dd,J=12.9,3.2 Hz,1H),2.69-2.55(m,2H),2.34-2.26(m,4H),2.06-2.01(m,1H),1.92-1.7 7(m,4H),1.68-1.40(m,10H),1.30-1.20(m,8H),1.19-1.15(m,3H),1.11(d ,J=6.9Hz,3H),1.02-0.93(m,6H),0.88(d,J=6.9Hz,3H),0.85-0.77(m,4H).

[0383] Preparation of Compound I-159 Compound I-159 (yield 36.8 mg, 56%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-158 obtained in [Preparation of Compound I-158] was used instead of compound I-48 in [Preparation of Compound I-132], and methylamine hydrochloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):6.52(q,J=5.2Hz,1H),5.88(dt,J=10.7,2.4Hz,1H),5.79-5.67(m,2H),5.45-5.39(m,2H),4.98-4.93(m,2H),4.77(d,J=3.4Hz,1H),4.71(d,J=2.3Hz,2H),4.69(s,1H),4.56(dd,J=8.0,4.0Hz,1H),3.95(br s,1H),3.86-3.75(m,2H),3.72-3.61(m,2H),3.53-3.46(m,1H),3.46-3.44(m,3H),3.44-3.42(m,3H),3.27-3.20(m,2H),3.18(t,J=9.2Hz,1H),2.80(d,J=5.2Hz,3H),2.75(dd,J=12.6,2.9Hz,1H),2.64-2.55(m,2H),2.54-2.47(m,1H),2.38-2.21(m,4H),1.99-1.83(m,4H),1.81-1.71(m,2H),1.71-1.64(m,4H),1.60-1.38(m,7H),1.31-1.23(m,8H),1.20-1.14(m,6H),0.98-0.91(m,6H),0.90-0.77(m,8H);MSm / z989.5950[M+H] + 。

[0384] Preparation of Compound I-160 Compound I-160 (yield 38.8 mg, 53%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-158 obtained in [Preparation of Compound I-158] was used instead of compound I-48 in [Preparation of Compound I-132], and ammonium chloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):8.04(br s,2H),6.80(d,J=2.9Hz,1H),6.72(d,J=2.9Hz,1H),5.88(dt,J=10.7,2.4Hz,1H),5.80-5.65(m,2H),5.47-5 .35(m,2H),4.98-4.91(m,2H),4.78(d,J=3.4Hz,1H),4.71-4.64(m,2H),4.57(dd,J=7.7,4.3Hz,1H),3.94(br s,1H),3.87-3.74(m,2H),3.72-3.59(m,2H),3.53-3.47(m,2H),3.45(s,3H),3.43(s,3H),3.28-3.20(m,2H),3. 18(t,J=9.2Hz,1H),2.73(dd,J=12.6,2.9Hz,1H),2.64-2.57(m,1H),2.55-2.46(m,1H),2.37-2.21(m,4H),1.99- 1.79(m,5H),1.78-1.73(m,1H),1.67(d,J=13.2Hz,1H),1.60-1.38(m,15H),1.30-1.24(m,6H),1.22-1.13(m,3H) ),1.00(t,J=7.4Hz,3H),0.93(t,J=7.2Hz,3H),0.84(d,J=6.3Hz,3H),0.82-0.75(m,4H);MSm / z992.6063[M+NH4] + .

[0385] Preparation of Compound I-161: Compound I-150 (15.0 mg, 0.016 mmol) obtained in [Preparation of Compound I-150] was dissolved in dichloromethane (0.32 mL), and then sodium bicarbonate (7.87 mg, 0.094 mmol) and Dess-Martin Periodinane reagent (19.9 mg, 0.047 mmol) were added sequentially, followed by stirring at room temperature for 2 hours. Water was added to the reaction solution, which was then extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by thin-layer preparative silica gel column chromatography (n-hexane:ethyl acetate=1:2) to obtain Compound I-161 (yield 9.0 mg, 60%). 1 H-NMR(500MHz,CDCl3,δ):6.45(d,J=2.3Hz,1H),5.92-5.82(m,1H),5.80-5.65(m,3H),5.57-5.49(m,1H),5.48-5.36(m,1 H),4.99-4.92(m,2H),4.84-4.74(m,1H),4.74-4.60(m,3H),4.41(q,J=6.3Hz,1H),4.20(dd,J=12.0,6.3Hz,1H),3.94(br s,1H),3.89(dq,J=9.8,6.3Hz,1H),3.74-3.63(m,2H),3.50(s,3H),3.46(s,3H),3.39-3.30(m,1H),3.21(d,J=7.4Hz,1H),2.73(dd,J =12.6,2.9Hz,1H),2.67-2.55(m,2H),2.55-2.45(m,1H),2.38-2.31(m,1H),2.31-2.22(m,2H),2.13(td,J=12.3,4.0Hz,1H),2.07(br s,1H),1.98-1.83(m,3H),1.77-1.70(m,1H),1.68-1.63(m,1H),1.58-1.37(m,14H),1.29-1.23(m,7H) ,1.19-1.14(m,5H),0.92(t,J=7.4Hz,3H),0.85-0.82(m,3H),0.81-0.73(m,4H);MSm / z959.5489[M+H] + .

[0386] Preparation of Compound I-162 Compound I-162 (yield 28.0 mg, 67%) was obtained in the same manner as in [Preparation of Compound I-132], except that O-ethylhydroxyamine hydrochloride was used instead of 5-aminopyrimidine in [Preparation of Compound I-132]. 1 H-NMR(500MHz,CDCl3,δ):9.20(s,1H),5.87-5.81(m,1H),5.79-5.64(m,2H),5.44-5.36(m,2H),4.96-4.90(m,2H),4.88(s,1H),4.76(br s,1H),4.74-4.61(m,4H),3.99-3.89(m,3H),3.85-3.79(m,1H),3.79-3.72(m,1H),3.70-3.59(m,2H),3.52-3.45(m,1 H),3.43(s,3H),3.41(s,3H),3.26-3.18(m,2H),3.16(t,J=9.2Hz,1H),2.77(d,J=11.5Hz,1H),2.69-2.55(m,2H),2.54 -2.44(m,1H),2.36-2.18(m,4H),1.96-1.78(m,1H),1.78-1.71(m,2H),1.66(d,J=10.9Hz,1H),1.58-1.35(m,12H),1. 30-1.21(m,11H),1.20-1.10(m,6H),0.95-0.89(m,3H),0.85-0.81(m,3H),0.80-0.74(m,4H):MSm / z1008.6008[M+NH4] + .

[0387] Preparation of Compound I-163 Compound I-163 (yield 167 mg, 74%) was obtained as a mixture of isomers that were difficult to separate in the same manner as in [Preparation of Compound I-153], except that methyl 2-bromo-3-methoxypropanoate was used instead of ethyl 2-bromo-2-fluoroacetate. 1H-NMR(500MHz,CDCl3,δ):5.93-5.81(m,1H),5.78-5.66(m,2H),5.47-5.30(m,2H),5.06(s,0.5H),5.02 (s,0.5H),5.00-4.91(m,1H),4.89-4.86(m,0.5H),4.85-4.82(m,0.5H),4.78(d,J=4.0Hz,1H),4.67(br s,2H),4.62(s,0.5H),4.51(s,0.5H),3.94(br s,1H),3.87-3.79(m,3H),3.79-3.74(m,4H),3.73-3.61(m,2H),3.53-3.48(m,1H),3.47-3.42(m,6H),3 .42-3.36(m,3H),3.29-3.14(m,3H),2.85-2.76(m,1H),2.69-2.57(m,1H),2.54-2.44(m,2H),2.37-2.1 9(m,4H),1.96-1.81(m,3H),1.79-1.72(m,1H),1.69-1.59(m,2H),1.57-1.35(m,11H),1.31-1.24(m,8H ),1.19-1.15(m,3H),1.15-1.10(m,3H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,3H),0.81-0.75(m,3H).

[0388] Preparation of Compound I-164 Compound I-164 (yield 57.9 mg, 71%) was obtained as a mixture of isomers that are difficult to separate in the same manner as in [Preparation of Compound I-154], except that compound I-163 obtained in [Preparation of Compound I-163] was used instead of compound I-153 in [Preparation of Compound I-154]. 1H-NMR(500MHz,CD3OD,δ):5.91-5.79(m,1H),5.79-5.58(m,2H),5.43-5.26(m,2H),5.03-4.88(m,1H),4.84-4.56(m,4H),3.94(br s,1H),3.87-3.70(m,4H),3.69-3.58(m,2H),3.52-3.32(m,10H),3.27-3.12(m,3H),2.70-2.60(m,1H),2.56-2.45(m,2H) ),2.40-2.18(m,3H),1.92-1.34(m,30H),1.30-1.23(m,8H),1.22-1.11(m,7H),0.92(t,J=7.4Hz,3H),0.86-0.73(m,7H).

[0389] Preparation of Compound I-165 Compound I-165 (yield 7.8 mg, 29%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-164 obtained in [Preparation of Compound I-164] was used instead of compound I-48 in [Preparation of Compound I-132], and methylamine hydrochloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):6.64(q,J=4.6Hz,1H),5.88(dt,J=10.7,2.4Hz,1H),5.79-5.65(m,2H),5.44-5. 38(m,2H),5.00(s,1H),4.96(d,J=10.9Hz,1H),4.79-4.76(m,2H),4.74-4.67(m,2H),4.65(s,1H),3.95(br s,1H),3.87-3.74(m,4H),3.72-3.59(m,2H),3.53-3.46(m,1H),3.45(s,3H),3.43(s,3H),3.36(s,3H), 3.28-3.20(m,2H),3.18(t,J=9.2Hz,1H),2.82(d,J=5.2Hz,3H),2.75(dd,J=12.6,2.9Hz,1H),2.67-2.58 (m,1H),2.58-2.47(m,2H),2.38-2.20(m,4H),2.00-1.81(m,3H),1.78-1.63(m,6H),1.60-1.39(m,8H),1 .32-1.23(m,7H),1.17(t,J=6.6Hz,6H),0.93(t,J=7.2Hz,3H),0.87-0.76(m,7H);MSm / z1005.5908[M+H] + .

[0390] Preparation of Compound I-166: Compound I-166 (yield 7.3 mg, 24%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-164 obtained in [Preparation of Compound I-164] was used instead of compound I-48 in [Preparation of Compound I-132] and ammonium chloride (8.2 mg, 0.157 mmol) was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):6.63(d,J=2.9Hz,1H),5.89-5.85(m,1H),5.79-5.66(m,2H),5.53(d,J=2.9Hz,1 H),5.46-5.36(m,1H),5.00(s,1H),4.96(d,J=11.5Hz,1H),4.81-4.76(m,2H),4.71-4.62(m,3H),3.95(br s,1H),3.87-3.75(m,4H),3.71-3.59(m,2H),3.53-3.46(m,1H),3.45(s,3H),3.43(s,3H),3.38(s,3H),3.2 9-3.20(m,2H),3.18(t,J=9.2Hz,1H),2.74(dd,J=12.6,2.9Hz,1H),2.67-2.58(m,1H),2.55-2.46(m,1H),2 .39-2.31(m,2H),2.31-2.18(m,2H),2.03-1.81(m,4H),1.79-1.63(m,8H),1.60-1.39(m,14H),1.31-1.24( m,3H),1.23-1.12(m,3H),0.93(t,J=7.4Hz,3H),0.89-0.82(m,3H),0.82-0.75(m,4H);MSm / z991.5753[M+H] + .

[0391] Preparation of Compound I-167: Compound I-2 (200 mg, 0.225 mmol) obtained in [Preparation of Compound I-2] was dissolved in THF (2.30 mL), and then sodium hydride (9.00 mg, 0.225 mmol) and methyl (E)-2-butenoate (23.7 μL, 0.225 mmol) were added sequentially at 0°C, followed by stirring overnight at 40°C. A saturated aqueous sodium chloride solution was added to the reaction solution, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound I-167 (yield 41.3 mg, 19%) as a mixture of isomers that are difficult to separate. 1H-NMR(500MHz,CDCl3,δ):5.87-5.80(m,1H),5.77-5.64(m,2H),5.45-5.35(m,2H),4.96(d,J=9.7Hz,1H), 4.91(dd,J=8.9,2.0Hz,1H),4.77(d,J=3.4Hz,1H),4.68-4.59(m,3.5H),4.54(d,J=6.3Hz,0.5H),3.94(br s,1H),3.87-3.75(m,2H),3.73-3.60(m,4H),3.53-3.46(m,1H),3.45(s,3H),3.44(s,3H),3.27-3.20(m,2H) ),3.18(t,J=9.5Hz,1H),2.84-2.75(m,2H),2.64-2.55(m,1H),2.53-2.47(m,2H),2.45-2.40(m,1H),2.38-2 .21(m,4H),1.93-1.81(m,3H),1.78-1.73(m,1H),1.67(d,J=12.0Hz,1H),1.62-1.46(m,12H),1.46-1.36(m ,3H),1.33-1.23(m,8H),1.16(d,J=6.3Hz,6H),0.93(t,J=7.4Hz,3H),0.86-0.82(m,3H),0.82-0.75(m,4H).

[0392] Preparation of Compound I-168: Compound I-167 obtained in [Preparation of Compound I-167] was used instead of Compound I-153 in [Preparation of Compound I-154], and the same procedure as in [Preparation of Compound I-154] was used to obtain Compound I-168 (yield 25.7 mg, 63%) as a mixture of isomers that are difficult to separate. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.89-5.79(m,1H),5.79-5.65(m,2H),5.46-5.33(m,2H),5.00-4.93(m,1H),4.92(d,J=2.3Hz,1H),4.78(d ,J=2.9Hz,1H),4.67(d,J=1.1Hz,3H),3.98-3.92(m,1H),3.88-3.76(m,2H),3.73-3.61(m,2H),3.53-3.47(m,1H),3.45(s,3H),3.44( s,3H),3.28-3.21(m,2H),3.18(t,J=9.2Hz,1H),2.88-2.75(m,2H),2.68-2.47(m,4H),2.37-2.20(m,4H),1.94-1.83(m,3H),1.76-1. 43(m,14H),1.36-1.33(m,3H),1.30-1.25(m,8H),1.21-1.14(m,6H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.3Hz,3H),0.81-0.78(m,4H).

[0393] Preparation of Compound I-169 and Compound I-170 Compound I-169 (yield 7.4 mg, 29%) and Compound I-170 (yield 7.3 mg, 28%) were obtained in the same manner as in [Preparation of Compound I-132], except that Compound I-168 obtained in [Preparation of Compound I-168] was used instead of Compound I-48 in [Preparation of Compound I-132], and ammonium chloride was used instead of 5-aminopyrimidine. (Compound I-169) 1H-NMR(500 MHz, CDCl3, δ): 6.24 (br s, 1H), 5.86 (dt, J = 10.5, 2.5 Hz, 1H), 5.79 - 5.64 (m, 3H), 5.46 - 5.36 (m, 2H), 4.96 (d, J = 10.9 Hz, 1H), 4.90 (s, 1H), 4.78 (d, J = 3.4 Hz, 1H), 4.70 - 4.61 (m, 2H), 4.61 - 4.54 (m, 1H), 3.94 (br s, 1H), 3.86 - 3.75 (m, 2H), 3.71 - 3.61 (m, 2H), 3.52 - 3.46 (m, 1H), 3.45 (s, 3H), 3.43 (s, 3H), 3.27 - 3.20 (m, 2H), 3.18 (t, J = 9.2 Hz, 1H), 2.76 (dd, J = 12.9, 3.2 Hz, 1H), 2.66 - 2.58 (m, 1H), 2.56 - 2.53 (m, 2H), 2.52 - 2.47 (m, 1H), 2.38 - 2.19 (m, 5H), 1.97 - 1.82 (m, 3H), 1.78 - 1.72 (m, 1H), 1.67 (d, J = 12.6 Hz, 1H), 1.60 - 1.38 (m, 13H), 1.33 (d, J = 6.9 Hz, 3H), 1.31 - 1.24 (m, 7H), 1.20 (d, J = 6.9 Hz, 3H), 1.16 (d, J = 7.4 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H), 0.85 (d, J = 6.3 Hz, 3H), 0.82 - 0.76 (m, 4H); MS m / z 997.5613 [M + Na] + . (Compound I-170) 1H-NMR(500MHz,CDCl3,δ):6.03(br s,1H),5.87-5.80(m,1H),5.78-5.65(m,2H),5.47(br s,1H),5.44-5.37(m,2H),4.98-4.91(m,2H),4.78(d,J=3.4Hz,1H),4.70-4.59(m,3H),3.94(br s,1H),3.87-3.75(m,2H),3.71-3.60(m,2H),3.54-3.47(m,1H),3.45(s,3H),3.44(s,3H),3.27-3.20(m,2H) ,3.18(t,J=9.2Hz,1H),2.86-2.75(m,1H),2.70-2.62(m,1H),2.62-2.45(m,4H),2.38-2.18(m,5H),1.96-1.7 9(m,4H),1.79-1.71(m,2H),1.67(d,J=12.6Hz,2H),1.60-1.38(m,9H),1.35-1.31(m,3H),1.31-1.24(m,7H), 1.17(t,J=6.6Hz,6H),0.93(t,J=7.4Hz,3H),0.85(d,J=6.9Hz,3H),0.82-0.75(m,4H);MSm / z997.5616[M+Na] + .

[0394] Preparation of Compound I-171 and Compound I-172 Compound I-171 (yield 1.7 mg, 16%) and Compound I-172 (yield 1.5 mg, 14%) were obtained in the same manner as in [Preparation of Compound I-132], except that Compound I-168 obtained in [Preparation of Compound I-168] was used instead of Compound I-48 in [Preparation of Compound I-132], and methylamine hydrochloride was used instead of 5-aminopyrimidine. (Compound I-171) 1H-NMR(500 MHz, CDCl3, δ): 6.28 - 6.18 (m, 1H), 5.88 - 5.82 (m, 1H), 5.76 - 5.65 (m, 2H), 5.44 - 5.37 (m, 2H), 4.95 (br d, J = 11.5 Hz, 1H), 4.89 (s, 1H), 4.76 (d, J = 3.4 Hz, 1H), 4.68 - 4.61 (m, 3H), 4.57 - 4.50 (m, 1H), 3.93 (br s, 1H), 3.86 - 3.73 (m, 2H), 3.69 - 3.60 (m, 2H), 3.51 - 3.45 (m, 1H), 3.44 (s, 3H), 3.42 (s, 3H), 3.26 - 3.19 (m, 2H), 3.16 (t, J = 9.2 Hz, 1H), 2.76 - 2.74 (m, 3H), 2.77 - 2.72 (m, 1H), 2.60 (dd, J = 12.3, 6.6 Hz, 1H), 2.51 - 2.47 (m, 3H), 2.36 - 2.19 (m, 4H), 1.96 - 1.84 (m, 3H), 1.77 - 1.72 (m, 1H), 1.70 - 1.39 (m, 13H), 1.33 - 1.23 (m, 11H), 1.19 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H), 0.81 - 0.75 (m, 4H); MS m / z 989.5947 [M + H] + ​​H-NMR(500MHz,CDCl3,δ):6.03-5.98(m,1H),5.83(td,J=2.3,10.3Hz,1H),5.77-5.65(m,2H),5.45 -5.36(m,2H),4.99-4.92(m,2H),4.80-4.70(m,2H),4.70-4.63(m,2H),4.61-4.54(m,1H),3.93(br s,1H),3.87-3.73(m,2H),3.70-3.61(m,2H),3.52-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.27-3.19(m,2H) ,3.16(t,J=9.2Hz,1H),2.83-2.78(m,1H),2.74(d,J=4.6Hz,3H),2.69-2.61(m,1H),2.54-2.41(m,3H),2.36- 2.19(m,4H),1.92-1.82(m,3H),1.75-1.71(m,1H),1.68-1.36(m,13H),1.31-1.23(m,10H),1.16(d,J=6.9Hz, 6H),1.17-1.14(m,6H),0.92(t,J=7.4Hz,3H),0.84(d,J=6.3Hz,3H),0.82-0.75(m,4H);MSm / z989.5945[M+H] + .

[0395] Reference Example 23: Production of methyl (S)-3-aminooxy-2-methylpropionate With reference to European Journal of Medicinal Chemistry (2001), 36, 799-807, methyl (S)-3-aminooxy-2-methylpropionate (yield 435 mg, 79%) was obtained using methyl (S)-3-hydroxy-2-methylpropionate (1.50 g, 12.7 mmol) as a starting material. 1 H-NMR (500MHz, D2O, δ): 3.74-3.68 (m, 1H), 3.68-3.61 (m, 1H), 3.61-3.56 (m, 3H), 2.81-2.73 (m, 1H), 1.01-0.97 (m, 3H).

[0396] Preparation of Compound I-173 Compound I-173 (yield 443 mg, 78%) was obtained in the same manner as in [Preparation of Compound I-2] except that methyl (S)-3-aminooxy-2-methylpropionate obtained in Reference Example 23 was used instead of hydroxylamine hydrochloride. 1 H-NMR(500MHz,CDCl3,δ):5.87-5.80(m,1H),5.76-5.64(m,2H),5.43-5.35(m,2H),4.95(br d,J=9.2Hz,1H),4.88(s,1H),4.76(br d,J=3.4Hz,1H),4.70-4.60(m,2H),4.60-4.51(m,1H),4.33(dd,J=11.2,6.6Hz,1H),4.08(dd,J=11.2,6.6Hz,1H),3.93(br s,1H),3.86-3.72(m,2H),3.67(s,3H),3.71-3.59(m,2H),3.52-3.45(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H) ),3.16(t,J=9.2Hz,1H),2.92-2.82(m,1H),2.79-2.75(m,1H),2.61-2.46(m,2H),2.34(dd,J=4.6,12.6Hz,2H),2.30-2. 16(m,2H),1.92-1.85(m,2H),1.85-1.79(m,1H),1.76-1.71(m,1H),1.69-1.36(m,12H),1.29-1.23(m,8H),1.16(t,J=6. 6Hz,8H),0.92(t,J=7.4Hz,3H),0.88(t,J=6.9Hz,1H),0.83(d,J=6.9Hz,3H),0.82-0.74(m,4H);MSm / z1007.5834[M+NH4] + .

[0397] Preparation of Compound I-174 Compound I-174 (yield 195 mg, 90%) was obtained in the same manner as in [Preparation of Compound I-154], except that compound I-173 obtained in [Preparation of Compound I-173] was used instead of compound I-153 in [Preparation of Compound I-154]. 1H-NMR(500MHz,CDCl3,δ):5.86-5.80(m,1H),5.76-5.64(m,2H),5.44-5.34(m,2H),4.94(br d,J=10.3Hz,1H),4.89(s,1H),4.76(br d,J=2.9Hz,1H),4.65(br s,2H),4.36-4.30(m,1H),4.16-4.11(m,1H),3.93(br s,1H),3.86-3.72(m,2H),3.70-3.56(m,2H),3.48(ddd,J=4.6,9.2,11.5Hz,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H) ),3.17(t,J=9.2Hz,1H),2.93-2.87(m,1H),2.77(dd,J=12.3,3.2Hz,1H),2.64-2.56(m,1H),2.52-2.46(m,1H),2.36-2.19(m ,2H),1.96-1.80(m,3H),1.77-1.71(m,1H),1.68-1.63(m,1H),1.59-1.36(m,12H),1.29-1.24(m,9H),1.20(d,J=7.4Hz,3H), 1.15(dd,J=6.6,2.6Hz,6H),0.92(t,J=7.4Hz,3H),0.88(s,1H),0.85-0.82(m,3H),0.80-0.74(m,4H);MSm / z998.5208[M+Na] + .

[0398] Preparation of Compound I-175 Compound I-175 (yield 15.7 mg, 39%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-174 obtained in [Preparation of Compound I-174] was used instead of compound I-48 in [Preparation of Compound I-132] and ammonium chloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):7.25(s,1H),5.97(br s,1H),5.86-5.80(m,1H),5.76-5.64(m,2H),5.49(br s,1H),5.45-5.36(m,2H),4.94(br d,J=10.3Hz,1H),4.91-4.88(m,1H),4.76(d,J=3.4Hz,1H),4.70-4.59(m,3H),4.25-4.18(m,1H),4.16-4.09(m,1H),3.92(br s,1H),3.85-3.72(m,2H),3.70-3.57(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.27-3. 18(m,2H),3.16(t,J=9.2Hz,1H),2.79-2.67(m,2H),2.65-2.46(m,2H),2.36-2.19(m,4H),1.93-1. 80(m,2H),1.75-1.71(m,1H),1.66(d,J=12.6Hz,1H),1.58-1.35(m,12H),1.28-1.23(m,9H),1.19- 1.11(m,8H),0.92(t,J=7.2Hz,3H),0.83(d,J=6.9Hz,3H),0.81-0.74(m,4H);MSm / z997.5370[M+Na] + .

[0399] Preparation of Compound I-176 Compound I-176 (yield 24.0 mg, 59%) was obtained in the same manner as in [Preparation of Compound I-132], except that compound I-174 obtained in [Preparation of Compound I-174] was used instead of compound I-48 in [Preparation of Compound I-132] and methylamine hydrochloride was used instead of 5-aminopyrimidine. 1H-NMR(500MHz,CDCl3,δ):5.93(br s,1H),5.83(d,J=10.3Hz,1H),5.77-5.64(m,2H),5.43-5.36(m,2H),4.94(d,J=11.5Hz,1H),4.89(s,1H),4.76(d,J=4.0Hz,1H),4.73-4.57(m,3H),4.22-4.09(m,2H),3.93(br s,1H),3.85-3.73(m,2H),3.71-3.58(m,2H),3.51-3.46(m,1H),3.44(s,3H),3.42(s,3H),3.26-3.19(m,2H),3.16(t,J=8.9Hz,1H),2.78-2.73(m,3H),2.65-2.57(m,2H),2.53-2.45(m,1H),2.33(dd,J=12.6,4.0Hz,2H),2.27-2.19(m,2H),1.92-1.81(m,2H),1.76-1.69(m,1H),1.69-1.61(m,1H),1.59-1.37(m,13H),1.26(dd,J=10.9,6.3Hz,8H),1.18-1.11(m,8H),0.92(t,J=7.4Hz,3H),0.83(d,J=6.9Hz,3H),0.80-0.74(m,4H);MSm / z1011.5554[M+Na] + 。

[0400] Preparation of Compound II-1 and Compound II-2 Ethyl 2-(diethoxyphosphoryl)acetate (37.7 μL, 0.189 mmol) was dissolved in THF and cooled to 0°C. Then, a 1 M solution of lithium bistrimethylsilylamide in THF (0.189 ml, 0.189 mmol) was added dropwise, and the mixture was stirred at the same temperature for 30 minutes. 3,4β-dihydro-5-oxo-ivermectin B1a (50.0 mg, 0.0570 mmol) dissolved in THF (0.457 mL) was slowly added dropwise, and the mixture was stirred at the same temperature for another 2 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was warmed to room temperature and then extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=3:2) to obtain Compound II-1 (yield 5.2 mg, 10%) and Compound II-2 (yield 19.4 mg, 36%). (Compound II-1) 1 H-NMR(500MHz,CDCl3,δ):5.93(s,1H),5.88-5.81(m,1H),5.76-5.66(m,2H),5.46-5.38(m,2H),4.95( d,J=10.88Hz,1H),5.78-5.65(m,3H),4.60-4.55(m,1H),4.19-4.10(m,2H),4.08-4.01(m,1H),3.93(br s,1H),3.86-3.74(m,3H),3.72-3.60(m,2H),3.51-3.40(m,7H),3.28-3.13(m ,3H),2.93(d,J=13.75Hz,1H),2.52-2.46(m,2H),2.36-2.15(m,5H),1.94-1.8 6(m,1H),1.79-1.70(m,1H),1.69-1.64(m,1H),1.59-1.38(m,17H),1.31-1.2 3(m,13H),1.15(d,J=6.87Hz,3H),0.94-0.74(m,10H);MSm / z962.5745[M+NH4] + (Compound II-2) 1H-NMR(500MHz,CDCl3,δ):6.01(s,1H),5.88-5.76(m,1H),5.75-5.66(m,2H),5.45-5.35(m,2H),5.17(s,1H) ,4.94(d,J=10.31Hz,1H),4.76(d,J=3.44Hz,1H),4.72-4.62(m,2H),4.52(s,1H),4.17-4.09(m,3H),3.93(br s,1H),3.87-3.71(m,2H),3.70-3.59(m,2H),3.52-3.35(m,7H),3.27-3.11(m,3H),2. 95-2.88(m,1H),2.75-2.67(m,1H),2.55-2.46(m,2H),2.36-2.19(m,5H),1.93-1.84( m,1H),1.83-1.71(m,1H),1.67-1.60(m,3H),1.58-1.37(m,13H),1.30-1.22(m,13H), 1.19-1.11(m,3H),0.91(t,J=7.16Hz,3H),0.86-0.74(m,7H);MSm / z962.5745[M+NH4] + .

[0401] Preparation of Compound II-3 Compound II-3 (yield 29.6 mg, 55%) was obtained in the same manner as in [Preparation of Compound II-1 and Compound II-2] except that 3,4α-dihydro-5-oxo-ivermectin B1a was used instead of 3,4β-dihydro-5-oxo-ivermectin B1a. 1H-NMR(500MHz,CDCl3,δ):5.95(d,J=1.7Hz,1H),5.84-5.77(m,1H),5.74-5.66(m,2H),5.41-5.33(m,3H) ,4.96-4.91(m,1H),4.76(d,J=3.4Hz,1H),4.67(d,J=2.3Hz,2H),4.46(s,1H),4.17-4.11(m,2H),3.92(br s,1H),3.85-3.73(m,2H),3.69-3.59(m,2H),3.50-3.46(m,1H),3.46-3.4 0(m,6H),3.25-3.13(m,3H),2.89-2.83(m,1H),2.67-2.60(m,1H),2.56(br s,1H),2.49(t,J=6.6Hz,1H),2.36-2.19(m,4H),1.92-1.85(m,1H),1.82-1.61(m,6H),1.57-1.36(m,14H),1 .29-1.22(m,10H),1.13(d,J=9.16Hz,3H),0.91(t,J=7.5Hz,3H),0.85-0.74(m,7H);MSm / z962.5745[M+NH4] + .

[0402] Preparation of Compound II-4: Compound II-2 (18.0 mg, 19.0 μmol) obtained in [Preparation of Compound II-1 and Compound II-2] was dissolved in dichloromethane (224 μL) and cooled to −78°C. A 1 M diisobutylaluminum hydride dichloromethane solution (66.7 μL, 66.7 μmol) was then added dropwise, and the mixture was stirred at the same temperature for 4 hours. Methanol and a saturated aqueous solution of Rochelle salt were then added dropwise, and the mixture was stirred at room temperature for 30 minutes, after which the reaction mixture was extracted with chloroform. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:3) to obtain Compound II-4 (yield 13.2 mg, 77%). 1H-NMR(500MHz,CDCl3,δ):5.97-5.89(m,1H),5.88-5.81(m,1H),5.77-5.63 (m,3H),5.40(d,J=3.4Hz,2H),4.98-4.90(m,1H),4.78-4.74(m,1H),4.70( s,1H),4.67-4.54(m,2H),4.40-4.36(m,1H),4.32(s,1H),4.25-4.14(m,2H ),3.94-3.89(m,1H),3.86-3.71(m,2H),3.70-3.60(m,2H),3.52-3.38(m,7H ),3.26-3.14(m,3H),2.87-2.76(m,1H),2.72-2.62(m,1H),2.58-2.53(m.1 H),2.49(t,J=6.87Hz,1H),2.38-2.30(m,2H),2.30-2.16(m,3H),1.94-1.85 (m,2H),1.79-1.71(m,2H),1.71-1.62(m,4H),1.58-1.37(m,14H),1.30-1. 19(m,9H),0.92(t,J=7.5Hz,3H),0.86-0.75(m,7H);MSm / z920.5573[M+NH4] + .

[0403] Preparation of Compound II-5 Compound II-5 (yield 20.3 mg, 76%) was obtained in the same manner as in [Preparation of Compound II-4] except that Compound II-3 was used instead of Compound II-2. 1H-NMR(500MHz,CDCl3,δ):5.90(td,J=7.0,2.0Hz,1H),5.86-5.78(m,1H),5.76-5.63(m,2H),5.41-5.35(m,2H),4.97-4 .91(m,1H),4.79-4.73(m,2H),4.63(dd,J=6.9,2.3Hz,2H),4.38(s,1H),4.31-4.26(m,1H),4.23-4.17(m,1H),3.92(br s,1H),3.86-3.71(m,2H),3.69-3.60(m,2H),3.52-3.38(m,7H),3.25-3.13(m,3H),2.7 8(dd,J=12.9,3.15Hz,1H),2.60(s,1H),2.52-2.45(m,2H),2.35-2.19(m,4H),1.93-1.8 0(m,2H),1.77-1.70(m,4H),1.68-1.60(m,2H),1.58-1.37(m,14H),1.28-1.22(m,6H),1 .13(d,J=12.0Hz,3H),0.91(t,J=7.5Hz,3H),0.84-0.74(m,7H);MSm / z920.5573[M+NH4] + .

[0404] Preparation of Compound II-6: Compound II-5 (98.0 mg, 0.109 mmol) obtained in [Preparation of Compound II-5] was dissolved in dichloromethane (2.17 mL), and then manganese dioxide (385 mg, 4.34 mmol) was added and stirred at room temperature for 14 hours. The reaction solution was filtered using Celite, and the solvent was distilled off under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography (n-hexane / ethyl acetate system) to obtain Compound II-6 (yield 67.7 mg, 69%). 1H-NMR(500MHz,CDCl3,δ):10.13(d,J=7.5Hz,1H),6.13(dd,J=8.0,1.7Hz,1H),5.85(s,1H), 5.73(dd,J=17.2,9.7Hz,2H),5.40(d,J=4.0Hz,2H),4.98(s,2H),4.79-4.67(m,6H),3.94(br s,1H),3.86-3.73(m,2H),3.71-3.58(m,2H),3.43(d,J=9.7Hz,7H),3.23(d,J=9.2H) z,2H),3.17(s,1H),2.85(s,1H),2.76-2.66(m,1H),2.50(d,J=1.2Hz,2H),2.33(br s,4H),1.82(s,4H),1.65(br s,1H),1.59-1.49(m,16H),1.41(t,J=12.0Hz,3H),1.31-1.22(m,7H),1.16(d, J=6.3Hz,6H),0.92(t,J=7.5Hz,3H),0.86-0.75(m,7H);MSm / z920.5573[M+NH4] + .

[0405] Preparation of Compound II-7 Compound II-7 (yield 26.8 mg, 71%) was obtained in the same manner as in [Preparation of Compound II-1 and Compound II-2] except that Compound II-6 was used instead of 3,4β-dihydro-5-oxo-ivermectin B1a. 1H-NMR(500MHz,CDCl3,δ):7.67(dd,J=15.2,11.7Hz,1H),6.32(d,J=11.5Hz,1H),5.95(d,J=14.9Hz,1H),5.88-5.80(m,1H),5.7 6-5.67(m,2H),5.43-5.35(m,2H),4.94(d,J=10.9Hz,1H),4.76(d,J=3.4Hz,1H),4.70-4.60(m,4H),4.21-4.15(m,2H),3.93(br s,1H),3.86-3.72(m,2H),3.72-3.57(m,2H),3.48-3.38(m,7H),3.27-3.13( m,3H),2.83(dd,J=12.6,3.44Hz,1H),2.64-2.54(m,2H),2.54-2.46(m,1H), 2.37-2.18(m,4H),1.89(dd,J=11.5,4.6Hz,1H),1.80-1.61(m,6H),1.58-1. 36(m,14H),1.31-1.14(m,17H),0.93-0.74(m,11H);MSm / z988.6065[M+NH4] + .

[0406] Preparation of Compound II-8: Compound II-6 (15.0 mg, 17.0 μmol) obtained in [Preparation of Compound II-6] was dissolved in methanol (200 μL), and then 2-(aminooxy)ethan-1-ol (5.13 mg, 67.0 μmol) and sodium acetate (5.46 mg, 67.0 μmol) were added, followed by stirring at room temperature for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, which was then extracted with chloroform. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:acetone=2:1) ​​to obtain Compound II-8 (yield 12.6 mg, 79%) as a mixture of isomers that are difficult to separate. 1H-NMR(500MHz,CDCl3,δ):8.20(d,J=10.3Hz,1H),7.45(d,J=9.7Hz,1H),6.27(dd,J=10.3,1.7Hz,1H),5.87-5.80(m,1H),5.71(t,J=9.7Hz,2H) ,5.45-5.33(m,2H),4.94(d,J=10.9Hz,1H),4.76(d,J=3.4Hz,1H),4.70 -4.60(m,3H),4.51(s,0.3H),4.43(s,0.7H),4.24-4.14(m,2H),3.93(br s,1H),3.89-3.71(m,4H),3.72-3.60(m,2H),3.52-3.38(m,7H),3.26-3.13(m,3H),2. 80(dd,J=12.6,3.4Hz,1H),2.63-2.53(m,2H),2.53-2.43(m,1H),2.36-2.16(m,5H),1 .89(dd,J=12.6,4.6Hz,1H),1.82-1.69(m,3H),1.68-1.62(m,3H),1.58-1.37(m,13H) ,1.29-1.14(m,12H),0.91(t,J=7.5Hz,3H),0.85-0.74(m,7H);MSm / z982.5557[M+Na] + .

[0407] Preparation of Compound II-9: Compound II-6 (15.0 mg, 17.0 μmol) obtained in [Preparation of Compound II-6] was dissolved in THF (333 μL), and then 2-aminoethan-1-ol (3.02 μL, 50.0 μmol), acetic acid (9.53 μL, 166 μmol), zinc chloride (3.40 mg, 25.0 μmol), and sodium cyanoborohydride (5.23 mg, 83.0 μmol) were added, followed by stirring at room temperature for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, which was then extracted with chloroform. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (chloroform:methanol:aqueous ammonium hydroxide solution=90:10:1) to obtain Compound II-9 (yield 8.5 mg, 54%). 1H-NMR(500MHz,CDCl3,δ):5.87-5.81(m,1H),5.79-5.68(m,3H),5.40-5.31(m,2H),4.9 8-4.91(m,1H),4.76(d,J=3.4Hz,1H),4.63(dd,J=4.6,2.3Hz,2H),4.38(s,1H),3.93(br s,1H),3.85-3.73(m,2H),3.69-3.60(m,4H),3.52-3.41(m,8H),3.38-3.33(m,1H) ,3.26-3.14(m,3H),2.83-2.73(m,3H),2.61-2.38(m,7H),2.38-2.17(m,6H),1.94 -1.88(m,1H),1.77-1.61(m,4H),1.58-1.35(m,14H),1.35-1.21(m,8H),1.13(dd, J=15.2,6.6Hz,7H),0.91(t,J=7.5Hz,3H),0.87-0.73(m,8H);MSm / z946.5779[M+H] + .

[0408] Preparation of Compound II-10: Compound II-7 (19.3 mg, 20.0 μmol) obtained in [Preparation of Compound II-7] was dissolved in methanol (397 μL) and then cooled to 0°C. Nickel chloride hexahydrate (0.95 mg, 3.97 μmol) and sodium borohydride (3.76 mg, 99.0 μmol) were then added, and the mixture was stirred at the same temperature for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the mixture was warmed to room temperature and then extracted with chloroform. The solvent was removed under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:1) to obtain Compound II-10 (yield 5.2 mg, 10%) as a mixture of isomers that are difficult to separate. The following 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.86-5.75(m,1H),5.73-5.50(m,3H),5.41-5.32(m,2H),4.94(d,J=11.5Hz ,1H),4.76(d,J=2.3Hz,1H),4.62(t,J=2.7,2.7Hz,1H),4.59-4.46(m,2H),4.14-4.08(m,2H),3.92(br s,1H),3.84-3.60(m,5H),3.50-3.37(m,7H),3.25-3.14(m,3H),3.07-3.06(m ,1H),2.77dd,J=12.9,3.2Hz,1H),2.58-2.40(m,4H),2.382.20(m,5H),1.92-1 .85(m,1H),1.79-1.70(m,2H),1.68-1.36(m,15H),1.27-1.21(m,10H),1.14(d ,J=6.9Hz,3H),1.08-1.03(m,2H),0.94-0.77(m,13H);MSm / z990.6157[M+NH4] + .

[0409] Preparation of Compound II-11: Compound II-7 (7.00 mg, 7.21 μmol) obtained in [Preparation of Compound II-7] was dissolved in dichloromethane (290 μL) and cooled to −78°C. A 1 M diisobutylaluminum hydride dichloromethane solution (36.0 μL, 36.0 μmol) was then added dropwise, and the mixture was stirred at the same temperature for 4 hours. Methanol and a saturated aqueous solution of Rochelle salt were added dropwise thereto, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was then extracted with chloroform / methanol (9:1). The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer chromatography (chloroform:methanol=9:1) to obtain Compound II-11 (yield 5.30 mg, 79%). 1H-NMR(500MHz,CDCl3,δ):6.66(dd,J=14.9,10.9Hz,1H),6.25(dd,J=10.9,1.7Hz,1H),5.94(d,J=14.9Hz,1H),5.87-5.78(m,1H),5.76- 5.66(m,2H),5.41-5.35(m,2H),4.98-4.89(m,1H),4.76(d,J=2.9Hz,1H),4.70-4.59(m,3H),4.57(s,1H),4.18(d,J=5.2Hz,2H),3.93(br s,1H),3.88-3.58(m,5H),3.52-3.41(m,7H),3.28-3.12(m,3H),2.80(s,1H),2.51(br s,3H),2.36-2.30(m,2H),2.27(s,2H),1.93-1.83(m,1H),1.77-1.62(m,5H),1.61-1.40(m,19H),1.38(s,2H) ),1.30-1.22(m,8H),1.15(d,J=6.9Hz,6H),0.91(t,J=7.5Hz,3H),0.84-0.75(m,7H);MSm / z946.5919[M+NH4] + .

[0410] Preparation of Compound II-12: Compound II-5 (30.6 mg, 34.0 μmol) obtained in [Preparation of Compound II-5] was dissolved in dichloromethane (339 μL) and ice-cooled to 0°C. Then, pyridine (5.48 μL, 68.0 μmol), 4-methylbenzoyl chloride (5.82 μL, 44.0 μmol), and DMAP (0.414 mg, 3.39 μmol) were added, and the mixture was warmed to room temperature and stirred at the same temperature for 24 hours. The reagents were then added again, and the mixture was stirred at room temperature for an additional 24 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the mixture was extracted with chloroform. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:1) to obtain Compound II-12 (yield 5.00 mg, 15%). 1H-NMR(500MHz,CDCl3,δ):7.93(d,J=7.6Hz,2H),7.21(d,J=8.0Hz,2H),5.89-5.82(m,2H),5.75-5.68(m,2H),5.42-5 .33(m,2H),5.02-4.92(m,3H),4.77(d,J=3.4Hz,1H),4.65(dd,J=5.2,2.3Hz,2H),4.53(s,1H),4.47(s,1H),3.93(br s,1H),3.87-3.72(m,2H),3.71-3.58(m,2H),3.51-3.36(m,7H),3.27-3.14(m,3H),2.83-2.78(m,1H),2.50(br s,3H),2.39(s,3H),2.37-2.30(m,2H),2.30-.2.17(m,2H),1.95-1.83(m,1H),1.79-1.62(m,5H),1.60-1.39(m,2 1H),1.31-1.21(m,7H),1.14(d,J=3.4Hz,3H),0.92(t,J=7.2Hz,3H),0.86-0.76(m,7H);MSm / z1038.6484[M+NH4] + .

[0411] Preparation of Compound II-13 Compound II-13 (yield 91.3 mg, 84%) was obtained in the same manner as in [Preparation of Compound II-3] except that allyl 2-(diethoxyphosphoryl)acetate was used instead of ethyl 2-(diethoxyphosphoryl)acetate. 1H-NMR(500MHz,CDCl3,δ):5.98(d,J=1.7Hz,1H),5.95-5.87(m,1H),5.82-5.79(m,1H),5.74-5.63(m,2H),5.40-5.27(m,4H),5 .24-5.18(m,1H),4.93(d,J=10.9Hz,1H),4.75(d,J=3.4Hz,1H),4.67(d,J=2.3Hz,2H),4.63-4.55(m,2H),4.46(s,1H),3.92(br s,1H),3.85-3.73(m,2H),3.69-3.60(m,2H),3.51-3.39(m,7H),3.25-3.13(m,3H),2.88-2.84(m,1H),2.65(dd,J=5.2,2.9Hz,1H),2.60(br s,1H),2.48(br s,1H),2.35-2.19(m,4H),1.92-1.87(m,1H),1.82-1.70(m,4H),1.64(d,J=12.6Hz,1H),1.57-1.35(m,14H),1. 35-1.21(m,8H),1.14(dd,J=8.6,6.9Hz,6H),0.91(t,J=7.5Hz,3H),0.86-0.74(m,7H);MSm / z974.6138[M+NH4] + .

[0412] Preparation of Compound II-14 Compound II-13 (15.0 mg, 16.0 μL) obtained in [Preparation of Compound II-13] was dissolved in dichloromethane (313 μL) and the solution was ice-cooled to 0°C. Thereafter, morpholine (13.7 μL, 157 μmol) and tetrakis(triphenylphosphine)palladium (1.81 mg, 1.57 μmol) were added, and the mixture was stirred at the same temperature for 30 minutes. The temperature was then raised to room temperature and the mixture was stirred for 30 minutes. The reaction solution was diluted with chloroform and washed with 1N hydrochloric acid. The solvent was distilled off under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:3) to obtain Compound II-14 (yield 11.6 mg, 81%). 1H-NMR(500MHz,CDCl3,δ):7.69-7.63(m,1H),7.53(dd,J=7.2,1.4Hz,1H),7.50-7.41(m,1H),5.98(s,1H),5. 85-5.78(m,1H),5.75-5.66(m,2H),5.42-5.33(m,3H),4.95(d,J=9.74Hz,1H),4.76(d,J=3.4Hz,1H),4.68(br s,2H),3.93(br s,1H),3.86-3.72(m,2H),3.72-3.57(m,2H),3.52-.3.40(m,7H),3.29-3.11(m,3H),2.94-2 .82(m,1H),2.72-2.62(m,1H),2.54-2.43(m,1H),2.38-2.16(m,5H),1.90(dd,J=12.0,4.0H z,1H),1.84-1.71(m,3H),1.65(d,J=12.6Hz,1H),1.58-1.36(m,14H),1.35-1.21(m,7H),1. 14(dd,J=6.3,3.4Hz,6H),0.91(t,J=7.5Hz,3H),0.87-0.73(m,7H);MSm / z934.5815[M+NH4] + .

[0413] Preparation of Compound II-15: Compound II-10 (13.4 mg, 14.0 μmol) obtained in [Preparation of Compound II-10] was dissolved in THF (275 μL) and ice-cooled to 0°C. Then, lithium triethylborohydride (62.0 μL, 62.0 μmol) was added, and the mixture was stirred at the same temperature for 1 hour. Methanol and a saturated aqueous solution of sodium bicarbonate were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:2) to obtain Compound II-15 (yield 7.90 mg, 62%) as a mixture of isomers that are difficult to separate. 1 The H-NMR spectrum is the analytical data for the major isomers. 1H-NMR(500MHz,CDCl3,δ):5.83-5.76(m,1H),5.74-5.66(m,2H),5.52-5.49(m,1H),5.40-5.34( m,2H),4.95-4.93(m,1H),4.76(d,J=2.3Hz,1H),4.63-4.61(m,1H),4.58-4.46(m,2H),3.92(br s,1H),3.85-3.74(m,2H),3.69-3.56(m,4H),3.50-3.40(m,7H),3.25-3.14(m, 3H),2.59-2.44(m,3H),2.35-2.20(m,5H),1.89-1.85(m,1H),1.75-1.36(m,25 H),1.26(dd,J=12.3Hz,6.0Hz,7H),1.16-1.10(m,4H),1.07-1.02(m,1H),0.95 -0.88(m,6H),0.83(d,J=6.3Hz,3H),0.79-0.76(m,4H);MSm / z948.5929[M+NH4] + .

[0414] Preparation of Compound II-16: Compound II-14 (11.6 mg, 13.0 μmol) obtained in [Preparation of Compound II-14] was dissolved in a dichloromethane solution (506 μL) and the solution was ice-cooled to 0°C. Subsequently, aniline (2.31 μL, 25.0 μmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-1-amine hydrochloride (4.85 mg, 25.0 μmol), and DMAP (3.09 mg, 25.0 μmol) were added, followed by stirring at room temperature for 16 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform. The solvent was evaporated under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:1) to obtain Compound II-16 (yield 9.80 mg, 78%). 1H-NMR(500MHz,CDCl3,δ):8.10(s,1H),7.55(d,J=8.0Hz,2H),7.30(t,J=7.7Hz,2H),7.08(s,1H),6.11(d,J=1.7Hz,1H),5.82(d,J= 10.3Hz,1H),5.76-5.61(m,2H),5.39(d,J=3.4Hz,2H),4.95(d,J=9.7Hz,1H),4.80(s,1H),4.74(s,2H),4.71-4.59(m,2H),3.92(br s,1H),3.86-3.72(m,2H),3.71-3.58(m,2H),3.42(d,J=10.3Hz,7H),3.23(s,3H),2.87-2.78 (m,1H),2.69-2.58(m,1H),2.58-2.53(m,1H),2.51-2.43(m,1H),2.37-2.18(m,1H),1.95-1.8 7(m,1H),1.87-1.71(m,3H),1.66(s,7H),1.58-1.37(m,13H),1.25(dd,J=12.6,6.3Hz,7H),1. 15(dd,J=18.9,6.9Hz,6H),0.92(t,J=7.5Hz,3H),0.86-0.76(m,7H);MSm / z1009.6273[M+NH4] + .

[0415] Preparation of Compound II-17 Compound II-17 (yield 10.6 mg, 77%) was obtained in the same manner as in [Preparation of Compound II-16] except that ethylamine was used instead of aniline. 1H-NMR(500MHz,CDCl3,δ):6.09(t,J=5.7Hz,1H),5.96(d,J=2.3Hz,1H),5.87-5.79(m,1H),5.76-5. 62(m,2H),5.39(d,J=4.0Hz,2H),4.98-4.91(m,1H),4.77-4.72(m,2H),4.68-4.57(m,3H),3.93(br s,1H),3.87-3.72(m,2H),3.71-3.58(m,2H),3.51-3.39(m,7H),3.36-3.14(m,5H),2.79 (dd,J=12.3,3.7Hz,1H),2.59-2.52(m,2H),2.51-2.45(m,1H),2.36-2.29(m,2H),2.29-2 .19(m,2H),1.94-1.86(m,1H),1.82-1.62(m,9H),1.58-1.36(m,13H),1.27(d,J=6.3Hz, 7H),1.17-1.10(m,9H),0.91(t,J=7.5Hz,3H),0.85-0.74(m,7H);MSm / z961.6087[M+NH4] + .

[0416] Preparation of Compound II-18 Compound II-18 (yield 18.9 mg, 57%) was obtained in the same manner as in [Preparation of Compound II-9] except that thiophen-2-ylmethanamine was used instead of 2-aminoethan-1-ol. 1H-NMR(500MHz,CDCl3,δ):7.19(dd,J=4.9,1.4Hz,1H),6.95-6.91(m,2H),5.86-5.80(m,1H),5.77(t,1H),5.74-5.66(m, 2H),5.45-5.29(m,2H),4.95(d,J=10.9Hz,1H),4.78-4.75(m,1H),4.66-4.57(m,2H),4.34(s,1H),3.98(s,2H),3.93(br s,1H),3.86-3.73(m,2H),3.70-3.60(m,2H),3.50-3.35(m,9H),3.27-3.14(m,3 H),2.77(dd,J=12.9,3.2Hz,1H),2.52-2.42(m,3H),2.40-2.17(m,8H),1.91(dd ,J=11.7,4.3Hz,1H),1.77-1.69(m,2H),1.68-1.61(m,2H),1.60-1.35(m,13H), 1.32-1.21(m,7H),1.21-1.05(m,6H),0.94-0.75(m,10H);MSm / z998.6152[M+H] + .

[0417] Preparation of Compound II-19 Compound II-19 (yield 23.1 mg, 72%) was obtained in the same manner as in [Preparation of Compound II-9] except that aniline was used instead of 2-aminoethan-1-ol. 1H-NMR(500MHz,CDCl3,δ):7.16(t,J=6.8Hz,2H),6.70(t,J=7.2Hz,1H),6.61(d,J=7.5Hz,2H),5.87-5.79(m,2H),5.74-5.65 (m,2H),5.43-5.36(m,2H),4.94(d,J=10.9Hz,1H),4.79-4.72(m,1H),4.68(s,1H),4.67-4.58(m,2H),4.42(s,1H),3.92(br s,1H),3.87-3.73(m,5H),3.73-3.60(m,2H),3.43(d,J=10.9Hz,7H),3.26-3.14(m,3H),2.81(d d,J=12.9,3.15Hz,1H),2.53(s,1H),2.51-2.44(m,2H),2.36-2.19(m,4H),1.90(dd,J=12.0,3.4 Hz,1H),1.77-1.70(m,2H),1.69-1.60(m,4H),1.59-1.38(m,14H),1.31-1.21(m,7H),1.13(dd, J=10.6,6.6Hz,6H),0.92(s,3H),0.83(d,J=6.3Hz,3H),0.74-0.81(m,4H);MSm / z978.6411[M+H] + .

[0418] Preparation of Compound II-20 Triphenyl(propyl)phosphonium bromide (30.8 mg, 80.0 μmol) was dissolved in THF (228 μL) and cooled to 0°C. Then, a 1 M potassium tert-butoxide THF solution (80.0 μL, 80.0 μmol) was added dropwise, and the mixture was stirred at the same temperature for 1 hour. 3,4α-dihydro-5-oxo-ivermectin B1a (20.0 mg, 23.0 μmol) dissolved in THF (228 μL) was slowly added dropwise thereto, and the mixture was further stirred at the same temperature for 20 hours. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was warmed to room temperature and then extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After distilling off the solvent under reduced pressure, the residue was purified by preparative thin layer chromatography (n-hexane:ethyl acetate=1:1) to obtain Compound II-20 (yield 2.6 mg, 13%) as a mixture of isomers that are difficult to separate. 1The H-NMR spectrum is the analytical data for the major isomers. 1 H-NMR(500MHz,CDCl3,δ):5.82(d,J=2.3Hz,1H),5.77-5.66(m,2H),5.57(s,1H),5.44-5.34(m,2H) ),4.98-4.91(m,1H),4.76(d,J=3.4Hz,1H),4.65(s,1H),4.60-4.50(m,2H),3.97(s,1H),3.92(br s,1H),3.87-3.73(m,2H),3.70-3.59(m,2H),3.39-3.52(m,7H),3.24-3.14(m,3H),2.75-2.67 (m,1H),2.63(dd,J=12.9,3.7Hz,1H),2.53-2.39(m,2H),2.38-2.14(m,7H),1.94-1.83(m,1H), 1.56-1.45(m,13H),1.82-1.33(m,37H),1.32-1.21(m,12H),1.21-1.08(m,6),1.07-0.96(m,4 H),0.92(t,J=7.5Hz,3H),0.83(d,J=6.8Hz,4H),0.78(d,J=5.7Hz,6H);MSm / z918.6136[M+NH4] + .

[0419] Preparation of Compound II-21 and Compound II-22 Compound II-6 (20.0 mg, 22.0 μmol) obtained in [Preparation of Compound II-6] was dissolved in THF (0.440 mL) and cooled to 0°C. Then, a 3M ethylmagnesium bromide THF solution (66.0 μL, 66.0 μmol) was added dropwise, and the mixture was stirred at the same temperature for 30 minutes. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by preparative thin-layer chromatography (n-hexane:ethyl acetate=1:1) to obtain Compound II-21 (yield 6.3 mg, 31%) and Compound II-22 (yield 6.6 mg, 32%). (Compound II-21) 1H-NMR(500MHz, CDCl3, δ): 5.83 - 5.81(m, 1H), 5.75 - 5.69(m, 2H), 5.63(dd, J = 8.3, 1.4Hz, 1H), 5.40 - 5.35(m, 2H), 4.95(d, J = 10.9Hz, 1H), 4.79(s, 1H), 4.76(d, J = 3.4Hz, 1H), 4.64(dd, J = 7.2, 2.6Hz, 2H), 4.43(s, 1H), 4.38(d, J = 8.0Hz, 1H), 3.93(br s, 1H), 3.85 - 3.75(m, 2H), 3.69 - 3.60(m, 2H), 3.50 - 3.42(m, 7H), 3.26 - 3.15(m, 3H), 2.80(dd, J = 12.9, 3.2Hz, 1H), 2.51 - 2.48(m, 3H), 2.36 - 2.20(m, 4H), 1.91 - 1.87(m, 1H), 1.78 - 1.72(m, 2H), 1.68 - 1.46(m, 25H), 1.45 - 1.37(m, 4H), 1.26(dd, J = 11.5, 6.3Hz, 7H), 1.15(d, J = 6.9Hz, 3H), 1.10(d, J = 6.3Hz, 3H), 0.91(td, J = 7.3, 7.3, 2.6Hz, 7H), 0.83(d, J = 6.3Hz, 3H), 0.78(m, 4H); MS m / z 948.6349[M + NH4] + . (Compound II-22) 1H-NMR(500MHz,CDCl3,δ):5.84-5.82(m,1H),5.74-5.68(m,2H),5.63)dd,J=8.1,2.0Hz,1H),5.40-5.35(m,2H),4 .96-4.94(m,1H),4.76(,J=3.44Hz,1H),4.66-4.60(m,2H),4.58(s,1H),4.48-4.44(m,1H),4.41(s,1H),3.93(br s,1H),3.84-3.75(m,2H),3.69-3.60(m,2H),3.51-3.42(m,7H),3.26-3.15(m,3H),2.76(dd, J=12.6,2.9Hz,1H),2.50-2.43(m,3H),2.36-2.20(m,4H),1.91-1.88(m,1H),1.79-1.70(m,3 H),1.67-1.64(m,2H),1.62-1.49(m,25H),1.45-1.36(m,4H),1.28-1.24(m,8H),1.13(dd,J= 12.0,6.9Hz,6H),0.92(td,J=7.5,7.5,2.9Hz,6H),0.84-0.77(m,7H);MSm / z948.6349[M+NH4] + .

[0420] Preparation of Compound II-23 and Compound II-24 Compound II-23 (yield 8.4 mg, 8%) and Compound II-24 (yield 78.1 mg, 71%) were obtained in the same manner as in [Preparation of Compound II-3] except that ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate was used instead of ethyl 2-(diethoxyphosphoryl)acetate. (Compound II-23) 1H-NMR(500MHz, CDCl3, δ): 5.88 (d, J = 10.9 Hz, 1H), 5.75 - 5.63 (m, 2H), 5.41 - 5.35 (m, 2H), 4.91 (d, J = 10.9 Hz, 1H), 4.76 (d, J = 3.4 Hz, 1H), 4.68 - 4.53 (m, 3H), 4.31 - 4.23 (m, 2H), 4.20 (s, 1H), 3.93 (br s, 1H), 3.87 - 3.74 (m, 2H), 3.71 - 3.55 (m, 3H), 3.51 - 3.38 (m, 7H), 3.27 - 3.14 (m, 3H), 2.58 (dd, J = 13.8, 5.2 Hz, 1H), 2.53 - 2.43 (m, 2H), 2.37 - 2.19 (m, 4H), 2.13 - 2.03 (m, 1H), 1.88 - 1.70 (m, 3H), 1.65 - 1.38 (m, 20H), 1.38 - 1.23 (m, 13H), 1.16 (d, J = 6.9 Hz, 3H), 0.91 (t, J = 7.5 Hz, 3H), 0.86 - 0.69 (m, 7H); MS m / z 980.5739 [M + NH4] + 。 (Compound II-24) 1 H-NMR(500MHz, CDCl3, δ): 5.83 (d, J = 10.3 Hz, 1H), 5.74 - 5.62 (m, 2H), 5.41 - 5.34 (m, 2H), 5.00 (s, 1H), 4.93 (d, J = 10.9 Hz, 1H), 4.76 (d, J = 3.4 Hz, 1H), 4.61 (d, J = 2.3 Hz, 2H), 4.46 (br s, 1H), 4.27 - 4.23 (m, 2H), 3.92 (br s, 1H), 3.85 - 3.73 (m, 2H), 3.69 - 3.60 (m, 2H), 3.50 - 3.39 (m, 7H), 3.25 - 3.13 (m, 3H), 2.83 - 2.76 (m, 1H), 2.73 (dd, J = 12.9, 3.15 Hz, 1H), 2.48 (t, J = 6.9 Hz, 1H), 2.35 - 2.19 (m, 4H), 1.97 - 1.85 (m, 2H), 1.79 - 1.70 (m, 2H), 1.70 - 1.61 (m, 2H), 1.57 - 1.34 (m, 17H), 1.34 - 1.22 (m, 11H), 1.15 (d, J = 7.5 Hz, 4H), 0.91 (t, J = 7.5 Hz, 3H), 0.72 - 0.87 (m, 8H); MS m / z 980.5739 [M + NH4] + 。

[0421] Preparation of Compound II-25 and Compound II-26 Compound II-6 (20.0 mg, 22.0 μmol) obtained in [Preparation of Compound II-6] was dissolved in nitromethane (59.1 μL, 1.10 mmol), triethylamine (46.0 μL, 330 μmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was evaporated under reduced pressure, and the residue was roughly purified by preparative thin-layer chromatography (n-hexane:ethyl aceta...

Claims

1. A compound represented by the following general formula (I): [In the formula (I), n represents an integer of 0, 1, or 2; X represents CH, CF, CCl, N, CHCH═N, CHCH═CH, or CHCH═CF; Y represents O, NH, or a single bond; Z represents a hydroxy group or an oxo group; R 1 represents a hydrogen atom; a halogen atom; a C1-C6 alkyl group; a 3- to 6-membered cycloalkyl group; a 4- to 8-membered heterocycloalkyl group; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group; a C2-C6 alkenyl group; a C2-C6 alkynyl group; -CO-R 2 a group represented by -COO-R 2 a group represented by -CONH-R 2 or a group represented by -B(OR 4 ) OR 5 where R 1 is other than a hydrogen atom or a C1-C6 alkyl group, 1 represents a halogen atom, a hydroxy group, an amino group, a cyano group, a nitro group, a formyl group, a sulfanyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 aminoalkyl group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -COO-R 2 a group represented by -CONH-R 2 a group represented by -NHCO-R 2 a group represented by -NHSO 2 -R 2 and —NHSO 2 NH-R 2 and R 1 is a C1-C6 alkyl group, the C1-C6 alkyl group is selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a nitro group, a cyano group, an oxo group, a hydroxy group, an amino group, and —CONH—R 2 a group represented by -NHCO-R 2 or a group represented by —NHSO 2 -R 2 a 3- to 6-membered cycloalkyl group optionally substituted with a group represented by the formula: 2 a group represented by -O-CO-R 2 a group represented by the formula: -O-CONH-R 2 a group represented by -N-R 2 R 3 a group represented by -S-R 2 a group represented by -CONH-R 2 a group represented by the formula: -NHCO-R 2 a group represented by -COO-R 2 a group represented by the formula: -NHCOO-R 2 a group represented by -NHCONH-R 2 a group represented by the formula: -NHSO 2 -R 2 a group represented by -CO-R 2 a group represented by the formula: 2 -R 2 and —NHSO 2 NH-R 2 and R 2 represents a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C3 haloalkyl group, a hydroxy group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkoxy group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered cycloalkyl C1-C3 alkyl group, a 4- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 6- to 10-membered aryl C1-C3 alkyl group, a 5- to 10-membered heteroaryl group, a 5- to 10-membered heteroaryl C1-C3 alkyl group, a C1-C3 alkoxy C1-C3 alkyl group, an amino group, a C1-C6 alkylamino group, a C1-C6 dialkylamino group, a sulfanyl group, or a C1-C6 trialkylsilyl group, wherein R 2 The 5- to 10-membered heteroaryl group represented by is a halogen atom, a hydroxy group, an amino group, a cyano group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 aminoalkyl group, a C1-C3 haloalkyl group, -N-R 2 R 3 and -CONH-R 2 and R 2 The heteroaryl group of the 5- to 10-membered heteroaryl C1-C3 alkyl group represented by R may be further substituted with an amino group or a C1-C3 alkyl group, 3 represents a hydrogen atom or a C1-C6 alkyl group, R 4 and R 5 are all hydrogen atoms or each independently represent a C1-C10 alkyl group which may be bonded to each other to form a ring structure, and the numbers 3, 4, 22, and 23 each represent the position numbers of carbon atoms, and the bond between positions 3 and 4, and between positions 22 and 23, may each independently be a single bond or a double bond.] or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein in said formula (I), X is N, Y is O, and there is a single bond between the 3-position and the 4-position.

3. In the formula (I), R 1 The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein is an optionally substituted C1-C6 alkyl group.

4. In the formula (I), R 1 is a 5- to 10-membered heteroaryl group, —CONH—R 2 or a group represented by —CO—R 2 4. The compound according to claim 3, wherein the C1-C6 alkyl group is substituted with a group represented by the formula:

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein in formula (I), X is N, Y is O, and there is a double bond between the 3- and 4-positions.

6. In the formula (I), X is N, Y is O, and R 1 is a hydrogen atom; a C2-C6 alkenyl group; a C2-C6 alkynyl group; a halogen atom; a 3- to 6-membered cycloalkyl group optionally substituted with a hydroxy group; a 4- to 8-membered heterocycloalkyl group; or -O-R 2 a group represented by —O—CONH—R 2 a group represented by -COO-R 2 a group represented by -CONH-R 2 a group represented by -NHCONH-R 2 a group represented by -CO-R 2 and —NHSO 2 -R 2 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the alkyl group is a C1-C6 alkyl group substituted with one or more substituents selected from the group represented by the following formula:

7. The compound represented by formula (I) is a compound represented by the following formulas (1) to (94):

2. The compound according to claim 1, wherein the compound is selected from the group consisting of the compounds represented by any one of the following formulas:

8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, in formula (I), X is CH, CF, or CHCH=CH, and there is a single bond between the 3- and 4-positions.

9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, in formula (I), X is CH, CF, or CHCH=CH, and there is a double bond between the 3- and 4-positions.

10. In the formula (I), X is CH, CF, or CHCH=CH, Y is a single bond, and R 1 a 4- to 8-membered heterocycloalkyl group optionally substituted by an oxo group; —COO—R 2 a halogen atom, a hydroxy group, an amino group, a cyano group, a formyl group, an oxo group, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C6 alkoxy group, a C1-C3 haloalkyl group, -N-R 2 R 3 a group represented by -NHCO-R 2 and -CONH-R 2 a 5- to 10-membered heteroaryl group optionally substituted with one or more substituents selected from the groups represented by the following formula: 2 and —COO—R 2 or a pharmaceutically acceptable salt thereof.

11. The compound represented by formula (I) is represented by the following formulas (201) to (271):

2. The compound according to claim 1, wherein the compound is selected from the group consisting of the compounds represented by any one of the following formulas:

12. In the formula (I), X is N, Y is NH, and R 1 Ga-CO-R 2 2. The compound according to claim 1, wherein the compound is a group represented by the formula: or a pharmaceutically acceptable salt thereof.

13. A compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, which has antiviral activity against coronavirus.

14. The compound or pharmaceutically acceptable salt thereof according to claim 13, wherein the coronavirus is a coronavirus classified in the genus Betacoronavirus.

15. The compound or pharmaceutically acceptable salt thereof according to claim 13, wherein the coronavirus is at least one selected from the group consisting of human coronavirus (HCoV), severe acute respiratory syndrome coronavirus (SARS-CoV), novel coronavirus (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV).

16. A composition for treating or preventing a disease or condition associated with coronavirus, comprising as an active ingredient a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

17. The composition of claim 16, wherein the coronavirus is a coronavirus classified in the genus Betacoronavirus.

18. The composition of claim 16, wherein the coronavirus is at least one selected from the group consisting of human coronavirus (HCoV), severe acute respiratory syndrome coronavirus (SARS-CoV), novel coronavirus (SARS-CoV-2), and Middle East respiratory syndrome coronavirus (MERS-CoV).

19. A method for treating or preventing a disease or condition associated with coronavirus, comprising administering to a subject a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

20. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof for the manufacture of a composition for the treatment or prevention of a disease or condition involving a coronavirus.